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Abstract 
Crystallization is a widely used purification and separation technique in the pharmaceutical 
industry. More than 90 % of the active pharmaceutical ingredients are produced in the crystalline 
form. The quality of the crystalline product greatly affects the downstream processing and 
bioavailability of the drug. The Food and Drug Administration (FDA) initiated in 2004 the use 
and implementation of process analytical technology (PAT) in the pharmaceutical development 
and production and encourages the pharmaceutical industry to adopt quality by design (QBD) 
approaches. The prime objective of this initiative has been to optimize the drug development and 
manufacturing process by reducing cost, improving product quality and reducing the number of 
failed batches. The work presented in this thesis focuses on expanding the use of two PAT tools, 
namely attenuated total reflection ultra violet/visible spectroscopy (ATR-UV/Vis spectroscopy) 
and focused beam reflectance measurement (FBRM). ATR-UV/Vis spectroscopy and FRBM are 
mostly used for process monitoring. The aim here was to develop sophisticated control 
approaches using these in situ tools for enhancing the product quality. Chemometrics is an 
integral part of PAT, and can provide valuable information about the system. This tool has also 
been used in this study for calibration model development and monitoring the cooling and anti-
solvent crystallization processes for single and muticomponent crystallisations. 
The development of an accurate and robust calibration model is necessary for qualitative and 
quantitative analysis of a system using spectroscopy. A systematic methodology was therefore 
presented for the selection of a suitable calibration model for ATR-UV/Vis spectroscopy. The 
developed model was then used as part of supersaturation control approach (SSC). SSC uses 
information from ATR-UV/Vis spectroscopy in a feedback control loop to keep the system at 
desired supersaturation. The developed approach resulted in the production of crystals of uniform 
size and can represent the bases for a model-free direct design approach for crystallization 
systems. 
A novel automated direct nucleation control approach (ADNC) based on FBRM was also 
evaluated. For most crystallisation systems significant variations exist in the metastable zone 
width (MSZW) due to changing operating conditions, scale and impurity profile. These 
variations can significantly deteriorate the quality of the final product. The ADNC approach, 
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which is a model-free approach, was able to detect all these dynamic changes and consistently 
produced high quality product. The performance of this control approach was tested against 
traditionally used linear and programmed cooling profiles and it was shown that ADNC approach 
always gave better results in terms of crystal size and crystal size distribution (CSD). A 
combined ADNC and SSC approach was also presented which was based on the concept of 
internal seed generation. This approach also outperformed the crystallisation processes controlled 
using linear and natural cooling profiles. A thorough evaluation of the ADNC approach was then 
carried out under different conditions including accidental seeding and external seed addition. 
During all these tests and evaluations ADNC yielded high quality products, demonstrating its 
robustness and efficiency.  A 100 L pilot plant crystallizer was used to test the applicability of the 
ADNC approach as a simple, efficient and robust scale-up tool. The results obtained showed that 
ADNC approach performed equally well on pilot scale generating crystals with larger size and 
less agglomeration. The approach was also compared with natural and linear cooling profiles on 
the 100 L scale. The product obtained from ADNC was superior (larger crystals, with narrower 
CSD and less fines) compared to crystals resulted from the open loop control approaches. 
Often compounds exist in mixtures especially after the synthesis stage during the drug 
development process. Separation and monitoring of the compounds is therefore necessary as a 
high degree of purity is required in the pharmaceutical industry. A complex nonlinear model 
capable of simultaneously monitoring the concentration of two isomers during cooling and anti-
solvent crystallization was developed. The model was based on the absorbance values provided 
by the in situ ATR-UV/Vis spectroscopy while two FBRM probes were used for monitoring the 
solid phase. A novel interconnected setup of two and three crystallizers was developed for the 
separation of the two and three positional isomers (ortho, meta and para) of amino benzoic acid, 
using seeded cooling crystallization. It was shown that seeded cooling crystallization can be used 
to obtain products of high purity from a mixture using the innovative crystallizer setup. The 
products obtained showed no signs of cross contamination, this demonstrated the successful 
implementation of this approach for the separation of the compounds, when present together in a 
mixture and offers a cost effective alternative to more expensive high performance liquid 
chromatography.
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Chapter 1 Introduction 
 
1.1 Background 
 
Drug development is a long, expensive and cumbersome process (DiMasi et al., 2003). Unlike 
other industries, which have made major changes in their research and development (R&D) 
processes, the situation in the pharmaceutical industry has not changed significantly since the 
1960’s (Kaitin, 2010). The traditionally followed research path is sluggish, low in efficiency, 
perilous and very costly (Kaitin, 2010). The drug development process is spanned over several 
stages, these are shown in Figure 1.1. 
 
Figure 1.1 Drug development stages 
 
According to Hinz, (2005) it takes 10-15 years on average to bring a drug to the market. The 
timeline varies depending on the therapeutic area (Kaitin, 2010). The pharmaceutical industry is 
now under pressure to reduce the historically accepted greater than 10 years development time. 
This has resulted in a shorter time available for route designing and scale-up (Federsel, 2008), 
motivated by the economic impact related to patent expiry, which can result in massive profit 
decline for the pharmaceutical industry (Keyhani et al., 2006). Typical examples are the drugs 
enalapril, fluoxetine and ranitidine, for which the profit decreased by 61 %, 51 % and 69 %, 
respectively, after their patent expired (Boersma et al., 2005). The issue was highlighted by 
Kaitin (2010), who reported the sales of the top 36 blockbuster drugs (drugs with annual sales of 
Target 
identification
Hit 
identification
Lead 
identification
Lead 
Optimization
Candidate drug  
prenomination
Concept 
testing
Development 
for launch
Launch Phase
Chapter 1 Introduction 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  2 
 
$1billion dollars or more) will amount to $112 billion, but after the patent expiry these figures 
will drop dramatically. It is worth noting that the average R&D cost is only matched by 3 out of 
10 products in terms of revenue (Grabowski et al., 2002).  Furthermore, companies now have to 
justify and show the superiority of their product in terms of therapeutic efficiency and cost.  
 
The cost of drug development has increased considerably in the last 30 years (Rawlins, 2004). 
According to DiMasi et al. (2003) the average cost for a new drug is $802 million, increasing at 
7.4 % per year. Boston Consulting Group (BCG) (E. Ref 1) estimated this to be $880 million. 
Adams and Brantner (2010) have calculated this to be in excess of $1 billion, depending on the 
therapeutic category. DiMassi and Grabowski (2007) stated that $1.24 billion would be required 
for launching a new biopharmaceutical product, while $1.32 billion will be required for a 
conventional drug including the cost of failures. Such high costs have resulted in R&D spending 
in excess of $50 billion only in USA in 2008 (Kaitin, 2010). The main factor responsible for the 
high drug costs is that a very small proportion of candidate drugs make it to the market. Out of 
5000-10000 compounds that are selected in the drug discovery phase only 250 make it to the 
preclinical phase, 5 enter the clinical trials and only 1 gets approved by FDA. These failures 
result in increased development times and cost. 
 
A breakup of the R&D expenses has been given by BCG (2001), and is shown in Figure 1.2. 
These figures reveal that substantial amount of money is invested during each phase of drug 
development. Reduction of time and minimization of failures during each of these phases can 
result in significant savings both in time and cost but also can help in extending the revenue 
generating period in the patent life of the product, and can bring new drugs to the market earlier. 
Pharmaceutical companies are under increasingly high pressure to decrease development time.  
 
The main purpose of the PAT initiative by FDA, introduced in 2004, was to improve the 
understanding and control of the processes during process R&D and the routine manufacturing of 
pharmaceutical products. A better understanding and control can lead to improved product 
quality, lower number of failed batches, less variability and consequently reduction in drug 
development and manufacturing cost and time. Although PAT is used at different processing 
stages, its most significant application is during crystallization, as 90 % of the active 
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pharmaceutical ingredients (API) exist in crystalline form. Downstream processes such as 
filtration, drying and tableting along with bioavailability are significantly affected by the quality 
of the crystalline product (Chung et al., 2000; Wibowo et al., 2001; Mullin, 2001). 
 
Figure 1.2 Breakup of drug development costs 
 
CSD, polymorphism, purity and crystal habit are some of the most important properties of 
crystalline products. Although crystallization is an old unit operation, still it is not well 
understood and obtaining products with required properties, and the consistent scale up of the 
process poses a significant challenge to the industry. With the availability of PAT, FDA 
encourages the industries to adapt QBD approaches rather than the traditional quality-by- testing 
(QBT). QBD ensures that quality is built into the product during processing by continuous 
monitoring and control. Using the available set of PAT tools any unwanted events that may occur 
during the processing can be detected and appropriate actions taken swiftly. This results in 
minimization of failures and improved quality, which then affect the overall economics and 
efficiency of the system (Bakeev, 2010).  
 
The QBD concept considers the application of PAT tools for the entire drug development process 
from the evaluation of raw materials until the final product rolls out of the plant. For example in 
situ near infrared (NIR) spectroscopy is frequently used for rapid screening and testing of the raw 
materials (Fevotte et al., 2004), ATR fourier transform infrared (FTIR) (Fevotte, 2002) and 
ATR-UV/Vis spectroscopy can be used at the synthesis stage (Thurston et al., 2004) or during 
the separation by crystallization for detection of any impurities and application of supersaturation 
control for improved quality. Similarly focused beam reflectance measurement (FBRM) can be 
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used to determine metastable zone width (MSZW) along with monitoring changes in CSD 
(Barrett and Glennon, 2002). Additionally, feedback control approaches based on the use of 
FBRM can be applied to enhance CSD. Raman spectroscopy can be employed for determination 
and characterization of polymorphic forms and hydrates (Hausman et al., 2005). All these tools 
give real time information and therefore their application is often more accurate and less time 
consuming than the traditional offline techniques. PAT has also enabled the development and use 
of more sophisticated control approaches (both first principles and direct design techniques) 
which is a major shift from trial and error or open loop control methodologies (Fujiwara et al., 
2005).  
 
Some of the challenges faced by the pharmaceutical industry have been discussed in the previous 
section. PAT can play a crucial role to overcome some of the problems faced during drug 
development and manufacturing and therefore is the way forward. It is crucial to fully exploit the 
benefits, uses and applications of all the PAT tools available, at laboratory, pilot and industrial 
scales. Only a handful of studies are available that deal with the application of FBRM as a 
process controlling tool, there is no research available that shows the use of ATR-UV/Vis 
spectroscopy in a feedback control approach and only a few publications deal with its application 
in the crystallization process. Also the literature that deals with the application of these 
approaches on pilot and industrial scale is scarce. The main aim of the work undertaken is 
therefore to expand the utility and application of these techniques both on laboratory and pilot 
scale as monitoring and control tools. 
 
1.2 Research Aims and Objectives 
 
The main aims and objectives of the work undertaken are as follows: 
 
i. To investigate the capability of ATR-UV/Vis spectroscopy for the qualitative monitoring 
and control of pharmaceutical crystallization processes. 
ii. To evaluate novel automated model-free control approaches for batch crystallization 
processes based on the use of ATR-UV/Vis spectroscopy and FBRM devices. 
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iii. To investigate the performance of the developed model-free control approaches for 
various pharmaceutical crystallization systems at different scales. 
iv. To compare the proposed automated direct nucleation control (ADNC) approach with 
other control approaches, such as open-loop control, linear cooling and supersaturation 
control. 
v. To investigate the use of the model-free control approaches as a means of rapid scale-up 
methodology. 
vi. To develop complex non-linear calibration procedures, which enable the simultaneous 
monitoring of several compounds in multi-component pharmaceutical crystallization. 
vii. To prepare novel crystallization systems for the separation of mixtures of compounds. 
 
1.3 Research Methodology 
 
The PAT tools used in the current work for process monitoring and control were ATR-UV/Vis 
spectroscopy and FBRM. ATR-UV/Vis spectroscopy gives absorbance data which can be used to 
determine the concentration(s) of compound(s) in a solution. This spectroscopic technique can 
provide both qualitative and quantitative information about the system. Concentration of a 
solution can be determined by using ATR-UV/Vis spectroscopy data by developing a calibration 
model. ATR-UV/Vis spectroscopy was used in the development of a control approach used in 
this research. FBRM was used for monitoring of the solid phase. The laser back-scattering tool 
measures chord lengths and can be used to obtain qualitative information about different 
crystallization related phenomena such as nucleation, dissolution, growth and agglomeration of 
particles. FBRM was used for the development of one of the feedback control strategies 
presented in the current work. Single and multi component cooling and anti-solvent 
crystallization processes were the main focus in this work especially cooling crystallization, 
because of its wide application in the industry. For scale up study cooling experiments were 
carried out at 1 L laboratory and 100 L pilot plant scale.  
 
Several different chemometrics aspects were used in the work, these include: calibration model 
development and assessment using principal component regression (PCR), partial least squares 
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regression (PLSR), artificial neural networks (ANN), principal component-artificial neural 
network (PC-ANN). Design of experiments (DOE) was also used to perform experiments in a 
systematic and optimal way for calibration model development. 
 
1.4 Research Contribution 
 
A summary of the major contributions of the work is as follows: 
 
 A systematic calibration model development approach for concentration determination in 
crystallization using ATR-UV/Vis spectroscopy is presented. A simple non linear model 
using derivative at a single wavelength will be developed. The developed model should 
be able to predict the concentration with high accuracy. Solubility data obtained using this 
model will be compared with the literature data to confirm its predictive ability. 
 
 A model-free crystallization control approach will be developed based on the real-time 
and in situ use of ATR-UV/Vis spectroscopy coupled with a non-linear calibration model. 
The approach should be able to follow a particular operating trajectory in the 
crystallization phase diagram, using the supersaturation feedback control concept. This 
will enable the production of uniform crystals, and can be used as a fast direct design 
approach for crystallization systems. The work will provide the first experimental 
demonstration of the ATR-UV/Vis spectroscopy for feedback supersaturation control. 
 
 A comprehensive analyses of a new ADNC model-free approach is provided. The ADNC 
approach adaptively drives the crystallization process in the phase diagram using a 
sequence of controlled nucleation and dissolution events so that a desired number of 
particle counts obtained from the FBRM probe is maintained. Detailed guidelines for the 
practical implementation of the ADNC will be provided. The performance of the 
approach to produce large uniform crystals will be demonstrated for cooling 
crystallization of paracetamol (PCM) and iso-propyl alcohol (IPA) system. 
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 Innovative internal seeding methodology is proposed based on the combined use of 
ADNC and SSC. The proposed ADNC-SSC approach will combine the information 
obtained from FBRM and ATR-UV/Vis spectroscopy for controlling crystallization 
process. It will be demonstrated that the in situ seed generation approach based on the 
combined ADNC approach outperforms the traditionally used linear and programmed 
cooling based operations using externally generated seed, yielding uni-modal distribution 
and larger mean crystal size. 
 
 A fast and robust scale-up methodology is proposed based on the use of the ADNC 
approach. The ability of the ADNC approach to adapt the operating profile to the 
changing conditions due to scale-up will be demonstrated for the model pharmaceutical 
compound ortho-aminobenzoic acid (OABA) in water. The control approach will be 
implemented on 100 L and 1 L scales and it will be shown that the ADNC based scale-up 
method outperforms common approaches used in the industry, which simply implements 
linear and natural cooling trajectories on both scales. 
 
 A new non-linear calibration model capable of simultaneously measuring concentrations 
of a mixture of OABA and para aminobenozic acid (PABA) for both cooling and anti-
solvent crystallizations will be developed using PC-ANN approach. This will be based on 
absorbance spectra measurements obtained by ATR-UV/Vis spectroscopy. 
 
 A novel setup comprising of two and three interconnected crystallizers will be developed 
and used for the simultaneous separation of two and three positional isomers of amino 
benzoic acid when present together in the solution. The simultaneous combined use of 
ATR-UV/Vis spectroscopy and FBRM probes will be demonstrated for the first time for 
the monitoring of multi-component crystallization in interconnected vessels. ATR-
UV/Vis spectroscopy and FBRM will be used for monitoring of liquid and solid phases 
respectively. The proposed approach will employ seeded cooling crystallization and 
sintered disk filters for the separation.  
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1.5 Structure of the Thesis 
 
The thesis comprises of seven chapters which are presented in the following order: 
 
 Chapter 1 introduces the economic aspects of the drug development process and the 
benefits of using PAT for optimizing the product quality and process costs are 
highlighted.  
 
 Chapter 2 reviews the relevant literature and concepts of crystallization processes are 
discussed, such as solubility, supersaturation, polymorphism and crystallization kinetics 
etc. Several PAT tools and their applications for monitoring and control of crystallization 
processes are discussed. 
 
 Chapter 3 presents a systematic methodology for calibration model development, this 
includes analysis of data for linearity/non-linearity, selection of a suitable calibration 
model, analysis of various calibration model development techniques and validation. A 
detailed analysis of the selected calibration model is also provided. 
 
 Chapter 4 introduces the ADNC, SSC, ADNC-SSC approaches. The working principle, 
advantages, disadvantages and comparison of several control policies used for 
paracetamol/IPA system are presented. The novel internal seeding approach based on the 
ADNC-SSC is introduced.  
 
 Chapter 5 analyzes the robustness of the ADNC approach when the system is subjected to 
disturbances common in industrial operation such as accidental seeding. The results of a 
detailed  comparison between seeded and unseeded ADNC operations are also presented 
in this chapter. 
 
 Chapter 6 proposes the novel feedback control based scale-up methodology, using 
ADNC. The previously described ADNC approach is extended here and applied on a 100 
L pilot plant scale. Ortho aminobenzoic acid (OABA) and water is used as the model 
Chapter 1 Introduction 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  9 
 
system. The application of the DNC as a scale up approach is discussed here by analyzing 
the results obtained on 100 L and 1 L scales. 
 
 Chapter 7 is divided in two sections. In the first part the development of a calibration 
model for the monitoring of a complex multi-component system using ATR-UV/Vis 
spectroscopy is discussed. Several chemometric approaches such as principal PCR, ANN 
and PC-ANN were used and tested for their concentration prediction ability. A systematic 
experimental design approach was used to significantly decrease the number of 
experiments required to develop the complex non-linear calibration model. The second 
part of the chapter proposes an innovative setup based on interconnected crystallizers, for 
the separation of aminobenzoic acid (ABA) isomers. The Separation of two and three 
isomers when present together in the solution is carried out using two and three 
interconnected crystallizers via seeded cooling crystallization and the process is 
monitored using ATR-UV/Vis spectroscopy and two FBRM probes.  
 
 Chapter 8 concludes the work presented and recommendations for future work are 
discussed. 
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Chapter 2 Literature Review 
 
2.1 Solubility and Supersaturation 
 
Solubility is the amount of a substance that can be dissolved in a solvent at a given temperature. 
Knowing the solubility curve in a given solvent (or solvent system) is required prior to the 
commencement of any crystallization process. Several important properties of the crystalline 
product i.e. polymorphic form, shape of crystals and yield are dependent on solubility and 
supersaturation (Karunanithi et al., 2007; Modarresi et al., 2008). Furthermore, the selection of 
the type of crystallization process e.g. cooling or anti-solvent crystallization is also dictated by 
the solubility of the compound in selected solvents. It is worth noting that for a given solute in a 
given solvent, the solubility curve is a function of temperature; however, impurities can affect the 
solubility. Often the solvent is selected during the early drug development phases i.e. during 
target and hit identification followed by hit refinement and lead refinement stages (Bleicher et 
al., 2003; Myerson, 2002). This therefore requires process engineers to be in contact with 
synthetic chemists for appropriate selection of the solvent for subsequent crystallization of the 
drug compound.  
 
The usage of high throughput screening has resulted in large number of poorly soluble drug 
compounds, posing a major challenge to the formulation scientists for oral delivery of these 
drugs (Leuner and Dressman, 2000). Although water is still one of the most widely used solvents 
because of its availability at lower cost and non-toxicity (Mullin, 2003) it has been reported that 
the number of drug candidate compounds with low aqueous solubility is increasing (Blagden et 
al., 2007). A number of different strategies have been reported to improve the solubility of the 
compounds. These include: increasing surface area of the particles by micronisation (Chaumeil et 
al., 1998), usage of co-solvents, solubility enhancement by using salt forms, micellar solutions 
and cyclodextrin complexes (Rajewski and Stella, 1996). However, the effectiveness of these 
methods is limited e.g. the use micellar systems are dependent on properties of therapeutic 
molecules and limited range of pharmaceutical excipients (Blagden et al., 2007). Micronisation 
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improves the dissolution profile of the drugs, but the equilibrium solubility still remains 
unchanged (Müller, 2001). 
 
In the crystal engineering framework, tailoring size and habit of crystals can be used to to 
enhance the solubility, dissolution profile and bioavailability of drugs with poor solubilities. For 
example, during the growth of the crystals, the mechanism shifts from screw dislocation to 
surface nucleation and ultimately to growth in the presence of certain solvents on additive 
molecules. These changes in growth mainly arise from change in solubility caused by additive 
molecules and solvents. Change in crystal habit has been observed to change the in vitro 
dissolution rate. For example, the dissolution of rod shaped dipyridamole crystals is quicker 
compared to rectangular needle shaped crystals (Adhiyaman and Basu, 2006). Other factors that 
contribute to solubility and dissolution rates include polymorphic form, crystalline versus 
amorphous form of drugs and co crystals. A review of how these factors influence solubility is 
provided by Blagden et al. (2006). Co-crystals is particularly an area of growing interest in terms 
of solubility enhancement and improvement of other physiochemical properties of the drugs, the 
advantages of using them are discussed in detail by Good and Rodriguez-Hornedo (2009). 
   
A variety of techniques are available for solubility measurements, these are classified as 
isothermal and non-isothermal methods. In the isothermal method solvent is kept at desired 
temperatures for 4-24 hours with excess of solids, and then a clear sample is taken and analyzed. 
The main purpose of using longer time is to make sure that thermal equilibrium has been reached 
and the dissolution rate is closer to the saturation point. Isothermal methods are considered more 
accurate compared to that of non-isothermal methods (Mohan et al., 2002).  Mohan et al. (2002) 
also demonstrated the use of differential scanning calorimetry (DSC) for solubility measurement. 
The results were close to typically employed techniques, except for the compounds having little 
change in the solubility with temperature. With advancement in PAT inline methods e.g. ATR-
FTIR can be used for determination of solubility (Barrett et al., 2005; Dunuwila et al., 1994). 
 
As mentioned before the selection of solvent and behaviour of solute plays a crucial role during 
crystallization. Often the experimental data is not available for new molecules. In these cases 
model based calculations are used to predict the solubility and selection of solvents. Computer 
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aided molecular design (CAMD) is used for solvent selection and design (Harper and Gani, 
2000). CAMD uses properties estimated by different available models, such as Universal 
Functional Activity Coefficient (UNIFAC) (Fredenslund et al., 1977), connectivity indices (CI 
model) (Gonzalez et al., 2007), combined UNIFAC/CI models, Non-random Two-Liquid 
segment activity coefficient model (NRTL-SAC) (Chen and Crafts, 2006) and others. A review 
on the use and limitations of these models is provided by Modarresi et al. (2008).  
 
The main driving force in crystallization is the difference in chemical potential between the 
solution and the solid phase. This is typically expressed in terms of the supersaturation, which is 
the difference between the solution concentration and the saturation concentration. 
Supersaturation can be created by several methods such as cooling, evaporation, and/or addition 
of anti-solvent, including changing the pH by addition of acid or base (Fujiwara et al., 2005). 
 
 
Figure 2.1 Phase diagram for crystallization process 
 
A typical phase diagram for a crystallization process is shown in Figure 2.1. Absolute 
supersaturation, S , here can be defined as the difference between the concentration of the 
solution, c ,  and the solubility concentration, 
sc , at a particular temperature: 
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The relative supersaturation is another way to express supersaturation and is described as:  
 
   
    
  
 (2.2) 
 
As shown in Figure 2.1 the area below the solubility curve is the undersaturated region where 
crystals cannot exist in equilibrium, while the area between the solubility curve and labile region 
is called metastable zone (MSZ). In this area crystal growth takes place without significant 
spontaneous nucleation. The labile zone is the metastable region where spontaneous nucleation 
dominates. Presence of foreign particles and crystals can significantly affect the metastable zone 
width (MSZW), a clear metastable limit is therefore difficult to define because of its dependence 
on various factors. Factors affecting the MSZW and subsequently the crystalline product will be 
discussed in the following sections. As mentioned previously several methods are available for 
generation of supersaturation. The degree of supersaturation dictates the nucleation, crystal 
growth and finally the CSD. A better control and management of supersaturation generation 
methods can be used to optimize the supersaturation level in the system and hence the crystals 
with desired properties can be obtained. 
 
2.2 Nucleation 
 
Nucleation can be termed as the first step towards the formation of a solid phase (Jones, 2003). 
Nucleation is often the decisive step in the crystallization process and is of practical importance 
in pharmaceutical systems. Nucleation phenomena are equally important in the control of crystal 
properties and in the selective crystallization of a particular polymorph (Rodriguez-Hornedo and 
Murphy, 1999). 
 
With reference to the phase diagram in Figure 2.1, when the supersaturation level exceeds a 
certain limit i.e. beyond labile zone spontaneous nucleation will take place. A supersaturated 
solution exists in unstable state, nucleation is therefore an attempt to reach a stable state by the 
solution. The mechanism of nucleation is still not very well understood. The classical nucleation 
theory is briefly described next. 
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Nuclei are formed by combination of embryos a few nanometres in size. These nuclei upon 
reaching a critical size grow to form crystals. The rate of nucleus formation is given by the 
following expression: 
 





 
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kT
G
AB cro exp  (2.3) 
 
where 
oB  is the rate of nucleus formation, A  is the pre-exponential factor having a value at the 
order of magnitude of 
3010  nuclei/cm3 sec-1, k  is the Boltzman constant 
123103805.1  JK , T  
is the temperature and 
crG  is the change in free energy for a nuclei of critical size. The free 
energy change for an aggregate undergoing a phase transition ∆G is given by: 
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where ∆Gs is the surface free energy change associated with the formation of the aggregate (a 
positive quantity),  ∆Gv is the volume free energy change associated with the phase transition (a 
negative quantity) and   is the interfacial tension, and r  is the radius of the aggregate . The 
right-hand terms of equation (2.4) are of opposite sign and depend differently on r  (radius), so 
the free energy of formation ∆G, passes through a maximum (see Figure 2.2). This maximum 
value ∆Gcr, corresponds to the critical nucleus, cr . The critical size is given by: 
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The critical size therefore represents the minimum size of a stable nucleus. Particles smaller than 
cr will dissolve, or evaporate if the particle is a liquid in a supersaturated vapour, because only in 
this way can the particle achieve a reduction in its free energy. Similarly particles larger than 
cr  
will continue to grow. 
crG  
is given by the following equation: 
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From the Gibbs-Thompson equation: 
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where   is the molecular volume and S is the supersaturation ratio,   
 
  
. From equation (2.6): 
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And from equations 2.7 and 2.5: 
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From equation (2.9) we can see that the nucleation rate is dependent upon supersaturation, 
temperature and interfacial tension. 
 
Although classical nucleation theory is widely accepted, discrepancies exist between 
experimental results and theoretically predicted mechanisms suggesting that the nucleation 
process is more complex than explained in the classical theory. A two step model has been 
proposed, it was originally considered for protein crystallization, but its application for small 
organic molecules suggest that this model can explain majority of the crystallization processes 
from solutions. According to this model solute molecules initially combine to form a cluster of 
sufficient size, the cluster is then reorganized in an ordered structure and finally the formation of 
crystals takes place. A detailed description and comparison of classical nucleation theory and the 
two step model is given by Erdemir et al. (2009) and Vekilov (2010).  
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Figure 2.2 Changes in Gibbs free energy (adapted from Myerson, 2000) 
 
Nucleation can be primary or secondary depending on whether supersaturated solution is free of 
crystalline surfaces or contain crystals, respectively (Seader and Henley, 2006). Primary 
nucleation can be divided into two types, namely homogeneous nucleation and heterogeneous 
nucleation. Homogeneous nucleation rarely occurs in large volumes since solutions contain 
random impurities that may induce nucleation. The heterogeneous nucleation of a solution can 
take place by seeding from embryos retained in cavities, e.g. in foreign bodies or the walls of the 
retaining vessels, under conditions in which the embryos would normally be unstable on a flat 
surface. Heterogeneous nucleation processes are of fundamental and of practical importance in 
pharmaceutical systems since unintentionally or intentionally added surfaces or interfaces may 
induces nucleation. The reactivity of crystals surfaces as heterogeneous nuclei has significant 
effects on the crystallization of the desired compound and in the control of conversions between 
these modifications, since the free energy required for the formation of two-dimensional nuclei is 
lowered by the presence of an appropriate substrate (Rodriguez-Hornedo and Murphy, 1999). 
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Figure 2.3 Variation in MSZW based on nucleation types (adapted from Mersmann, 2001) 
 
The presence the foreign bodies such as dust in pharmaceutical plant can induce nucleation at 
degrees of supercooling lower than those required for spontaneous nucleation. The MSZW based 
on each of these nucleation mechanisms appears at different points in the phase diagram as 
shown in Figure 2.3. These variations in the MSZW can have profound effects on the outcome of 
the crystallization process and will be discussed in the following sections. Nucleation in 
industrial crystallizer occurs mainly by secondary nucleation caused by the presence of existing 
crystals in the supersaturated solution. Secondary nucleation can occur by mechanisms 
mentioned in Table 2.1 (Tavare, 1995): 
 
Table 2.1 Different mechanisms of secondary nucleation 
No. Type Cause 
1 Initial breeding Dust on dry seeds 
2 Needle breeding Breakage of dendritic growth on parent crystals 
3  Polycrystalline breeding Breakage of agglomerates 
4 Shear nucleation Fluid shear on growing crystal face 
5 Contact nucleation Collision breeding: crystal-crystal, crystal-impeller, crystal-vessel 
internals 
 
Contact nucleation is the most common type of secondary nucleation and since it can occur at the 
low values of supersaturation that are typically encountered in industrial applications.  
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2.3 Polymorphism 
 
The ability of a molecule to exist in more than one crystalline forms is termed as polymorphism. 
The difference in crystalline structure can arise from different arrangement or conformation of 
the molecules in the crystal lattice (Brittain, 2009). It is convenient here to mention some other 
attributes of crystal structures arising from the formation of solvates, hydrates or an amorphous 
form of a compound. In solvates, the crystals contain solvent in certain amounts, when the 
solvent used is water, the term hydrate is used. In amorphous solid molecules are arranged in a 
disorderly manner as compared to ordered arrangement of molecules in a crystal. Generally, the 
most stable polymorphic form is used in the drug development, however, there are a few 
exceptions; e.g. if the stable polymorph has a lower solubility and the desired dosage form cannot 
be achieved a more soluble metastable form can be selected. A metastable form can also be used 
to achieve faster dissolution (Singhal and Curatolo, 2004).  
 
During drug development a thorough knowledge of polymorphs and their formation and stability 
conditions is crucial. Polymorphs can have different physical and chemical properties e.g. 
different solubility, this in turn can affect the bioavailability of the drug in the human body. 
Downstream processes such as filtration, drying, milling and tableting are also affected by 
different polymorphs as they have different habits, packing and mechanical properties etc. 
Polymorphs can have significant commercial and economic impact. The classical example is the 
discovery of a new polymorphic form in the drug ritonavir which caused a disruption in the 
production (Bauer et al., 2001). On the other hand a pharmaceutical company manufacturing 
Zantac successfully defended another polymorph for the same drug and fended off the 
competition after the patent had expired (Brittain, 2009). Polymorphs and their properties take 
center stage in generic drug production and abbreviated new drug applications, where 
bioequivalence of the product must be proved prior to its approval for production (Raw et al., 
2004).  
 
The polymorphs of a particular compound can be either enantiotropically or monotropically 
related to each other, these two phenomenon are shown in Figure 2.4. In enantiotropic system a 
particular polymorph is stable below a certain temperature, while the other is metastable, it 
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should be noted that transformations in enantiotropic systems are reversible. Both kinetic and 
thermodynamic factors determine the interconversion rates of different polymorphs. In terms of 
nucleation of a polymorphic form, Ostwald’s rule of stages states that the metastable form will 
nucleate first and will subsequently convert to the most stable form (Ostwald, 1897). In 
monotropic systems there is no crossover of the solubility curves and therefore only one form is 
stable, while the other forms are metastable. Enantiotropic systems require a careful selection of 
processing conditions under which a particular polymorph can be obtained, in contrast obtaining 
a stable polymorph is monotropic systems is generally easier (Mangin et al., 2009). 
 
 
Figure 2.4 Phase diagram showing enantiotropic and monotropic polymorphic systems 
 
Factors that can lead to the formation of a particular polymorph during crystallization include 
temperature, supersaturation, solvent, heating/cooling rates and hydrodynamics. When a change 
occurs in the polymorphic form in the presence of a solvent, this is termed as a solvent mediated 
transformation. Seeding can be used as a way to produce the desired polymorph as long as the 
crystals do not undergo a solvent mediated transformation. This requires knowledge of the 
MSZW and temperature dependency of the stability of different polymorphic forms. 
Characterization and screening of polymorphs, solvates, hydrates and amorphous forms is carried 
out by using various techniques, including, x-ray diffraction, powder x-ray diffraction, raman 
spectroscopy (Hu et al., 2005; Hausman et al., 2005), DSC, microscopy and others.  
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2.4 Crystal Size Distribution 
 
During drug production several steps are involved after crystallization before the final product is 
obtained. The performance of all these processes therefore strongly depends on the quality of the 
crystalline product. Poor CSD can be characterized by the presence of excessive fines, a very 
broad or narrow distribution and unacceptable average crystal size. Table 2.2 summarises the 
effects of the CSD on different downstream processes (Wibowo et al., 2001). The presence of 
fines can result in longer filtration times and can also clog the filtration medium. Similarly 
smaller average size can extend the washing and drying duration. Solvent inclusion is another 
problem which can be caused by the presence of excessive fines, and can affect the quality of the 
product. A suitable crystallization control approach therefore must be able to address these 
issues. 
 
Table 2.2 Effect of CSD on downstream processing 
 
Downstream Processes 
Too much 
fines 
CSD too  
wide  
 
CSD too  
narrow  
 
Avg. size too 
small 
Filtration 
Higher solvent requirement, large filter area, 
clogging 
 
X 
 
X 
  
X 
Washing 
Higher solvent requirement, longer washing time 
  
X 
  
X 
Deliquoring  
Longer time or larger than what is available, high 
residual liquid in cake 
 
X 
 
X 
 
 
X 
 
X 
 
Drying 
Longer drying time and high energy consumption, 
dust 
 
X 
 
X 
 
X 
 
 
X 
Compaction 
Low agglomeration strength 
   
X 
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2.5 Control of Crystallization Processes 
 
Crystallization is predominantly used as a batch process in the pharmaceutical industry as very 
large quantities of active pharmaceutical ingredients (API) are seldom required. Furthermore 
same crystallizers are used for crystallization of different compounds. Since these compounds 
may require significantly different control recipes, batch operation offers the flexibility to 
implement different operating policies with relative ease. Therefore in the following section 
commonly used crystallization methods will be discussed along with their advantages and 
disadvantages, with main emphasis on batch processes. 
 
2.5.1 Cooling Crystallization 
 
Cooling is the most widely used method to generate supersaturation in crystallization processes, 
it can be used for both seeded and unseeded systems. Typically, cooling crystallization is 
employed for systems which show an increase in solubility as the temperature increases and are 
not prone to thermal degradation. Another advantage of this approach is that it is not limited by 
the volume of the vessel, which could potentially be a limiting factor for anti-solvent 
crystallization. Cooling crystallization is used both for external seed addition and in situ seed 
generation. It should be noted that seeding is a popular method for obtaining desired crystal size 
distribution and polymorphic forms. Depending on the requirements the seed amounts can be 
adjusted. The effect of the various seed amounts is summarized as follows (Tung et al., 2009): 
 
 A very small amount can be helpful in elimination of oiling out and crashing out of the 
solution. 
 
 Less than 1% can give some control over nucleation, the system is prone to secondary 
nucleation events and bi-modal distribution in the final product can be expected. 
 
 5-10% of seeds can suppress secondary nucleation events and improve CSD. 
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 Large amounts of seed crystals are typically used in continuous or semi batch operations, 
to increase production yield. 
 
Seeded cooling crystallization is also termed as controlled crystallization as the presence of seeds 
prevents the system from going into the labile zone.  Several cooling profiles have been purposed 
for obtaining product with desired qualities, some of these are: 
Natural cooling  
 
In natural cooling (Figure 2.5) the system is cooled rapidly in the beginning resulting in high 
amounts of supersaturation causing significant nucleation event(s) (Jones and Mullin, 1974). The 
crystalline product obtained consists of large amounts of fines often leading to bi-modal 
distribution. Other issues with the product may include dendritic growth and occlusions of 
solvent or impunities in the crystals (Mullin, 2001). 
 
Figure 2.5 Different Cooling Profiles 
        
Linear Cooling 
 
In linear cooling a constant cooling rate is adopted, as shown in Figure 2.5, this profile eliminates 
the higher supersaturation levels generated in the case of natural cooling and can lead to 
improved CSD (Jones, 1974). The main attraction for using linear cooling profile is that it can be 
implemented easily especially on larger scale. However, it does require the existence of suitable 
temperature control systems, as opposed  to the natural cooling operation, which can be achieved 
without temperature control 
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Programmed Cooling 
 
The aim of programmed cooling profile is to ensure that the supersaturation always matches the 
available crystal surface area on which the crystal mass forms. This means that initially when the 
surface area of the crystals existing in the solution is small, the rate of supersaturation production 
has to be slow and therefore low cooling rates are used to prevent nucleation. If the initially 
generated large amount of supersaturation can be controlled, then an improved CSD can be 
obtained. This can be achieved by introduction of seeds in the system and then maintaining the 
operating curve within the metastable zone (Mullin, 2003). A simple correlation for determining 
an approximation of the optimal cooling curve is given by Mullin (2003) as follows: 
 
 
3








t
TTTT foot  (2.10) 
 
where
oT , fT  and tT  are the temperatures at the beginning, end and at any time t  during the 
process, and   is the overall batch time.  
 
2.5.2 Anti-solvent Crystallization 
 
Anti-solvent crystallization is another way of attaining supersaturation. Anti-solvent processes 
have been widely used to crystallize pharmaceuticals, because the technique eliminates the use of 
thermal energy that may degrade the biological activity of actual pharmaceutical ingredients 
(Guo et al., 2005). In anti-solvent crystallization, supersaturation is created by mixing a third 
component with the saturated solution, to reduce the solubility of the solute. It normally takes 
place at or near ambient temperatures and is effective in crystallization of thermally degradable 
substances (Yu et al. 2006 a; b), further the compounds which show little change in their 
solubility at different temperatures are also crystallized by addition of appropriate anti-solvent. 
 
Anti-solvent crystallization is usually performed in a semi-batch manner, whereby anti-solvent is 
pumped into the crystallizer at a constant or varying flow rates. It has been found that a 
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predetermined time-varying flow rate can yield a better particle size distribution (PSD) by 
matching the generation rate of supersaturation with the growing crystal (Mullin, 2001). The 
derivation of such a flow-rate profile requires prior knowledge of the exact crystallization 
kinetics, which is difficult and time consuming to obtain for industrial conditions. Furthermore, 
operating conditions such as seed size  distribution, seeding timing, impurity content, mixing and 
starting solute concentration often change from batch to batch and are difficult to be tracked 
precisely, which will render the predetermined profile not optimal anymore. 
 
The composition of solvents (and also anti-solvents) is known to influence the crystallization 
behaviour of polymorphs. For example, the relative nucleation, growth rates and transformation 
rates of the polymorphs of L-histidine are known to be influenced by the composition of the 
solvent (i.e. mixture of water and ethanol) (Kitamura and Sugimoto, 2003). 
 
2.5.3 Combined cooling and anti-solvent crystallization 
 
Nagy et al., (2008) have compared the combined cooling and anti-solvent crystallization 
technique using lovastatin as the model system. Optimal profiles for cooling, anti-solvent and 
combined system for both seeded and non-seeded systems were implemented, and compared 
crystal quality. The results obtained showed that a combination of both cooling and anti-solvent 
crystallization gave better results, producing more uniform crystal size distribution with larger 
mean size as compared to the individual approaches. Lindenberg et al. (2009) showed that the 
combined approach gave superior results for acetylsalicylic acid compared to the conventional 
approaches. 
 
Combined cooling and anti-solvent crystallization processes are often used in the pharmaceutical 
industries. For example anti solvent can be added at the beginning of the batch to induce 
nucleation, or at the end to increase yield. However optimal design of the simultaneous cooling 
and anti-solvent addition policies require more sophisticated model based design approaches. 
 
Chapter 2 Literature Review 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  25 
 
The heuristic choice of temperature or anti-solvent addition profiles based on the conditions 
described in the previous sections is the most common approach applied in the pharmaceutical 
industries because of ease of implementation. There is a growing interest now to switch to more 
sophisticated control methodologies to consistently obtain products of desired quality. These 
methodologies can be classified as model-based and model-free (direct design) approaches and 
will be described in the next section. 
 
2.6 Model-based Approaches 
 
Model based approaches for crystallization have gained popularity in the last decade. One of the 
main reasons has been to shift the research paradigm from an art towards a better understood 
scientific process. Other factors include availability of in situ sensors for measuring 
concentration and CSD such as ATR-FTIR, FBRM etc. The model-based approaches for 
controlling and optimizing a crystallization process, typically consider a certain property of the 
CSD, such as mean crystal size, as coefficient of variation. Material and energy balance 
equations are then used to obtain the best operating conditions that optimize the selected 
property. (Fujiwara et al., 2005; Aamir et al., 2010, Braatz and Hasebe, 2002; Ma et al., 2002; 
Nagy and Braatz, 2004; Shi et al., 2006, Braatz, 2002). For the material balance, population 
balance equations are used, in which nucleation and growth kinetics are included along with 
certain assumptions to simplify the model development. Generally, agglomeration or dendritic 
growth are neglected and change in shape is considered. Furthermore lumped models are 
preferred over distributed parameter models because of simplicity and computational efficiency. 
Since crystallization is inherently non-linear process therefore non-linear control approaches are 
used with dynamic optimization methods. 
 
Continuous efforts have been made to develop more efficient models e.g. two dimensional 
growth was included in the model for potassium dihydrogen phosphate system by Ma et al. 
(2002), agglomeration which frequently occurs in crystallization was included by Costa et al. 
(2005). Sarkar et al. (2006) used multi-objective optimization for obtaining narrow CSD, 
Worlitschek and Mazzotti (2004) developed a model for paracetamol/ethanol system that 
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included thermodynamics, crystal growth and secondary nucleation for obtaining desired 
monomodal CSD. Aamir et al. (2010) demonstrated how the prediction capability of a model can 
be affected by certain parameters for potassium dichromate and water system. In their work the 
predicted CSD matched with the measured CSD when crystalline seeds were used, however the  
model was unable to predict accurately the shape of experimental CSD when very fine particles 
were used as seeds. The use of fine particles caused significant agglomeration and different 
growth dispersion rates. These phenomena were not included in the model causing the significant 
deviations between predicted and measured CSDs. This demonstrates that for accurate and 
prediction all the relevant parameters must be included in the model. The accuracy of the model 
can greatly facilitate the control of a crystallization process to obtain a CSD with desired 
properties. Schematic working of the model based approach is shown in Figure 2.6. 
 
 
Figure 2.6 Schematic representation of first principle approach (adapted from Nagy et al., 2008) 
 
2.7 Model-free (direct design) Approaches 
 
One of the main objectives in crystallization is to obtain crystals of desired size distribution. For 
this generally the operating curve is kept within the metastable limit. Any crystallization process 
operating very close to the metastable limit has a higher tendency for secondary nucleation 
Model selection
Optimization using selected 
model
Implementation of the profile
In time domain
MSZW and solubility data
Required 
performance 
achieved ?
Experimental Design
No
Desired Profile
Yes
Nominal optimal profile
Chapter 2 Literature Review 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  27 
 
resulting in undesired CSD, on the other hand any operating curve very close to the solubility 
curve will avoid secondary nucleation, but will lead to slow growth and longer batch times, 
which can yield economic losses.  The selection of an operating curve is mostly done by trial and 
error, trying to find a suitable compromise between these two effects, this approach is not only 
time consuming but can lead to batch to batch variability and poor control of the process. 
 
The use of PAT has enabled the development and implementation of much more efficient and 
robust control approaches. These control strategies, which are termed as model-free or direct 
design, use feedback control based on information from in situ sensors (Zhou et al., 2007). The 
system typically follows an adjustable supersaturation setpoint within the metastable zone. 
Unlike the model-based approach where a certain objective function is optimized, the main aim 
in this methodology is to avoid secondary nucleation and maximize crystal growth. A significant 
advantage of these approaches is that no information about process kinetics is required. This is a 
major advantage of this approach as multiple phenomena take place during crystallization, for 
which the parameters estimation and modelling can be very difficult.  
 
The direct design approach is sometimes termed as concentration control or supersaturation 
control. Supersaturation is not directly measured and therefore is determined through 
concentration measurements using spectroscopic tools such as ATR-FTIR, ATR-UV/Vis 
spectroscopy, and from the known solubility data for the system. A schematic representation of 
the direct design approach is shown in Figure 2.7. 
 
 
Figure 2.7 Schematic representation of direct design approach (adapted from Nagy et al., 2008) 
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The direct design approach has been successfully used for enhancing the crystalline product 
quality in many applications. Zhou et al. (2006) used this approach based on ATR-FTIR for anti-
solvent crystallization of a proprietary pharmaceutical compound. They demonstrated that the 
approach provides rapid determination of an optimal recipe for suppressing secondary nucleation 
and enhancing crystal growth. Liotta and Sabesan (2004) reported significant improvement in 
crystal size when supersaturation control was applied for cooling crystallization of a drug 
compound. Kee et al. (2009) showed how the direct design approach can be used for production 
of the α-form of L-glutamic acid, by using ATR-FTIR based supersaturation control. 
 
2.8 Process Analytical Technology and Chemometrics 
 
Process analytical technology (PAT) has gained popularity and momentum in the pharmaceutical 
industry in the past five to ten years. The main reasons that led to this was the initiative by the 
FDA which promoted to use modern sensor technologies and monitoring and control concepts to 
achieve reduction in process time and cost, decrease variability, improve product quality and 
minimize batch failures (Yu et al., 2004). This guidance was initially launched by the FDA in 
2004 and was further emphasized by the International Conference on Harmonization (ICH) (E. 
Ref 2) in 2008. The later commented on PAT as an “opportunity to develop more flexible 
regulatory approaches”. PAT comprises of the tools shown in Figure 2.8. 
 
 
 
Figure 2.8 Classification of different tools used under PAT  
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The main benefit of PAT is the ability to monitor and control the system in real time resulting in 
a better overall control and improved product quality. The quality control in this case is in-
process, which was previously carried out in the laboratory on the final product.  
 
In view of the use of PAT, the concept and practice of QBD was introduced by ICH (ICH Q8, 
2005), the generally accepted definition of QBD is that, “quality should not be tested into a 
product, it should be by design”. This practice is a shift from the conventional QBT approach in 
the pharmaceutical industry. PAT is the most feasible way for the application of QBD concepts 
and can be considered as integral part of each other. For QBD, a design space with multiple 
variables is initially outlined encompassing raw materials and the process leading to a required 
product quality. This offers flexibility of applying changes to the manufacturing process within 
the design space if required by regulatory procedures. The protocol developed based on this 
design space and regulations becomes part of the marketing plan for the product being 
developed. The design space is initially developed on the laboratory scale and later applied on the 
pilot and industrial scale, whilst controlling the process in the same boundaries. This is often 
referred to as QBD Control Strategy. The role of PAT in the context of QBD is clear as the 
defined variables are mostly controlled and monitored by PAT approaches. Design of 
experiments and development of control strategies further enhances the effectiveness of QBD 
approach (Yu et al., 2004).  
 
PAT provides valuable information about different processes at various stages of the drug 
development. This includes measurement of solubility and MSZW, supersaturation and 
concentration measurement, monitoring and formation of polymorphic forms, hydrates, solvates, 
and CSD monitoring and enhancement, as well as crystallization process scale up. A division of 
PAT tools based on their market share (E. Ref 3- Strategic Directions International (SDI)) along 
with other instrumentation is shown in Figure 2.9. 
 
These statistics show that the field of PAT is dominated by spectroscopy followed by 
electrochemistry tools (e.g. pH measurement etc). According to market research (E. Ref 3) PAT 
used in pharmaceutical industry was worth nearly $150 million in 2005, this has grown to nearly 
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$195 million in 2010 and it is expected to be nearly $279 million worth in 2015 with an expected 
growth rate of 7.4% ,  (E. Ref 4 - Business Cooperation Company (BCC)). 
 
Note that a significant part of the market share is attributed to the dedicated software systems, 
indicating that the successful application of PAT requires both hardware and suitable software 
tools. 
 
 
Figure 2.9 Classification of different process tools based on market share 
 
In the following section working, advantages and disadvantages of the most common PAT tools 
will be presented. 
 
2.9 ATR-UV/Vis Spectroscopy 
 
UV/Vis spectroscopy for in situ analysis is a relatively new technique.  Its more conventional 
applications were limited to colour and concentration measurements through filter photometers. 
The availability of UV resistant optical fibres, cheap diode array detectors and chemometrics has 
facilitated its inline/online applications in many fields. The application of UV/Vis spectroscopy 
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is limited as most of the compounds or functional groups are transparent in the UV/Vis 
spectroscopy range i.e. 190 nm to 800 nm (Bakeev, 2010). 
 
The absorbance of energy in the UV/Vis region of the electromagnetic spectrum causes 
transitions between electronic energy levels. This energy causes the electrons to shift from an 
occupied orbital to an unoccupied orbital of higher potential energy. The shifting of electrons 
normally takes place from highest occupied molecular orbital (HOMO) to lowest unoccupied 
molecular orbital (LUMO). The arrangement of these energy levels is shown in Figure 2.10.  
 
 
Figure 2.10 Electronic energy levels and possible electron transitions (adapted from Pavia et al., 2009) 
 
As shown in Figure 2.10 σ orbitals have the lowest energy, π orbitals are at higher energy level 
and n orbitals are at even higher energy levels. The anti-bonding orbitals π* and σ* have the 
highest energy and the amount of energy involved in n to π* transfer is less than for the π to π* 
transfer (Pavia et al., 2009). 
 
Although the shifting of electrons play a vital role in the creation of a UV/Vis spectrum, the 
presence of chromophores and conjugation is very important. In a bond, the nuclei that hold the 
electrons together influences the wavelengths at which the light is absorbed, as the former affects 
the excited and ground states for electrons. Such groups of atoms are called chromophores. 
Normally σ to σ* transitions are observed in the case of alkanes. Sulphur compounds undergo n 
to π* transitions. Alkenes and alkynes show π to π* transitions, while carbonyl compounds 
mostly undergo n to π* changes. The presence of conjugation and hence delocalization of 
electrons brings the energy levels in chromophores closer to each other and therefore less energy 
is required to cause an electronic shift. The radiation is thus absorbed at longer wavelengths. This 
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delocalization effect can be observed in case of phenolphthalein, which changes its colour in an 
alkaline medium. The alkaline form (magenta in colour) shows a peak at 553 nm, the peak at this 
longer wavelength is the result of extended delocalization covering the whole molecule.  
 
Absorbance is correlated with the concentration of a compound according to the Beer-Lambert’s 
Law: 
 
       
  
 
      (2.11) 
 
where   is the absorbance,    is the incident light intensity,   is intensity of light leaving,   is the 
molar concentration of the solute,   is the path length (cm) and   is the molar absorptivity. 
 
Based on this law absorbance is linearly dependent on concentration, provided that molar 
absorptivity and path length remain constant. However, absorbance also depends on the 
temperature. The presence of more than one absorbing species, interaction between solute and 
solvent can also cause deviations from this law. 
 
The instrumentation used for UV/Vis can be classified into the following four types (Cazes, 
2005): 
 
 Scanning instruments 
 Diode-array instruments 
 Photometers 
 Fibre-optic diode array and CCD instruments 
 
The former two are more suitable for offline measurements, whereas the latter two are suitable 
for online/in situ analysis.  
 
Photodiode array (PDA) spectrometers coupled with fibre optics are the best option for online or 
in-situ measurements. Sample interface is provided by an ATR probe. The advent of the non-
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solarising fibre optics has made it possible to have the spectrometer away from the process, and 
the light is carried through the fibre optics. The working of the ATR probe is described next. 
 
The ATR probe is based on the difference in refractive indices of the ATR crystal and that of the 
solution. An evanescent wave propagates (Figure 2.11) through the optically rare medium 
(solution) when it comes in contact with an optically dense medium (the crystal). Inside the 
crystal the light goes through internal reflection. The penetration depth of this evanescent wave is 
only a few microns, as a result of this the signal obtained has minimum disruption from the 
particles or the bubbles present in the solution. The penetration depth can be calculated from the 
following equation: 
 
   
 
            
  
  
 
 
 
    (2.12) 
 
where    is the penetration depth,   is the wavelength (nm),   is the angle of incidence of the 
propagating wave,    is the refractive index of the ATR crystal, and    is the refractive index of 
the solution. 
 
 
Figure 2.11 Working of ATR probe 
 
The path length mentioned in Beer Lambert’s law,  , is a function of the penetration depth (dp) 
and the number of reflections     in the ATR crystal,       (Billot et al., 2010). The number of 
internal reflections can affect the absorbance significantly. It was shown that an ATR crystal with 
3 internal reflections resulted in absorbance values greater by a factor of 4.48 compared to the 
crystal with one reflection (E. Ref 5). Refractive indices of commonly used materials for ATR 
crystal are shown in Table 2.3: 
Io
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Whilst ATR probes are commonly used in conjunction with FTIR spectroscopy, very few studies 
are available that demonstrate the use of ATR-UV/Vis spectroscopy in crystallization. Anderson 
et al., (2001) for the first time reported the use of ATR-UV/Vis spectroscopy for monitoring the 
crystallization of sulfathiazole. Thompson et al., (2005) used ATR-UV/Vis spectroscopy for in 
situ concentration measurements of a drug candidate and developed calibration model using 
partial least squares regression (PLSR). Recently Abu Bakar et al., (2009) used ATR-UV/Vis 
spectroscopy for monitoring the seeded cooling crystallization of sulfathiazole. They developed a 
simple non-linear calibration model, which included a single absorbance, temperature and 
temperature-absorbance interaction term. Billot et al., (2010) gave an overview of this technique 
using several compounds. 
 
Table 2.3 Refractive indices of different ATR materials 
Material Refractive index at 20°C 
Sapphire 1.65-1.73 
Silicon 3.4-3.5 
Germanium 3.9-4.1 
Zinc Selenide 2.3-2.5 
Zinc Sulphide 2.0-2.3 
AMTIR (Ge33As12Se55) 2.5-2.6 
Diamond 2.4 
 
2.10 ATR-Fourier Transform Infrared Spectroscopy (ATR-FTIR) 
 
ATR- Fourier transform infrared spectroscopy (FTIR) is a form of vibrational spectroscopy and 
perhaps one of the most widely used techniques in pharmaceutical crystallization (Togkalidou et 
al., 2001; 2002) . The IR region covers the spectral range from 4000 cm
-1
 to 400 cm
-1
 (2.5 µm to 
25 µm) and is bounded by near infrared and far infrared regions. An IR spectrum is usually 
expressed as transmittance versus the wavenumber. A major advantage of using IR is the 
structure determination of the molecules as the spectrum generated is a fingerprint of a particular 
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molecule. The IR energy corresponds to the energy related to bond vibrations e.g. bond 
stretching, bending etc. The frequencies at which IR energy is absorbed is a characteristic of a 
molecule, this fact can be used to identify a compound and hence the term fingerprint is used. IR 
absorptivities occur in CH, OH and NH groups, either of these exist in any organic molecule and 
therefore IR is extensively used in pharmaceutical crystallization.  
 
The availability of IR spectrometers with ATR probe have enabled real time monitoring and 
control of crystallization, some of the applications include determination of metastable zone 
width, concentration measurement (Wang and Berglund, 2000), supersaturation control, 
detection of impurities etc. These applications are listed in Appendix A. 
 
2.11 Near Infrared Spectroscopy (NIR) 
 
Near infrared (NIR) spectroscopy is another form of vibrational spectroscopy along with Raman 
and IR. NIR covers the 4000 cm
-1
 to 12500 cm
-1
 range in the electromagnetic spectrum. NIR 
detects overtones and combinations arising from X-H bond vibrations. The intensity of the NIR 
bands is weaker than the corresponding fundamental bands, as a result of this no sample dilution 
is required. Another advantage of this approach is that it allows the measurement of thick 
samples. The penetration depth of NIR beam is up to a few millimeters, this is particularly 
helpful in analysis of bigger sample volumes such as raw materials etc. Applications of NIR are 
listed in Appendix A. 
 
2.12 Raman Spectroscopy 
 
Raman spectroscopy belongs to the vibrational spectroscopy family along with IR and NIR. The 
approximate spectral range of Raman spectroscopy is between 50-4000 cm
-1
. When 
monochromatic light is incident on a material, the majority of the light or photons undergo 
Rayleigh scattering, i.e. there is no change in the energy or frequency of photons. A very small 
quantity of photons (0.0001%) however, undergoes Stokes and anti-Stokes scattering. When the 
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energy of the photon is absorbed by the molecule, it is termed as Stokes scattering resulting in 
red-shifted scattered light. An electron in the ground state is excited and lifted to a higher 
vibrational energy level. In case of anti-Stokes scattering, molecules give energy to the photon, 
resulting in blue shifted light, with a shorter wavelength and higher energy. An electron in the 
ground state is lifted to a higher level through a virtual state and ends up at a low vibration 
energy level. Raman spectrum is due to a change in the polarizability of the molecule. The 
qualitative aspect of Raman spectroscopy lies in the fact that change in the wavelength of 
scattered light is dependent upon the vibrational energy levels of the molecules. This fact is used 
to identify the state and nature of bonds present in a molecule. 
 
Both IR and Raman are based on the vibrational energy levels of a molecule. The difference 
between the two is that IR measures the loss of intensity of light between incident, absorbed and 
scattered light, while Raman instruments measure the amount of photons emitted as a function of 
their wavelength. Most of the pharmaceutical compounds show clear and well resolved bands, 
Raman spectroscopy is therefore a very powerful tool for qualitative and quantitative analysis 
and can be used at different stages during the drug production. 
 
In a multiphase mixture of solids and liquids many properties can be monitored and controlled 
through Raman spectroscopy. Since Raman spectroscopy is based on vibrational energy changes, 
it can distinguish almost all the crystal forms. This property is extremely useful for characterizing 
different forms of a pharmaceutical compounds, such as polymorphic forms, hydrates and 
solvates. 
 
Raman spectroscopy is a nondestructive technique and requires very small amounts of sample, 
especially for pharmaceutical compounds, which are prepared in small amounts during the early 
stages of development. It does not require special sample preparation, which is another 
advantage, since some compounds can undergo changes during sample preparation, required for  
using other techniques (Vergote et al., 2004). 
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2.13 Focused Beam Reflectance Measurement (FBRM) 
 
FBRM is an extensively used in situ technique that gives information about nucleation, 
dissolution, metastable zone width, polymorphic transformation, growth and size distribution in 
particulate systems in real time (Barthe and Rousseu, 2006, Doki et al., 2004, Barrett and 
Glennon, 2002; Barthe et al., 2008; Sheikhzadeh et al., 2008a; Sheikhzadeh et al., 2008b; 
Howard et al., 2009; Abu Bakar et al., 2009).  
 
The probe is directly inserted in a crystallizer and provides in situ information about the system. 
A laser is used to scan a certain region. The beam is highly focused and is projected through the 
sapphire window of the probe. This beam rotates at a speed of 2-6 m/s (Pons et al, 2006) and 
scans the particles on which it is being focused. The beam after hitting the particles is back 
scattered and received by an optical receiver. The focused beam crosses the particles on a straight 
line between any two points on the edge of the particle as shown in Figure 2.12. Based on the 
rotating speed of the laser (    and back scattering time (    , the chord length distribution 
(CLD) for the particles is obtained using the following equation. 
 
                   (2.13) 
 
 
 
 
Figure 2.12 Chord length measurement by FBRM 
 
The chord length distribution (CLD) measured by the FBRM can be related to different 
phenomena, such as nucleation, growth, agglomeration and attrition (Yu et al., 2007). The CLD 
obtained from FBRM is grouped in 90 channels from 0.8 – 1000 µm.  The readings obtained 
from FBRM can be displayed in a variety of formats from simple total number of counts per 
second to square weighted or cubic weighted distributions.  
vs
Δt
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Three of the most important statistics used by FBRM are the cubic weighted (CWMCL), square 
weighted (SWMCL) and length weighted (LWMCL) mean chord lengths:  
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where 
i
n ,is the counts in an individual measurement channel, and Mi, is the midpoint of an 
individual channel. 
 
FBRM can be used for measurement of solubility, nucleation detection and MSZW 
determination (Barett et al., 2002), controlling CSD (Doki et al., 2004), monitoring of crystal 
growth and nucleation (Barrett et al., 2005) and detection of agglomeration in crystals (Loan et 
al., 2002). FBRM does not require any sampling or isolation of samples and thus prevents any 
changes in crystal size or distribution because of breakage or agglomeration (Kougoulos et al., 
2005; Barrett et al., 2005), FBRM also enables the use of a robust crystallization process control 
approach without any prior knowledge of the kinetics of a particular system (Woo et al., 2009; 
Abu Baker et al., 2009). 
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The conversion of chord length distribution (CLD) to CSD is difficult due to the large number of 
variables involved (Braatz, 2002), especially for dense crystal slurries (Monnier et al., 1996; 
Monnier et al.,1997). Numerous studies have been carried out in an attempt to carry out this 
conversion (Worlitschek et al., 2005; Li and Wilkinson, 2005; Tadayyon and Rohani, 1998; Ruf 
et al., 2000). The main limitation in these approaches, is that they require an assumption about a 
fixed particle shape, which in most cases is assumed to be spherical unlike the shape of most 
crystals, therefore it is critical to use the right geometry of the crystals as shown by Ruf et al., 
(2000). 
 
FBRM can oversize small particles less than 150 µm (Law et al., 1997) undersize particles 
greater than 300 µm and over size particles greater than 500 µm (Heath et al., 2002). Deposition 
of particles on the FBRM probe window can also give false readings. 
 
FBRM has mostly been used as a monitoring tool along with other in situ tools. Very limited 
research is available in which FBRM has been used to control the process. The control studies 
along with application of FBRM are outlined in Table 2.4. Appendix A contains a more 
extensive review of FBRM applications for various purposes. 
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Table 2.4 Various applications of FBRM 
Process Control 
Reference System Investigated Application Area Other Tools used in  
the study 
Doki et al., (2004) Cooling crystallization of 
glycine in water 
Production of stable 
polymorph size and 
monitoring 
ATR-FTIR 
Chew et al., 2007(b) Cooling crystallization of 
glycine in water 
Improving CSD by 
applying feedback control 
using FBRM 
ATR-FTIR 
Abu Baker et al., 2009 Cooling and anti-solvent 
crystallization of glycine, 
ethanol as anti-solvent 
Improving CSD by 
applying feedback control 
using FBRM 
 
Woo et al., 2009 Cooling crystallization of 
paracetamol in water 
Combination of 
concentration control with 
FBRM 
ATR-FTIR 
 
Hojjati et al., 2006 Anti-solvent crystallization 
of paracetamol in IPA with 
water as anti-solvent 
Enhancement of CSD ATR-FTIR 
Chew et al., 2007(a) Cooling crystallization of 
glycine in water 
Improving CSD by 
applying feedback control 
using FBRM 
 
Hermanto et al., 2010 Anti-solvent crystallization 
of glycine in water with 
ethanol as anti-solvent 
Applied feedback control 
using FBRM for better 
CSD 
 
 
The in situ techniques mentioned so far provide information about the liquid and solid phase. 
However, these tools are often accompanied by various offline analysis techniques for a thorough 
assessment and characterization of crystalline product (Howard et al., 2009). Some of the 
techniques used and their applications are summarized in Table 2.5. 
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Table 2.5 Summary of various offline and inline techniques used in crystallization 
Technique Description and Application 
Optical microscopy Size analysis, characterization of polymorphic forms 
based on different shapes and colour. 
Hot stage microscopy The technique can reveal any changes that may appear 
in crystals because of thermal events e.g. conversion 
of polymorphic form. 
Scanning electron microscopy Provides images of crystals, can be used to detect any 
defects in the crystals 
Differential Scanning Calorimetry (DSC) Very commonly used technique especially for 
polymorphic characterization and determination of 
polymorphic transformation temperatures. A melting 
or crystallization event appears as peaks on curve. 
Solvate and hydrate detection can also be carried out. 
Thermogravimetry Characterization of solvates and hydrates is carried 
out by using this method.  
X-ray diffraction (XRD) Determines crystal structure and useful in 
characterization of polymorphic forms. 
Nuclear magnetic resonance (NMR) A complex technique used for determining structure 
of compounds. 
 
Some of the other useful techniques which are used for monitoring crystallization processes are 
briefly described as follows: 
 
Particle vision and measurement (PVM), gives real time information about changes in crystal 
shape and morphology, and often used as a complementary technique alongside FBRM and 
spectroscopic tools. Bulk video imaging (BVI) is a cheap but useful alternative to PVM, 
combined with image analysis it can provide useful information about crystallization such as 
MSZW, solubility etc. Turbidimetry is another monitoring tool, it measures the changes in 
optical properties of the solution and can be used for detection of nucleation or dissolution during 
crystallization processes. 
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2.14 Chemometrics 
 
PAT is fast becoming an integral part of the drug development process. Many in situ sensors are 
used at various drug development stages. These sensors produce large amounts of data and quite 
often several sensors are used simultaneously, which increases the process related data 
manifolds. In order to extract maximum information from these data, multivariate statistical data 
analysis and mathematical tools are used. These tools are termed “Chemometrics” (Yu et al., 
2004). Chemometrics combined with PAT provides useful information about the system, Figure 
2.13. The information provided can be used for modelling, monitoring and controlling the 
process, which helps in obtaining products of required quality, which may include a particular 
size distribution, manufacturing of a particular polymorphic form or others etc.  
     
Figure 2.13 Benefits of using PAT and chemometrics 
 
Some of the key features of chemometrics are as follows (Geldai, 2003): 
 Experimental design 
 Acquisition and enhancement of data 
 Feature selection and extraction 
 Pattern recognition  
 Calibration and regression analysis 
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Spectroscopy is widely used in crystallization in conjunction with chemometrics for monitoring 
and controlling of this separation process. Aaltonen et al. (2003) did rapid screening of 
sulfathiazole polymorphs using NIR spectroscopy and PCA. Falcon and Berglund (2004) showed 
that PCA was very helpful in monitoring of the anti-solvent crystallization of progesterone using 
in situ Raman spectroscopy. Caillet et al. (2006) used Raman spectroscopy for monitoring the 
phase transition of citric acid in water from anhydrous to monohydrate form, PLSR was used for 
development of the calibration models. The robustness of the equipment was checked after 20 
months based on the calibration model and no drift was observed. Starbuck et al., (2002) used 
PCA and Raman spectroscopy for process optimization and polymorphic characterization of a 
complex pharmaceutical system. Pollanen et al. (2005), characterized different polymorphic 
forms of sulfathiazole using diffuse reflectance Fourier transform–infra-red (DRIFT) 
spectroscopy, while ATR-FTIR was used for concentration measurements. Multi-variate 
statistical process control (MSPC) and PCA were used for quality evaluation of crystals from 
DRIFT spectra. The results obtained from DRIFT spectra and X-ray powder diffraction (XRPD) 
was subjected to PLS analysis. These analyses confirmed the quantification made by XRPD and 
provided a complimentary method for polymorph characterization. Chen et al. (2009) proposed 
an extended loading space standardization method for monitoring the concentration of 
monosodium glutamate and L-glutamic acid during cooling crystallization using ATR-FTIR. A 
comparison was made between PLS based model and shown that the proposed technique can 
handle nonlinear data much better than PLS model. A simpler but non linear calibration model 
was used with ATR-UV/Vis spectroscopy for monitoring and concentration measurement in 
sulfathiazole crystallization (Abu Bakar et al., 2009). Aamir et al. (2010) used a similar model 
for concentration determination of potassium dichromate by ATR-UV/Vis spectroscopy during 
cooling crystallization. Thurston et al. (2003) used ATR-UV/Vis spectroscopy for reaction 
monitoring of phenylhydrazine and benzophenone along with crystallization. PCA plots were 
used to monitor the different stages of the reaction and interpretation of spectral data. Borissova 
et al. (2009) used ATR-FTIR for determining concentration of L-glutamic acid using advanced 
chemometric techniques. In the following section some of the commonly used chemometric 
techniques will be discussed. 
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2.15  Calibration Model Development Techniques 
 
Calibration refers to the development of a relationship between a set of variables such as spectra 
to some property(s) of interest e.g. concentration. Several methods are available for development 
of calibration models; the simplest one is a uni-variate method in which the concentration of a 
single compound is measured using a single variable e.g. absorbance at a particular wavelength. 
Multivariate methods are used when a number of variables are used to predict the 
concentration(s). In the following section all these methods will be briefly discussed along with 
their advantages and disadvantages.  
 
Assuming that a linear relationship exists between spectral measurements (variables from here 
onwards will refer to spectral measurements) and concentration (independent variable or 
parameter of interest), there are two ways to predict concentration   from the spectral 
measurements   by least squares. The first method assumes absorbance as a function of 
concentration, this method is closer to the Beer-Lambert’s law and therefore called as direct 
method. The second method assumes concentration as a function of absorbance and called as the 
inverse method. This method is preferred because the objective is to predict concentration from 
the data not the vice versa. Multivariate methods such as PCR and PLSR, all are based on the 
inverse method. A classification of calibration development methods is shown in Figure 2.14. 
The discussion in this case will be limited to inverse methods and ANN. 
 
Figure 2.14 Classification of calibration model development methods (adapted from Bakeev, 2010) 
 
Calibration Model Development Methods
Direct Method
Classical least 
squares
Extended 
mixture 
model
Inverse Method
MLR PCR PLSR
Searching and 
learning methods
ANN
Support 
vector 
machines
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2.15.1 Univariate Calibration 
 
Univariate calibration model is developed using only one response variable, e.g. in the case of 
concentration determination using a spectroscopic tool the employment of absorbance at a single 
wavelength. In univariate calibration it is assumed that no interferences are present that might 
affect the response variable, furthermore this is normally carried out at a constant temperature. 
The general form of the model in mathematical terms can be represented as (Bakeev, 2010; 
Gamperline, 2006; Brereton, 2003); 
 
              (2.17) 
 
where    are the concentration values in experiments  , (         with   being the number of 
experiments), corresponding to the absorbance (or derivative)   . If the experimental data are 
pre-processed (e.g. via mean centring), the intercept (free) term (  ) can be neglected from the 
calibration equation:  
           (2.18) 
 
In vector  notation the above equation can be represented as: 
        (2.19) 
 
Here   is the concentration vector,            
 ,   is response vector,            
  e.g. 
absorbance,     is the regression coefficient and   is the error vector,            
 . The 
intercept can be added by adding a column of ones in the   and consequently an additional 
regression coefficient:  
   
   
  
   
  (2.20) 
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In this case the coefficient vectors will contain both the intercept and the slope terms 
          
 . Least squares regression can be used to estimate the regression coefficients 
from known   and   values as: 
 
     
         (2.21) 
 
If a non-zero intercept is used, equation (2.21) can be written as: 
 
b             (2.22) 
 
Here   and   represents the estimated values of the regression coefficients (a single scalar in the 
first case and a vector with two elements in the second case), and can be used to predict the 
concentration as: 
 
              (2.23) 
 
or considering the intercept term, the prediction can be carried out as: 
 
             (2.24) 
 
The subscript “meas” is used to denote the vectors of measured absorbances for the samples with 
unknown concentrations. 
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2.15.2 Multivariate Calibration 
 
In multivariate calibration, as the name suggests, more than one response variables are involved. 
This is particularly helpful if the variability in the independent variable can be explained in a 
better way by using multiple variables (Bakeev, 2010; Gamperline, 2006; Brereton, 2003). The 
linear regression equation then takes the following form: 
 
       (2.25) 
 
where   is an     matrix of multiple variables such that each row corresponds to a complete 
spectra recorded at   wavelengths. A column of ones can be introduced to account for the 
intercept term; in this case   will have         dimensions. The 
vector                    has all the regression coefficients, each corresponding to a specific 
variable present in the   matrix. The equation used for determining the coefficients is same as 
that of (2.22), and the prediction can be performed with equation (2.24). Note that the 
concentration matrix   can also be multivariate, e.g. the concentration of several species in the 
solution can be predicted simultaneously. In this case   is an     matrix, with   being the 
number of species for which the concentration is determined from the calibration model. 
 
A necessary condition for this calibration model is that the number of samples     must be 
greater than the measured variables     otherwise the matrix inversion in equation (2.22) will 
not be possible. A possible disadvantage of this approach comes from the existence of 
multicollinearity in the data. Multicollinearity refers to the fact that some of the variables can be 
expressed as linear functions of some of the other variables. The presence of such properties in 
the data can lead to an unstable model with poor prediction capability.  
Some of the techniques that can overcome these issues will be discussed in the next section. 
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2.15.3 Principal Component Analysis (PCA) and Principal Component  
 Regression (PCR) 
 
Generally a large amount of data is produced from PAT tools, in particular from spectroscopic 
measurements, which e.g. produce the absorbance values in a large number of wavelengths for 
each concentration. Sometimes part of the data generated is not required or irrelevant and thus 
can be made redundant. Removal of such data improves efficiency of the models developed, e.g. 
by eliminating collinearity. PCA is one of the most widely used techniques for data compression 
and dimensionality reduction (Bakeev, 2010; Gamperline, 2006; Brereton, 2003; Adams, 2004). 
Principal components are the linear combinations of the original variables. Geometrically these 
components give a new coordinate axes by rotating the original axes. PCA is used to simplify the 
data structure and still account for the as much of the total variation in the original data set as 
possible. PCA reveals the internal structure of the data in a way that lett explains the variance in 
the data. 
 
Mathematically PCA represents an orthogonal linear transformation that maps the data into a 
new coordinate system such that the greatest variance by any projection of the data will be in the 
first coordinate (called the first principal component), the second greatest variance in the model 
in the second coordinate and so on. The directions of the new coordinate system are determined 
by the eigenvectors of the data correlation (variance-covariance) matrix, whereas the eigen values 
correspond to the principal components. To explain the PCA we consider the data matrix   with 
dimensions    , corresponding to the absorbances measured at different wavelengths in   
samples. 
 
The first step in performing the PCA is to pre-process the data to obtain normalized data matrix 
  , with zero empirical mean and unit variance, using the scaling parameter vectors   
          
  and            
  as the empirical (sample) mean and variance vectors of the 
process variables in the data matrix, respectively. The elements of the normalized data matrix    
are defined as: 
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                           (2.26) 
 
The normalized data matrix can be represented as: 
 
          (2.27) 
 
where   is the     latent (or score) matrix and   is the     principal components matrix 
(loadings), with   being the number of principal components retained in the model  . The 
residual matrix    represents the error since only     principal components are selected.   
can be obtained from the normalized data correlation matrix, defined as: 
 
  
 
   
      (2.28) 
 
Applying singular value decomposition (SVD) to  : 
 
       (2.29) 
 
  can be obtained by selecting the first   columns of  . This factorization produces a diagonal 
matrix                    where    are the eigenvalues of   sorted in decreasing order 
                , and the corresponding columns in   are the eigenvectors    and are the 
so called principal components. 
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For the data reduction                 and                     are selected, and every 
normalized sample vector      with dimensions     is projected in the principal component 
space generated by   , obtaining the principal score vector of reduced dimension    . 
 
            (2.30) 
 
The selection of the number of principal components   used for the data reduction can be done 
by calculating the cumulative percent variance     . 
 
        
   
 
    
         
    (2.31) 
 
The       is a measure of the percent variance captured by the first   principal components. 
Generally     accounts for a significant part of the variations in the data. 
 
After applying the data reduction a calibration model can be developed by using multi-linear 
regression to the principal score vector called principal component regression, PCR. This 
approach significantly reduces the number of model parameters to be determined. After the 
selection of principal components, the regression coefficients can be determined as: 
 
       (2.32) 
 
and the regression coefficients are 
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             (2.33) 
 
The prediction step is then carried out as follows: 
1. Take new measurement       
2. Calculate normalized measurement matrix        using   and    
3. Project the measurement data in the reduced space determined by the PCA 
 
                      (2.34) 
 
4. Calculate predicted concentration 
 
                            (2.35) 
 
The root mean square error of prediction (     ) can be used to check the predictive capability 
of the model as: 
 
       
          
 
   
 
 (2.36) 
 
2.15.4 Partial Least Squares Regression 
 
Partial least squares regression (PLSR) is another popular calibration model building technique 
similar to PCR. The main difference between PCR and PLSR comes from the way the data is 
compressed. In PCR regression is applied only to those variables that account for variance in   
data, in case of PLSR variance present in both   and   are considered during model building. The 
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compressed variables obtained from PLSR are different from the ones obtained through PCR and 
are termed as latent variables (Bakeev, 2010; Gamperline, 2006; Brereton, 2003); 
 
According to this approach both the inputs and (matrix of predictors e.g. absorbances) and the 
responses (e.g. concentrations) are represented as: 
 
      
     (2.37) 
  
     
     (2.38) 
 
where    has the dimensions    ,   has      dimensions   (latent variables)     and   
    are the loading matrices and        and        are the error matrix and error vector 
respectively,   and    are the score matrices for    and   respectively, both having dimensions 
     where     . PLSR using eigen value decomposition is described as follows: 
 
The scores for    matrix are calculated as: 
 
       (2.39) 
 
where  is the eigenvector corresponding to the first eigenvalue of         . The first score for 
   is calculated as: 
 
      (2.40) 
 
where   is the eigen vector corresponding to the first eigenvalue of         . Once these vectors 
are calculated as they are subtracted from the original values of    and    as: 
 
           
    (2.41) 
 
         
   (2.42) 
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The above process is then repeated to extract the second factor and so on and so forth. 
 
The latent variables can then be calculated as: 
 
  
     
    
  
  
      
      
      (2.43) 
 
The final regression coefficients are given by: 
 
             (2.44) 
 
The prediction steps are similar as described for PCR. The performance of PLSR is quite similar 
to that of PCR, the former can sometime over fit the data. Although it is more complex than PCR 
as it uses information simultaneously from dependent and independent variables, some authors 
claim that PLSR can give reasonable solutions for low precision data.  
 
2.15.5 Artificial Neural Networks 
 
Artificial neural networks (ANN) can be used in chemometrics for modeling nonlinear data 
(Massart, 1997). This technique is different from the previously mentioned techniques for several 
reasons: 
 
 The ANN model structure is explained by a map or architecture unlike the other methods 
where a simple equation is used. 
 
 ANN uses searching algorithm for finding out model variables instead of regression. 
 
 ANN can easily deal with non-linear data by using non-linear transfer functions. 
 
ANNs are composed simple elements, called neurons, operating in parallel. These neurons are an 
abstraction of the biological neuron and are interconnected (Agatonovic and Beresford, 2000). 
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The structure of a neuron is shown in Figure 2.15. A neuron can have a number of inputs but 
only one output, the input(s) are passed onto the neuron where they are weighted and summed; 
after this a transfer function   is applied. A bias term   may also added before the transfer 
function is applied. Each input is multiplied by its associated weight. The sum of this product is 
the argument of the transfer function. The connection between the neurons and their associated 
weights control the propagation of signal. The associated weights also determine the strength of 
the connection between the neurons. 
 
 
Figure 2.15 Structure of a neuron 
 
The neurons can be arranged to form layers which in turn can form a network. The typical 
structure of a multi-layer feed forward network, is shown in Figure 2.16. 
 
 
Figure 2.16 Structure of a feed forward network 
 
The network architecture gives information about the number of layers in the network, number of 
neurons in each layer and the way the layers are connected. The network shown has an input 
layer, a hidden layer and an output layer. A network can have more than one more hidden layers. 
The outputs from the neurons of a layer serve as inputs for the neurons of the next layer.   
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The ANN has the advantage of handling nonlinear data (Bourquin et al., 1997), however, at the 
same time, ANN are very prone to over-fit the data, since the number of parameters in the ANN 
model quickly increases with its complexity. Longer computational times are sometimes required 
to develop the required model. The models developed through ANN are more difficult to 
interpret compared to the models obtained through PCR and PLSR. 
 
To reduce the dimensions of the ANN and decrease computational time quite often PCA is 
applied to the data prior to model development using ANN. The combination of these two 
methods is termed as PC-ANN and has been reported to give better results and reduced 
computational times (Dou et al., 2007; Dou et al., 2006; Zhou et al., 2007) 
 
2.15.6 Pre-Processing Techniques 
 
Large amounts of data are produced during spectroscopic measurements, part of this data 
sometimes is irrelevant because of various reasons such as base line drift, multiplicative effects 
etc. In order to build a robust calibration model it is recommended to remove this part of data by 
using several pre processing techniques (Bakeev, 2010). In the following section some of the 
commonly used techniques will be discussed: 
Mean Centring 
 
Mean centring is frequently used as a pre processing technique. In this method an average data 
vector or spectrum is calculated by calculating a vector of  averages by calculating the average 
of the   absorbances in each column, this mean is then subtracted from each vector in the data. 
Mathematically this can be described as: 
 
   
      
    
 
   
 
 for                     (2.45) 
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where    
  is the mean centred absorbance at     sample and     wavelength. A mean centred 
matrix can be transformed into the original matrix by simply adding the mean values. A potential 
benefit of mean centring is the removal of any absolute values from the spectral data. 
 
Baseline Correction 
 
Baseline correction is another technique similar to mean centring for removing baseline drifting 
in spectroscopic instruments. Baseline can sometime appear in the instruments with a particular 
trend such as gradually going up or down slope.  The spectral intensity at wavelength(s) where 
no activity is observed i.e. no change in the intensity, the average values for this particular region 
can be calculated and subtracted from each spectrum. Sometimes a polynomial function can be 
used if the background signal is curved. 
Standard Normal Variate Transformation 
 
Standard normal variate (SNV) transformation is useful if variable path lengths are encountered 
(e.g. in reflectance spectroscopy), such differences give rise to multiplicative variations in the 
spectral data. Other sources may include variations in the samples such as particle size or 
thickness or even variations in spectrometer optics. These variations can disturb the quantitative 
information aspect of the data such as concentration of samples. 
 
In transformation each spectrum is treated by subtracting its mean and normalizing it by dividing 
with the standard deviation. These parameters come from the individual variables that constitute 
a spectrum, as described by equation (2.26) in PCA section.  
Derivative Spectroscopy 
 
Derivative spectroscopy is another useful pre-processing and filtering technique. The derivative 
of a continuous function removes any baseline shift as the derivative of a constant is zero. The 
other benefits include enhancement of spectral features in case of overlapping spectra. Savitzk-
Golay filters are frequently used for smoothing and derivative calculations (Brereton, 2003). 
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These filters are applied by using the adjustable parameters which include size of the window, 
derivative order and polynomial order. 
 
A predefined set of coefficients is available corresponding to the afore-mentioned parameters. 
The application of the filter is performed by sequential multiplication of a set of absorbances by 
these coefficients in a moving window manner. In this way the derivative of each point is 
calculated.  First order derivative normally removes the baseline offset, while second order 
derivative removes both the baseline offset and difference in baseline slopes due to drift in the 
spectral data. Use of high window size is recommended for noisy data, however, this may come 
at a cost of loss in spectral resolution.  
 
2.15.7 Design of Experiments 
 
Design of experiments (DOE) plays a very crucial role in development of calibration models 
using PAT tools. The main aim of DOE is to extract and collect as much as information possible 
through experiments with minimum experimental and financial effort (Bakeev, 2010; 
Gamperline, 2006; Brereton, 2003).  
 
The data used for calibration model development should cover the expected range of instrument 
response with respect to the independent variables in real time operation e.g. absorbance data 
covering a specific temperature and concentration(s) range. It should also include any other 
factors that might affect the instrument response. A strong emphasis is placed on defining the 
working boundary of the model within which the model would be used. If a nonlinear system is 
encountered the data used for model development must be able to provide enough information 
for a model that can describe these effects. A part from development of calibration models, DOE 
can also be used to analyze the effect of a particular design variable on the response.  
 
After setting the objectives, all those variables that can affect the instrument response must be 
identified. In the case of crystallization, temperature, pH, solvent/anti-solvent ratio, composition 
of various species (if more than one compounds are present) should be carefully considered. 
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Once the variables have been identified the next step is to select the number of levels. In 
calibration model development the objective can be to predict concentration of multiple 
compounds at various temperatures and solvent/anti-solvent ratios. In this case the limits for each 
of these variables must be defined and based on that suitable levels must be chosen, so that the 
application of model in real time situation can yield the desired output as accurately as possible 
under different conditions. Calibration models such as ANN and PCR can be very efficient, if the 
data generated covers all the linear and non linear relationships between the independent 
variables and instrument response.   
 
Factorial design is the simplest DOE method, based on this method experiments have to be 
performed for all the variables at selected levels. For example for a 2 level design with 3 factors 
i.e. variables      experiments have to be performed. The 2 levels here correspond to the 
minimum and maximum limit of a particular variable, similarly 3 levels will correspond to 
minimum, middle and  maximum limits.  The factorial design approach is suitable in cases where 
a smaller number of variables and levels are investigated, however, any increase in the number of 
levels and variables can exponentially increase the number of experiments required, practically 
making it impossible to use this technique e.g. 5 variables at 3 levels would require 243 
experiments which is extremely difficult and impractical to carry out.  
 
In order to overcome this issue several other DOE methods were developed, such as Box-
Behnken, Face-Centered Cube, Central Composite Design (CCD) and others (Brereton, 2003). 
These methods differ in the way they characterize the interaction between different variables 
along with the number of experiments recommended. CCD is briefly described here. Figure 2.17 
shows the design for a three variable two level design. The full factorial 2 level design is changed 
by adding axial or star points, while some of the replicate measurements are also carried out. 
 
The number of experiments required can be calculated using the following equation: 
 
           (2.46) 
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Here   represents the number of experiments,   is the number of levels and    the number of 
centre points. The main advantage of CCD is that they consider non linear relationship between 
variables, this property is particular helpful in model development for non linear and systems. An 
application of CCD for non linear model development will be discussed in chapter 7. 
 
 
 
Figure 2.17 Central composite design for three factors at two levels 
 
2.16 Summary 
 
Crystallization is a complex and nonlinear process, the outcome of which is governed by the 
solubility, nucleation, growth and MSZW. A better control and monitoring of these mechanisms 
by various PAT tools can help in enhancing the quality of the crystalline product. More and more 
sophisticated control approaches using these in situ tools are gaining popularity as they 
consistently provide products with desired properties. Chemometrics combined with PAT 
provides qualitative and quantitative information about the system and can help in designing and 
implementation of model-free control approaches. 
 
The literature shows the advantages of using these new control approaches. For example 
supersaturation control based on ATR-FTIR spectroscopy provided a better control of the 
crystallization process. Similarly control studies using FBRM show that the product quality is 
improved compared to the traditionally used linear or natural cooling profiles. It has been 
identified that only a handful of monitoring studies are available that deal with the application of 
ATR-UV/Vis spectroscopy in pharmaceutical crystallization. Unlike other spectroscopic tools for 
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which detailed methodologies are available for calibration model development, not much 
information is available for calibration model development for this technique. In case of FBRM, 
very few applications are available that show its use as a control tool.  
 
The literature review highlights the importance of PAT and chemometrics for process monitoring 
and control. It also shows the underutilization of ATR-UV/Vis spectroscopy and FBRM for 
process control. The aim of the thesis is therefore to expand the application and use of these two 
tools both on laboratory and pilot plant scale for process monitoring and control. Two control 
approaches, namely, supersaturation control using ATR-UV/Vis spectroscopy and automated 
direct nucleation control approach using FBRM were developed and implemented. 
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Chapter 3 Calibration Model Development for ATR-UV/Vis 
 Spectroscopy for Crystallization Monitoring 
3.1 Introduction 
 
The use of PAT tools has become an integral part of drug development and manufacturing 
processes. These in situ tools as discussed before provide useful information but at the same time 
generate large amounts of data. Sophisticated mathematical and statistical tools are therefore 
required to analyze and extract meaningful information from the data. Chemometrics can be 
employed for this purpose. The general scope of chemometrics has been discussed in the 
previous chapter. The main purpose of this chapter is to demonstrate that ATR-UV/Vis 
spectroscopy can be used for quantitative crystallization monitoring and to introduce a calibration 
model development methodology for this monitoring tool. Several different calibration methods 
will be evaluated for their prediction ability.  
 
3.2 Experimental Setup and Methodology 
 
The experiments were carried out in a 500 mL jacketed glass vessel fitted with an overhead 
PTFE coated 4-pitched blade turbine and thermocouple. The temperature was controlled by a 
thermo fluid circulator bath (Huber Variostat CC-415 VPC). An FBRM probe (model D600, 
Lasentec) was used to measure chord length distributions. FBRM data collection and monitoring 
was carried out by the FBRM control interface software (version 6.7). FBRM was used during 
the experiments as a monitoring tool of the solid phase and provides useful information about 
dissolution and nucleation events. The UV/Vis spectra of the solution were measured using a 
Hellma 661.822 ATR probe connected to a Carl Zeiss MCS621 UV/Vis spectrometer. Software 
written in LabVIEW (National Instruments) using libraries provided by Carl Zeiss was used for 
spectra collection. The FBRM, UV/Vis and temperature data were recorded every 10 seconds. 
The data collected by computers connected to FBRM and UV/Vis were sent to a third computer, 
running the Crystallization Process Informatics System (CryPRINS) software (in-house 
developed software) written in LabVIEW. This software is capable of receiving and sending data 
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through an RS232 interface, by file sharing, or using an OPC (OLE - Object Linking and 
Embedding - for Process Control) server. The software enables the simultaneous monitoring of 
the data from various PAT tools and the implementation of the required temperature profiles in 
an automated way. 
 
The experiments were carried out using paracetamol (4-acetaminophenol, 98% purity, purchased 
from Aldrich), analytical grade 2-propanol (isopropanol, IPA). A schematic representation and 
picture of the equipment are shown in Figure 3.1 (a) and (b). 
 
 
 
  
 
 
Figure 3.1 Schematic representation (a) and picture (b) of the experimental setup used for calibration model 
development and crystallisation monitoring 
 
CryPRINS 
(a) 
 
 
 
 
 
  
 
 
(b) 
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The development of the calibration model followed the following generic steps: 
 
1) Determination of solubility for the desired system. This can be done using literature data 
or experimental solubility determination procedures (e.g. gravimetric analysis). 
2) Identification of the operating envelope or design space (e.g. determination of 
concentration and temperature ranges). In this step the number of data sets within the 
range (levels) must also be determined. The operating envelope should include both 
undersaturated and supersaturated regions. Note that the temperatures ranges change with 
concentration hence the selection of these ranges can be done based on the metastable 
zone width of the process. Often before or during the calibration experiments a metastable 
zone determination is performed, for the more precise identification of the operating 
envelope. 
3) Calibration experiments that cover the design space are performed based on the process 
limits selected. 
4) Analysis of the raw data for outlier detection and nonlinearity check. At this stage 
plotting absorbances versus temperature at constant concentrations and absorbances 
versus concentration data at constant temperature can help in the selection of the 
calibration model structure. Whether preprocessing is needed or whether absorbance or 
derivative data should be used can also be decided at this stage. 
5) Model structure identification. In this step the form of the calibration equation is chosen. 
A decision whether a nonlinear or linear model structure will be used is made based on 
the analysis of the data in the previous step. 
6) Model identification. The parameters of the model are determined using appropriate 
model identification methods 
7) Model validation. 
 
For the current study paracetamol in IPA was selected as the model system as it is a widely used 
compound and relevant solubility data are easily available, and the aforementioned steps of the 
calibration model development were followed. 
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3.3 Results and Discussion 
 
Absorbance measurements from the ATR-UV/Vis spectroscopy spectrometer were used to 
develop a calibration model. Spectra were measured in the range of 242-400 nm. An example of 
an absorbance spectrum and the corresponding first derivatives are shown in Figure 3.2.   
 
 
Figure 3.2 Spectrum of paracetamol in IPA at constant temperature and concentration, lower half of the 
figure shows the first derivative of the absorbance with respect to wavelength 
 
For the calibration model development, experiments were conducted at 8 different 
concentrations. In each experiment the data was recorded at several temperatures to ensure that 
absorbance data are available for both supersaturated and undersaturated regions. For validation 
of the developed models, an additional validation experiment was carried out. A summary of the 
concentrations used for model development and validation is given in Table 3.1. 
 
The general practice is to measure the concentration in “mass/volume” units, in accordance with 
Beer-Lambert’s law. In crystallization monitoring, the volume based measurement has the 
drawback that the actual total volume is based on the volume of the solid and the solvent used, 
which can both change during the crystallization process. As crystallization progresses, both the 
concentration in the liquid phase and the volume of the solid phase change, causing variations in 
the total volume, which can lead to errors in the concentration prediction. The use of “mass of 
solute/mass of solvent” units eliminates this problem and therefore is recommended for 
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crystallization monitoring. The concentrations used in this work are expressed in “grams of 
solute/grams of solvent” and from here onwards will be denoted as “g/g”. 
 
Table 3.1 Summary of the calibration experiments 
 
Training Data Saturation Temperature 
(approximate values in C) Concentration (g/g)  
0.2109 58 
0.205 55 
0.187 49 
0.172 43 
0.1505 34 
0.135 30 
0.1 18 
0.093 13 
Validation Data   
Concentration (g/g)   
0.18   
 
A typical experiment carried out at a concentration of 0.18 g/g is shown in Figure 3.3. Spectral 
data was recorded at several different temperatures to obtain a comprehensive set of data. The 
temperature effect on all absorbances, dissolution and nucleation events are shown in Figure 3.3. 
The evolution of the absorbance at 252 nm is shown in Figure 3.4. The temperature steps helped 
in analyzing the reproducibility and repeatability of the absorbance data at the same temperatures 
but at different times. This experimental procedure with the decreasing and increasing 
temperature steps is important to identify baseline shift, drift or hysteresis in the signal. No 
significant drift was observed in this case even when the instrument was used for fairly long time 
continuously. The sensitivity of the ATR-UV/Vis spectroscopy for the nucleation and dissolution 
events can be observed. Both these events are clearly identified from the absorbance plot as the 
concentration keeps increasing because of the continuous dissolution of the solids as the 
temperature was increased, this dissolution was also highlighted by decrease in FBRM counts/s. 
The absorbance increased until the solids were completely dissolved. The decrease in absorbance 
after that dissolution shows the temperature effect on absorbance. Absorbance increases as the 
temperature is decreased and decreases vice versa. These variations indicate the importance of 
including a correction of the temperature effect in the calibration models and will be discussed 
later. The nucleation event is also detected by ATR-UV/Vis spectroscopy by a sharp decrease in 
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absorbance at the time of nucleation. An increase in the FBRM counts/s approximately at the 
same time also shows the nucleation event. 
 
 
Figure 3.3 Variation of absorbance values at different wavelengths and time during a typical crystallisation 
experiment. 
 
 
Figure 3.4 Absorbance at 252 nm, total counts/s and temperature profile for a typical calibration experiment 
 
Prior to calibration, a decision must be made on (1) the form of the calibration model and (2) the 
method used to determined the coefficients in the model. If a linear relationship exists between 
the concentration and spectral data then multivariate methods such as MLR, PCR and PLSR can 
be used. Since crystallization processes are often conducted under large ranges of concentrations 
which generally includes high concentrations, nonlinearities between the absorbance and 
concentration are often encountered. If nonlinearities are present in the data then linear methods 
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may not be used, and approaches that can take these nonlinearities into account may need to be 
considered. The nonlinearities can be classified in to following types: 
 
1) The nonlinearity in variables e.g. in the spectral data between two absorbance values as a 
result of wavelength shift or interaction between absorbance and temperature. 
2) Nonlinearity between concentration and absorbance at a certain wavelength; such 
nonlinearities are called univariate nonlinearities. 
3) Total nonlinear relationship between absorbance and all variables, such as concentration, 
temperature, solvent composition and others. 
 
Two main approaches can be used to incorporate potential nonlinearities in the calibration model 
development. The first approach is to use a nonlinear regression method with nonlinear 
relationships e.g. ANN. This method is capable of modelling any nonlinear relationship as 
mentioned above, however leads to a complex calibration model structure with a large number of 
parameters. Special care has to be taken during the development to avoid over-parameterization 
which can significantly reduce the prediction ability of the ANN model. An alternative approach 
is to model nonlinearity (first two types of nonlinearities) by introducing higher order terms, e.g. 
quadratic, interaction (between variables) and in some cases even cubic terms. These additional 
variables along with the original variables can be used for prediction by application of 
multivariate linear regression (Berglund and Wold, 1997).  An example of such model is shown 
in equation (3.1). The model has nonlinear variable terms, however the coefficients can be 
determined by a typical linear regression methods. 
 
                     
  (3.1) 
 
where c  is the concentration, T  is the temperature, x  can be the absorbance or the derivative of 
the absorbance at a particular wavelength and            are the model parameters to be 
determined during the calibration procedure. During model building it is recommended to 
determine the magnitude of nonlinearity and if possible its source. If a minor nonlinearity exists 
then linear models can still be reliably used.  
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Preprocessing is an essential part of calibration model building. The data used in the models were 
mean centered and the 1
st
 derivative of spectral data (with respect to wavelengths) was also used 
for the calibration model development. The 11 point derivative was calculated using the 
Savitzky-Golay algorithm (Brereton, 2003). The derivative of the absorbance retains the essential 
information in the spectral data, while at the same time eliminates any drift that may have been 
present. It is important to note that the application of the derivative increases noise in the signal 
hence it is important to use smooth absorbance spectra.  This was achieved by collecting in all 
experiments 100 spectra with a sampling rate of 10-20 ms, and averaging the values before 
applying the derivative calculation. Additionally the approach used for the derivative includes a 
filtering methodology (Savitzky-Golay method), which was built in the LabVIEW interface of 
the ATR-UV/Vis spectrometer. In case of the PCR and PLSR calibration methods, PCA is 
applied to the data which can also remove baseline effects therefore absorbance data treated with 
PCA was used as input for the PCR and PLSR models instead of the derivative. For the 
subsequent simpler but nonlinear calibration models the derivative of the absorbance at 266 nm 
was used, since at this wavelength it shows high sensitivity to change in concentrations. Using a 
derivative or absorbance in the low sensitivity region, makes the calibration model more prone to 
be affected by noise in the data. 
 
First the range of concentration was selected to cover the operating range during the 
crystallization process both in terms of concentration and temperature. Figure 3.5 shows how the 
measurement points covered the operating region in the phase diagram. Measurements were 
taken for each concentration at different temperature steps, both in the under-saturated and 
supersaturated regions.  
 
In order to investigate the presence of nonlinearity between the variables used, the 1
st
 derivative 
of the absorbance was plotted against temperature at constant concentrations (see Figure 3.6), 
and against concentration at constant temperature (see Figure 3.7). These plots help in 
understanding whether the variation in absorbance (or derivative of absorbance) is linear or 
nonlinear for different concentrations and at different temperatures. These plots show that a 
linear relationship exists between absorbance and temperature at individual concentrations. On 
the other hand a change in slopes can also be observed, showing that an interaction between 
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temperature and absorbance exists. This observation suggests the addition of an interaction term 
(between the absorbance and temperature) in the calibration model be required. 
 
Figure 3.5 Concentrations used in the calibration model development  
 
 
Figure 3.6 Variation of 1
st
 derivative at 266 nm with respect to temperature at different concentrations, except 
for the validation experiment  
 
Similarly the behaviour of absorbance derivatives against concentration was also investigated at 
constant temperatures (a sample plot at 30 °C is shown in Figure 3.7), and no nonlinearities were 
observed. The same analysis carried out at several temperatures showed the same results, 
therefore eliminating the need to add a quadratic term in the nonlinear model. 
10 20 30 40 50
0.1
0.12
0.14
0.16
0.18
0.2
Temperature C
C
o
n
c
e
n
tr
a
ti
o
n
 (
g
/g
)
 
 
0.205 g/g
0.187 g/g
0.172 g/g
0.151 g/g
0.135 g/g
0.121 g/g
Solubility
10 20 30 40 50
-0.03
-0.025
-0.02
-0.015
-0.01
Temperature C
D
e
ri
v
a
ti
v
e
 a
t 
2
6
6
 n
m
 
 
0.205 g/g
0.187 g/g
0.172 g/g
0.151 g/g
0.135 g/g
0.121 g/g
Chapter 3 Calibration Model Development for ATR-UV/Vis Spectroscopy for Crystallization Monitoring 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  70 
 
 
Figure 3.7 1st derivative at 266 nm versus different concentrations at 30°C 
 
From these analyses it can be concluded that only a slight moderate nonlinearity exists in the data 
hence linear calibration methods may provide acceptable performance. Therefore different linear 
and nonlinear models will be discussed and compared for their predictive capabilities in the next 
section. 
 
3.3.1 Performance analysis of Calibration Models 
 
When developing a calibration model it is always preferred to have the simplest possible model 
which can give satisfactory results. By intuition, uni-variate model involving just wavelength is 
the first choice. In the previous section temperature dependency of absorbance was demonstrated 
and the need for adding an interaction term. To illustrate this further quantitatively, results using 
a simple uni-variate method are presented. Absorbance at 252nm was used in the model in the 
development of the following calibration model: 
 
                                   (3.2) 
 
where c  is the concentration in g/g and x  is the absorbance. The residuals (which are the 
difference between the actual and the predicted values) were used to test the predictive capability 
of the model. The spread and high absolute values of the residuals indicate poor performance of 
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the model. A plot of the predicted versus actual concentration and corresponding residuals is 
shown in Figure 3.8 These results indicate that this simple model did not perform well and hence 
is not suitable for crystallisation monitoring. These results clearly indicate that uni-variate 
models should only be used if the system’s absorbance is only dependent on the concentration of 
a single species without any interference from other compounds and temperature.  
 
Next a multivariate model was considered with temperature as the added term built in the model, 
using the following calibration equation: 
 
0 1 2c b b x bT= + +              (3.3) 
 
 The results are shown in Figure 3.9.  
 
 
Figure 3.8 Actual and predicted concentration using uni-variate model 
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Figure 3.9 Actual and predicted concentrations using multivariate model with temperature term 
 
The results show an improvement in the prediction performance of the model. The much less 
spread of the data indicates that the addition of the temperature term has improved the prediction 
performance of the model.  
 
To further increase the prediction performance of the model the effect of adding additional 
absorbance terms in the model was evaluated. A calibration model of the form: 
 
                 
  
                (3.4) 
 
was used, with xN  being the number of absorbances used in the model. The prediction results 
when three absorbances ( 3xN = ) were used (at wavelengths 242 nm, 252 nm and 280 nm) are 
shown in Figure 3.10. It was expected that the addition of multiple absorbances would improve 
the model prediction, however, this was not the case; in fact the performance of this model was 
lower than the previously developed model. To investigate the reason behind this result, the data 
were checked for multicollinearity. It was mentioned in the previous chapter (section 2.15.2) that 
the presence of multicollinearity in the data can give rise to unstable models with poor predictive 
ability.  
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Figure 3.10 Actual versus predicted concentration values for multivariate model with 3 absorbances 
 
 
Figure 3.11 PCM spectra in IPA at different temperatures (10 °C – 60 °C) 
 
PCM spectra at constant concentration and varying temperatures are shown in Figure 3.11. The 
absorbance pattern at different wavelengths indicates that the majority of the absorbances 
increase or decrease in a similar fashion. This implies that absorbances can be expressed as linear 
functions of each other. This linearity can be regarded as the cause of multicollinearity. A 
covariance matrix for the spectral data can be developed for detection of this property. The 
covariance values between four selected absorbances in correlation to the rest of the spectrum are 
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shown in Figure 3.12. The wavelengths were selected at different points in the spectrum for the 
collinearity check. The absorbances which are closer to the peak values behave in a similar way, 
the wavelengths further away from 280 nm and close to 310 nm vary in a different way, 
however, at these wavelengths the sensitivity reduces and more noise is involved, using these 
wavelengths for calibration model development is therefore not recommended. The absorbances 
in the range of 240-290 nm are highly correlated and show the highest covariance. Compared to 
the absorbances at wavelengths higher than 300 nm, the covariances with the lower wavelengths 
quickly decrease (for the larger wavelength which is in this range the covariance increase as 
expected), indicating decreased collinearity between absorbances in the 240-300 nm range and 
above. However, due to their low sensitivity, absorbances above 290 nm are not suitable for 
calibration model development. These results demonstrate the strong multicollinearity between 
the absorbances at different wavelength, and suggest that models with a single absorbance 
anywhere in the range of 240-290 may perform similarly. These results also indicate that if 
absorbances at multiple wavelengths are to be used, multivariate methods such as PCR and PLSR 
should be employed to avoid the strong multicollinearity in the data. 
 
 
Figure 3.12 Covariance between different wavelengths 
 
The results of using the PCR and PLSR calibration methods are presented next.  
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Both PCR and PLSR determine a calibration model similar in form to equation 3.2, but the 
variables ix  are no longer directly the absorbance (or derivative) values, instead they represent 
linear combinations of the absorbances (derivatives) at all wavelength in the range considered. 
These linear combinations are determined by the PCR and PLSR methods to eliminate the 
collinearity between the variables  , and their actual structure will depend by the method 
employed. In this case all absorbances within a range of wavelength are automatically considered 
but the number of calibration model coefficients is significantly reduced since those are 
determined for only a small number of xN  linear combinations between the absorbances.   
 
The major benefit of these approaches is that the selection of wavelengths is carried out by the 
method itself based on the contribution of each wavelength (or factor) as a result, wavelengths 
that show little sensitivity towards changes in concentration or temperature would not be 
considered critical by the model. The representation of the data in the new geometric coordinates 
results in variables that are independent (perpendicular to each other) of each other but linear 
combinations of the original variables. This property solves the collinearity issue and a reduced 
number of variables can be used for model development. 
 
It is always desirable to have an accurate model therefore the number of factors capturing more 
than 90 % of the variance can be selected and used for model development. It should be 
mentioned that including too many factors may give rise to unstable solutions as noise would be 
included in the model. Another important issue is the selection of the model development 
technique. In the literature it has been mentioned that both techniques essentially give similar 
results and no appreciable difference exists between the two (Naes et al., 2002). The results here 
showed that 8 factor PCR and PLSR gave the best results and by selecting the same number of 
factors for both techniques a direct comparison could be performed. 
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Figure 3.13 Regression coefficients for 8 factor PCR 
 
 
Figure 3.14 Regression coefficients for 8 factor PLSR 
 
The regression coefficients generated by PCR and PLSR are shown in Figure 3.13 and Figure 
3.14, respectively. The trends in both these plots are similar indicating that both PCR and PLSR 
give similar regression coefficients. The coefficients corresponding to the absorbances above 310 
nm appear as random variables with zero mean, which also suggest that those absorbance values 
have very low (close to zero) sensitivities hence should not be taken into account for the 
calibration model. This is in correlation with the results in Figure 3.11 where very little change in 
absorbance values is seen for these wavelengths. A high value for regression coefficient for 
temperature can be seen here, indicating that both models recognized the contribution of 
temperature towards the spectra.  
 
The prediction results from both models are shown in Figure 3.15 and Figure 3.16, respectively. 
Compared to the multivariate models shown in Figure 3.9 and Figure 3.10, both these models 
gave significantly better results. Smaller values were obtained for both models and predicted 
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values were much closer to the actual values than the previous multivariate models. The 
improved results by these techniques show that the models capable of dealing with 
multicollinearity perform better than the simple multivariate models. 
 
 
Figure 3.15 Actual and predicted concentrations using 8 factor PCR 
 
 
Figure 3.16 Actual and predicted concentrations using 8 factor PLSR 
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The preliminary analysis of the calibration data identified a moderate level of nonlinearity in the 
data. It was therefore decided to also develop a model using nonlinear terms. This method offers 
flexibility of using different types of equations containing any nonlinear terms, including 
polynomial, exponential or various interaction terms. The model evaluated has the similar form 
as the nonlinear equation (3.1), and consists of the linear terms for the temperature and derivative 
of the absorbance at wavelength 266 nm, and a nonlinear term expressed as a product between 
the absorbance derivative and temperature to incorporate the nonlinear effect in the data. The 
equation used therefore has the form: 
 
                  (3.5) 
 
where   represents the derivative of the absorbace at 266 nm. The coefficients of the model were 
determined using a standard nonlinear least square optimisation approach implemented in the 
MATLAB function “fmincon”. The results are shown in Figure 3.17 and are very similar to PCR 
and PLSR results, but are better than the results obtained with the simple bivariate calibration 
model with no interaction term. 
 
 
Figure 3.17 Actual and predicted concentrations, nonlinear method using 1
st
 derivative 
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A major benefit of using a single wavelength nonlinear calibration model with derivative is that 
there is no issue of multicollinearity as only one spectral variable is used. Secondly this is 
computationally much more efficient and extremely easy to implement for real time monitoring,  
especially on the industrial scale, where programming complex calibration equations with a large 
number of parameters that result from PCR and PLSR into the DCS is often difficult. The linear 
and the moderately nonlinear methods both gave similar performances, however PCR and PLSR 
required more components to give a similar prediction to the nonlinear model. According to Naes 
et al. (2004) PCR based linear models can give a stable solution by using a larger number of 
principal components for slightly nonlinear data, but a nonlinear model can give much better 
solutions using fewer variables. This has been observed in this case too, since by using only two 
variables and their interaction term (essentially three terms), the performance of the nonlinear 
model was similar to that of the 8 factor PCR and PLSR. The performance of the nonlinear, PCR 
and PLSR models was further evaluated by using the validation experiment. The RMSEP was 
used to quantify the prediction performances for all three models. The values obtained are shown 
in Table 3.2. The RMSEP values are similar for all three models, with the smallest prediction 
error corresponding to the nonlinear model. 
 
Table 3.2 Root Mean Square Error of Prediction values for different models used 
 
 
RMSEP 
PCR PLSR Nonlinear model 
0.0035 0.0040 0.0034 
 
In the light of the analyses presented in this section the nonlinear model was selected as a 
suitable calibration model to be used with ATR-UV/Vis spectroscopy, because of its simplicity 
and accuracy. To check the robustness of the model a number of tests were performed. 
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3.3.2 In situ and real-time monitoring of crystallization using ATR-UV/Vis 
spectroscopy  
In the first case a slurry experiment was performed as shown in Figure 3.18. The main purpose 
was to obtain data that can be fed to the developed model and obtain solubility data points at the 
selected temperatures. A solution of PCM corresponding to saturation temperature of 45°C was 
prepared. The solution was then heated up in several steps, and the temperature was maintained 
for 1 hour at the selected temperatures to establish near thermal equilibrium conditions at the 
specified temperatures. This resulted in stepwise partial dissolution of the crystals present in the 
solution.  
 
Figure 3.18 Total counts/s, temperature and absorbance profiles for slurry experiment 
 
Figure 3.19 Comparison of model predicted solubility and literature values 
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The stable FBRM counts and constant UV/Vis absorbance values both indicate that an 
equilibrium between the solid and liquid phases was achieved, as no appreciable change in 
counts or absorbance was observed at the constant temperatures. The absorbance values collected 
in these equilibrated points should correspond to the solubility concentration of the compound at 
each temperature value.  
The results obtained by the application of the model to the data obtained are shown in Figure 
3.19. The results indicate that the solubility predicted by the model is in good agreement with the 
solubility data available in the literature and capable of measuring concentrations with high 
accuracy and precision. 
The robustness of the model developed was further checked by monitoring the concentration of 
PCM in real time during a more complicated crystallisation experiment. The result of monitoring 
the crystallisation process using ATR-UV/Vis spectroscopy coupled with the simple nonlinear 
calibration model is shown in the phase diagram in Figure 3.20 and, by plotting the operating 
curve during the experiment. The solubility curve (obtained from the literature) is also plotted 
here as a reference point.  
 
Figure 3.20 Performance analysis of nonlinear calibration model 
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Figure 3.21 Total counts/s, concentration and absorbance profiles for experiment shown in Figure 3.20 
because of the continuous increase in the temperature. The concentration (as predicted by the 
model) closely followed the solubility curve until complete dissolution took place. The 
concentration profile remained flat after dissolution as the temperature increased and then 
decreased until nucleation took place. The flatness of the profile indicates that the model 
captured the temperature effect properly. The temperature of the solution was then increased until 
the nucleated crystals partially dissolved. The second heating curve followed very well the 
operating curve from the previous heating cycle, but stopped at a lower temperature since only 
partial dissolution of the nucleated solid was required. This indicates the repeatability and 
reproducibility of the model. After the second heating phase a slower cooling profile was applied 
and the supersaturation was kept at a much lower value to promote growth and avoid secondary 
nucleation. The results indicate that the model developed gave satisfactory results and was able 
to give accurate quantitative information about the system. 
3.4 Conclusions 
This chapter presented a methodology for calibration model development. The building of a 
robust and accurate model requires knowledge about the relationship that exists between the 
variables and the property of interest. A linear calibration model can be used if the relationship is 
linear, in case of nonlinearity the selection of the method depends on the type of nonlinearity. 
Several procedures are available to model nonlinear behaviour. The performance of different 
linear calibration methods was analysed and compared to a simple nonlinear model which 
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included linear absorbance (derivative) and temperature terms and a simple interaction terms 
(expressed as the product between the absorbance and temperature). The simple nonlinear model 
provided slightly better results than PCR and PLSR, however with significantly less model 
parameters. The robustness of the model developed was checked by determining solubility of 
PCM in IPA, and comparing the results with the literature data, obtaining very good agreement. 
The developed model satisfactorily captured the temperature effects and detected nucleation and 
dissolution events. The chapter provided a methodology description and experimental validation 
of the capability of ATR-UV/Vis spectroscopy with a relatively simple moderately nonlinear 
calibration model as an efficient tool for in situ and real-time crystallization monitoring and 
control. 
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Chapter 4 Comparative Investigation of Supersaturation and 
 Direct Nucleation Control of Crystal Size Distributions 
 using ATR-UV/Vis Spectroscopy and FBRM 
 
This chapter presents a thorough evaluation of different control policies used in cooling 
crystallization, namely: unseeded linear cooling, seeded linear cooling, supersaturation control, 
direct nucleation control and combined direct nucleation and supersaturation control. The 
sensitivity and robustness of supersaturation and direct nucleation control approaches are 
checked by varying different process parameters such as seed loading, heating and cooling rates 
for paracetamol crystallization in isopropyl alcohol. The supersaturation control approach uses 
concentration information provided by ATR-UV/Vis spectroscopy, while the direct nucleation 
control approach is based on FBRM.  
4.1 Introduction 
 
During crystallization obtaining a narrow and reproducible CSD is important to achieve efficient 
downstream processing and desired final product properties with reduced variability. The most 
widespread control approach applied for industrial scale cooling batch crystallisation systems is 
based on open loop temperature control strategies, in which the system follows a pre-set 
temperature profile. Typically a linear cooling profile is used because of its simplicity. However, 
this often results in a poor CSD (Chew et al., 2007). So-called programmed cooling profiles are 
another option in which the temperature is decreased slowly at the beginning and at a faster rate 
towards the end of the batch to promote growth (Mullin, 2001; Jones, 1974). These simple 
approaches ignore any disturbances, as they are unable to respond to changes that occur in the 
system. This may result in a broad bi-modal CSD and batch to batch variability. Therefore 
developing monitoring and control approaches which can detect and react to disturbances and 
adapt to changing operating conditions can result in a significant improvement of the 
crystallisation process and product quality. 
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One of the most widespread methods for monitoring concentration during the crystallisation 
process is ATR-FTIR spectroscopy. ATR-UV/Vis spectroscopy, however can also be used as a 
cheaper alternative with more robust and faster calibration procedures. The main limitation of the 
ATR-UV/Vis spectroscopy is its applicability only to compounds with chromophoric groups 
(which absorb in the UV/Vis range). This is however fulfilled by the large proportion of 
pharmaceutical compounds that are chromophoric, making ATR-UV/Vis spectroscopy an 
excellent candidate for monitoring pharmaceutical crystallisation processes. Despite its potential 
advantages there is very little literature available on the application of ATR-UV/Vis spectroscopy 
in pharmaceutical crystallization. Some of the earliest studies were carried out by Anderson et al. 
(2000) and Thompson et al. (2005), and recently ATR-UV/Vis spectroscopy has been used as a 
monitoring and concentration measuring tool in the crystallisation of pharmaceuticals and 
inorganic compounds (Abu Bakar et al., 2009; Aamir et al., 2010). This is the first time that a 
feedback control approach, SSC, based on ATR-UV/Vis spectroscopy will be applied in a 
pharmaceutical crystallization process.  
 
The current work also proposes a novel combined ADNC and SSC approach using ATR-UV/Vis 
spectroscopy and FBRM, based on the sequential application of the ADNC and SSC approaches 
with automatic switching between the two. The approach is applied for automated in situ seed 
generation. A comparison study is carried out using various operating modes and control 
strategies, including unseeded and seeded operating modes, with linear cooling, SSC, ADNC and 
ADNC-SSC approaches. The aim is to identify the advantages and disadvantages of each control 
strategy in terms of its ability to produce a narrow and uniform CSD, whilst remaining 
insensitive to variations in process conditions. 
 
In the current work paracetamol (PCM) in IPA is used as a model system. The high solubility of 
PCM in IPA, slow growth and significant variations in the MSZW for primary and secondary 
nucleation events make it a challenging system to test the robustness of the various control 
strategies to obtain a desired CSD.  
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4.2 Methodology 
4.2.1 Supersaturation Control Approach for Cooling Batch Crystallisation   
 
In the supersaturation control approach, the system follows an operating curve in the phase 
diagram which generally corresponds to constant supersaturation. The feedback control requires 
concentration measurement, which in this work is obtained using ATR-UV/Vis spectroscopy 
used in conjunction with a suitable calibration model. The supersaturation is computed using the 
concentration measurement and the solubility information for the compound in the particular 
system. The solubility curve can be represented as any (nonlinear) function of the temperature 
( )
sol sol
C C T= . This function can be expressed by the van’t Hoff solubility equations; however 
often simple empirical polynomial expressions are used. The solubility curve in this study was 
represented by a second-order polynomial fitted to experimental data: 
 
           
         (4.1) 
 
In the current study the absolute supersaturation ( S ) has been used, which is the difference 
between the solution concentration     and the equilibrium concentration (solubility) at a 
particular temperature, given by: 
 
         (4.2) 
 
Introducing equation (4.1) into (4.2) and setting the supersaturation equal to the desired setpoint 
supersaturation (
set
S ), allows the calculation of the temperature (
set
T ) required to achieve the 
target supersaturation, by simply solving the following generic nonlinear equation: 
 
        
 
                      
 
(4.3) 
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When the polynomial equation (4.1) is used for the solubility term, this reduces to the solution of 
a simple polynomial equation. The resulting temperature setT  is tested to be within the physical 
limits for the process and is used as the setpoint for the lower level temperature control system. 
 
The concentration is computed from the derivative of the absorbance at a characteristic 
wavelength for the compound corrected for the effect of the temperature, using the calibration 
model of the following form: 
 
                   (4.4) 
 
where   is the concentration in (g/g solvent) and,    ,    ,    and    are the regression 
coefficients,   is the derivative absorbance at the selected wavelength and   is the process 
temperature (see Experimental Procedures section). 
 
In this case, the temperature profile is a function of the measured concentration and the 
supersaturation setpoint. SSC is implemented using feedback control and requires a 
chemometrics-based calibration model, but it does not need extensive experimentation to obtain 
kinetic model parameters, such as growth and nucleation rate constants. A block diagram for the 
SSC approach is shown in Figure 4.1, while its operation in the phase diagram is shown in Figure 
4.2. 
 
If a slow growing system is used or the solid density is low, a supersaturation setpoint closer to 
solubility curve should be selected and maintained throughout the process as shown in Figure 
4.2. The seed addition point is also critical. If the system is seeded at a higher supersaturation 
there is a possibility of nucleation in the system therefore it is preferred to seed the system at 
lower supersaturations. Solubility data, in the form of equation (4.1), for the specific system to be 
used are input to the software. Once the seeds have been added, or generated in situ, SSC can be 
started. The setpoint is selected or can be adjusted depending on the number of particles, or 
growth characteristics of the system. Concentration is continuously measured and fed to the 
supersaturation controller, which then sends a signal for temperature manipulation based on the 
process conditions and obtained from equation (4.3). In this way a constant supersaturation may 
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be maintained throughout the batch time. In practice, maximum and minimum temperature limits 
should also be specified to define the process boundaries, reflecting the operating range of the 
cooling / heating system.   
 
 
 
Figure 4.1 Block diagram for the supersaturation control approach for batch cooling crystallisation processes 
  
 
Figure 4.2 Phase diagram showing a typical operating curve during supersaturation control 
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a model-free feedback control approach, which makes use of FBRM to measure chord length 
Setpoint
Calculation
Temperature 
Controller
Crystallizer
Tset (t)
Tjacket(t)
+
-
ATR-UV/Vis +
Chemometrics
C
A
b
so
rb
a
n
ce
T
Csol (T)Sset
MSZW for primary nucleation
Operating profile 
for SSC
Solubility curve
Temperature
S
o
lu
te
 c
o
n
ce
n
tr
a
ti
o
n
Seed addition
  
Chapter 4 Comparative Investigation of Supersaturation and Direct Nucleation Control of Crystal Size 
Distributions using ATR-UV/Vis spectroscopy and FBRM 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  89 
 
distributions, which can be related to the number and size of the particles present in the system. 
The chord lengths given by FBRM are grouped into 90 size bins from 0.8 – 1000 µm. From these 
raw data, weighted and un-weighted statistics may be calculated by the FBRM software; e.g., 
total counts/s is the number of chord length measurements for the whole size range. An increase 
in the total counts/s indicates nucleation or breakage in the system. The FBRM software also 
produces a SWMCL, which is sensitive towards the larger particles and can be used as a 
growth/agglomeration and average particle size indicator in the system (Abu Bakar et al., 2009).  
 
The ADNC approach is based on the fact that a major source of variability in the CSD comes 
from primary and secondary nucleation events that occur in the system. In situ fines removal 
through heat addition can therefore help in improving the CSD by promoting the growth of 
bigger crystals and reducing the number of fines. This also eliminates the use of external heating 
loops in some crystallizer designs that are used for removing fines. A schematic block diagram 
for the ADNC approach is shown in Figure 4.3. The total counts/s measured by the FBRM are 
continuously sent to the nucleation controller, where they are compared against the target 
counts/s. The nucleation controller sends a signal to temperature controller which then varies the 
vessel jacket temperature accordingly. The operating profile is therefore based on the real time 
detection of nucleation and dissolution events in the process and does not follow a predetermined 
temperature profile.   
 
A typical ADNC operating profile is shown in Figure 4.4. It is a well known fact that large 
variations exist in MSZW because of the presence of impurities and particles. If a control 
strategy based on keeping the operating curve within the meta-stable zone for primary nucleation 
does not detect changes in the MSZW this may result in secondary nucleation during the process, 
yielding a broad product CSD. The ADNC approach is based on feedback control based on the 
measurements related to variations in the number of particles in the system and hence is able to 
respond to any changes in the MSZW because of the presence of for example impurities, 
particles or crusting. 
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Figure 4.3 Block diagram for the Direct Nucleation Control approach for batch cooling crystallisation 
 
 
 
 
Figure 4.4 Phase diagram indicating a typical operating profile in the case of direct nucleation control 
approach 
 
The continuous heating and cooling cycles remove fines and promote growth; in addition these 
cycles also help in preventing agglomeration and solvent inclusion in the crystals. Thus, in 
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Figure 4.5 illustrates the feedback control approach for the ADNC approach used to maintain the 
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lower limits and proportional gains (i.e. kh and kc) for the heating and cooling phases. When the 
counts/s fall between the lower and upper limits, proportional control is applied to the jacket 
temperature. When the counts/s fall outside these lower and upper limits then the heating and 
cooling is achieved following linear heating and cooling curves with predetermined slopes. The 
jacket temperature is set to the minimum and maximum values, whenever these limits are 
achieved. Thus, in Figure 4.5, initially the counts/s are below the lower limit and the temperature 
setpoint follows the predetermined fastest linear cooling profile. This should force nucleation, 
causing an increase in the counts/s.  When the counts/s crosses the lower limit, the cooling rate is 
reduced. Typically, nucleation causes an overshoot and the counts/s exceed the target value; at 
that point the ADNC switches to heating rather than cooling and operates under proportional 
control. If the counts/s exceeds the upper limit, the heating rate is set to its maximum value. Fine 
particles are removed by dissolution and the counts/s returns towards its target value. Thus the 
controller requires specification of the setpoint or target number of counts/s, the upper limits for 
the heating and cooling rates, the minimum and maximum temperatures in the crystallizer and 
the adjustable kh and kc values. 
 
From a clear solution, the ADNC process begins with cooling the system at a specified rate until 
the nucleation takes place and target counts are reached. During the process slow cooling (based 
on the kc value) starts once the counts have crossed the lower limit. Slow heating (based on kh) 
will turn on if the number of counts is between the target counts and upper limit. Once the upper 
limit is crossed maximum heating mode will be switched on. The heating and cooling cycles will 
continue until the total counts have reached the target value.  
 
The FBRM measurements are transmitted to the Crystallisation Process Informatics System 
(CryPRINS) software, in which the various crystallisation control approaches have been 
implemented. In the current work, ADNC using total counts/s as the target was implemented, but 
the software has the option of implementing ADNC using any other statistics.  
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Figure 4.5 Schematic representation of the working principle of the automated direct nucleation control 
(ADNC) approach 
 
4.3 Experimental Procedures 
4.3.1 Materials and Instrumentation   
 
The experiments were carried out using paracetamol (4-acetaminophenol, 98 % purity, purchased 
from Aldrich). The experimental setup described in chapter 2 was used here. ATR-UV/Vis 
spectroscopy was used for monitoring the liquid phase and implementation of SSC, while FBRM 
was used for monitoring phase and ADNC application. 
 
4.3.2 Calibration Model Development 
 
The details of calibration model development approach have been described in chapter 3. The 
same methodology was used here and the non-linear model was selected for determining the 
concentrations from ATR-UV/Vis spectroscopy data.  
 
Spectra were recorded over a range of different concentrations and temperatures for 
undersaturated and supersaturated (single phase) solutions. A model using seven different 
concentrations (0.1106 to 0.1840 g/g) across a range of temperatures was built, using derivative 
spectra at 266 nm. The concentrations used are shown in a phase diagram in Figure 4.6.  
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Figure 4.6 Concentration and temperature points covered in the phase diagram 
 
 
Figure 4.7 1st derivative at 266 nm for various concentrations at different temperatures 
 
The nonlinear model as described in the previous chapter consisted of intercept term, derivative, 
temperature and interaction terms. The model parameters which were obtained from the 
calibration model were          ,             ,           and           ; the 
temperature was measured in °C and the first derivatives are in nm
-1
. The root mean square error 
of prediction, calculated using this model was 0.0013 g/g, while maximum and minimum relative 
errors were       and       , respectively. In order to check the robustness of the model a 
separate calibration experiment was performed in which samples were withdrawn from the slurry 
in the vessel at different temperatures and checked by gravimetric analysis.  The calibration 
model gave concentrations which were within     of the gravimetric analyses.  The results 
obtained from gravimetric analysis were compared with the results obtained from the model and 
are shown in Figure 4.8. 
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Figure 4.8 Predicted concentrations plot against gravimetrically determined concentrations 
 
4.4 Results and Discussion 
4.4.1 Unseeded Linear Cooling Crystallization Experiments 
 Table 4.1 summarizes the conditions for all the experiments carried out. Two unseeded linear 
cooling crystallization experiments were carried out to provide a base case and to check the 
maximum number of nuclei that could be generated by the system. A concentration of 0.206 g/g 
was used for both runs, with cooling rates of 0.5 °C/min and 0.05 °C/min. The results are shown 
in Figure 4.9.   
 
For the fast cooling experiment the nucleation took place at a lower temperature, 5 °C and hence 
at a higher supersaturation, resulting in a greater number of total counts than for slow cooling. 
For the latter, as expected, nucleation took place at a higher temperature and a lower 
supersaturation, resulting in a smaller number of total counts. The SWMCL for both experiments 
is shown in Figure 4.10 (a) and (b).  
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Table 4.1 Summary of the experimental conditions for all experiments 
 
No. Experiment Heating /cooling 
rate (°C/min) 
Amount of 
seeds (mass %) 
SSC 
setpoint 
(g/g) 
ADNC setpoint 
(Total counts/s) 
and bounds 
1 Unseeded slow linear cooling   0.05    
2 Unseeded fast linear cooling 0.5    
3 Seeded linear cooling  5   
4 Programmed cooling  5   
5 SSC1  5 0.010  
6 SSC2  5 0.012  
7 SSC3  10 0.010  
8 ADNC1 0.2/0.4   8000 (±1000) 
9 ADNC2 0.2/0.4   8000 (±  100) 
10 ADNC3 0.2/0.4   4000 (±1000) 
11 ADNC4 0.2/0.4   4000 (±  100) 
12 ADNC5 0.2/0.2   4000 (±  100) 
13 ADNC6 0.4/0.4   4000 (±  100) 
14 ADNC-SSC1 0.2/0.4  0.010 8000 (±1000) 
15 ADNC-SSC2 0.2/0.4  0.005 14000 (±1000) 
 
 
 
Figure 4.9 Unseeded cooling crystallization experiments with slow and fast cooling rates. Slow run was 
selected for comparison with other approaches; ADNC target counts were also selected based on slow run 
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Figure 4.10 SWMCL plots (a) slow cooling crystallization experiment (b) fast cooling crystallization 
experiment 
  
Clearly there is more growth during slow cooling experiment as fewer particles were generated. 
Based on these results, the unseeded slow cooling crystallization experiment was selected for 
comparison with other control strategies. For ADNC experiments target counts of 8000 and 
4000, since they were well below the counts/s recorded for either of the unseeded cooling 
crystallization experiments. 
 
4.4.2 Seeded Crystallisation Experiments using Linear Cooling or 
Supersaturation Control 
 
The aim of the next stage of the study was to investigate the effect of different seed loadings and 
supersaturation setpoints on the final CSD using SSC. In all the experiments the saturation 
temperature was 50 °C (0.206 g/g) and seeds were added after cooling to 48 °C. Crystalline seeds 
in the size range of 125-185 µm obtained using sieve analysis were used in all these experiments, 
as they are less prone to agglomeration (Fujiwara et al., 2002). Three SSC experiments were 
carried out at with different seed loadings and supersaturation setpoints, details are given in 
Table 4.1. 
 
Seeded crystallization experiments with linear and programmed cooling were also conducted for 
comparison (see Table 4.1). The duration of these experiments was based on SSC1 experiment, 
i.e. the time from seed addition till the process reached 5 °C (Figure 4.11). The programmed 
cooling profile (Figure 4.12) successfully suppressed nucleation until 350 minutes, contrary to 
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the linear cooling profile where a slow and steady increase in the counts was observed. In the 
case of the programmed cooling profile significant nucleation took place at about 25 °C. The 
system also nucleated during the linear cooling run but the magnitude was smaller than the 
former case. This is due to the fact that linear cooling generated a small but continuous 
nucleation during the entire process, and hence the supersaturation was kept at a lower value, 
whereas in the case of the programmed cooling the number of particles was constant until the 
onset of the sudden nucleation, which occurred at a higher supersaturation. The late nucleation 
event significantly affected the final CSD for programmed cooling profile, the size distribution in 
Figure 4.13 shows presence of higher number of fines. These results also indicate that the system 
is characterised by slow growth, which is not enough to use the increasing supersaturation as the 
cooling rate increases during the programmed cooling, leading to the significant secondary 
nucleation when the supersaturation exceeds a certain limit. Longer batch times would be needed 
to avoid secondary nucleation in this case. Based on this comparison, the linear cooling profile 
was selected for comparison with SSC and ADNC experiments. 
 
 
 
Figure 4.11 Seeded crystallisation experiment with 5 % seed and linear cooling 
 
Total counts/s, temperature and concentration profiles for all SSC experiments are shown in 
Figure 4.14, Figure 4.15 and Figure 4.16. To demonstrate the control performance and show the 
ability of the system to keep the supersaturation at the desired level, a supersaturation plot for 
SSC1 is shown in Figure 4.17. The controller throughout the run managed to keep the 
supersaturation at the desired level; similar profiles were obtained for the other SSC runs, too. 
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Figure 4.12 Programmed cooling experiment with 5 % seed 
 
 
 
Figure 4.13 Comparison of CSD for programmed and linear cooling profiles 
 
 
 
Figure 4.14 SSC1 experiment with 5 % seed and 0.010  g/g as supersaturation setpoint 
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Figure 4.15 SSC2 experiment with 5 % seed and 0.012 g/g as supersaturation setpoint 
 
 
 
Figure 4.16 SSC3 experiment with 10 % seed and 0.010 g/g as supersaturation setpoint 
 
 
Figure 4.17 Supersaturation profile for SSC1 experiment 
 
The temperature profiles are obtained automatically from the SSC, as the controller manipulates 
the temperature to maintain constant supersaturation. Compared to the linear cooling profile, the 
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decrease in temperature can be related to slow consumption of supersaturation by the seed 
crystals. As the crystals grow and more surface area is available the temperature decreases faster 
to keep the supersaturation constant. However the slow growth of the particles ultimately resulted 
in significant secondary nucleation events for both SSC1 and SSC2 runs. In the SSC2 
experiments higher supersaturation setpoint was used, which as expected, led to more significant 
nucleation, which started at an earlier stage of the batch than in the case of SSC1. When the 
concentration started to decrease due to the secondary nucleation event the SSC2 decreases the 
temperature even faster than SSC1, to try to keep a higher supersaturation, which in turn 
generates even more significant nucleation. The temperature was decreased rapidly after the 
nucleation event by the controller to maintain the supersaturation at the desired level.  
 
To create more surface area to promote growth the amount of seed was doubled and another 
supersaturation control experiment was performed using the same, (lower) setpoint as for SSC1. 
This run (SSC3) resulted in a fast cooling profile since due to the larger number of particles the 
supersaturation generated was consumed rapidly. The amount of secondary nucleation was less 
in SSC3 compared to the other experiments. This is in correlation with other observations in the 
literature that indicate that the large number of crystals suppresses secondary nucleation (Doki et 
al., 2004), due to their higher surface area which promotes growth (Hojjati and Rohani, 2005).   
 
Secondary nucleation affected the average particle size, as shown in Figure 4.18 (a), (b), (c) and 
(d). Only the data after nucleation is shown because of presence of noise when the solution was 
clear. In all the experiments the average particle size decreased after nucleation as more fines 
were generated in the system. As noted earlier SSC3 was less affected by nucleation events 
indicated by the smaller decrease in the SWMCL. The results suggest that the rate of secondary 
nucleation events dominated compared to the growth in this particular system. Paracetamol is a 
slow growing system, especially as the temperature is lowered while maintaining constant 
supersaturation. SWMCL plots also show that the average crystal size remained more or less 
between 100 - 110 µm for all the experiments, before nucleation took place, showing very little 
growth. This is in agreement with growth kinetic studies (Omar et al., 2008; Shekunov et al., 
1996), which showed the growth velocity of crystal surface steps decreased as the temperature 
was lowered at constant supersaturation.  
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Figure 4.18 SWMCL plots for seeded experiments (a) linear seeded crystallization (b) SSC1 (c) SSC2 (d) 
SSC3. The inset for linear seeded run shows high levels of noise in SWMCL when the solids are completely 
dissolved, hence only the SWMCL after nucleation is used for analysis. 
 
The comparison of the square weighted chord length distributions (SWCLD) indicate that a 
broader and bi-modal distribution was obtained (Figure 4.19) for linear cooling and the SSC 
experiments with the exception of SSC3, the uni-modal CSD for seeds is also shown. Bi-
modality is obvious in case of linear cooling, SSC1 and SSC2, as in these cases significant 
nucleation occurred and hence large number of small particles was generated. In case of SSC3 
although nucleation took place the number of new particles generated is less compared to the 
previously discussed profiles, hence bi-modality is not observed, except for a small shoulder on 
the CSD at smaller sizes. Similar results are indicated by Figure 4.18 (d), too, where the SWMCL 
for SSC3 run does not decrease significantly compared to the other profiles after nucleation. For 
ease of comparison the SWMCL will be referred as CSD from here onwards.   
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Figure 4.19 Comparison of CSDs (at the end of the batches) for seeded cooling crystallization experiments. 
The CSD of the seed crystals used in all cases is also shown. 
 
4.4.3 Direct Nucleation Control Experiments 
 
Six ADNC experiments were carried out with the aim to investigate the effects of different target 
counts/s, different upper and lower bounds and different heating/cooling rates on the control of 
the CSD. The details for these experiments are presented in Table 4.1. 
 
In all ADNC experiments cooling was initiated after complete dissolution, resulting in significant 
primary nucleation; several heating and cooling cycles were required in each case before the 
counts stabilized around the target value. 
 
 
Figure 4.20 ADNC1 with 8000 target counts and ±1000 limits 
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Figure 4.21 ADNC2 with 8000 target counts and ±100 limits 
 
 
 
Figure 4.22 ADNC3 with 4000 target counts and ±1000 limits 
 
 
 
Figure 4.23 ADNC4 with 4000 target counts and ±100 limits 
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The difficulty in maintaining the counts at smaller target values can also be seen: the number of 
heating/cooling cycles doubled for the target of 4000 counts/s (Figure 4.22 and Figure 4.23) 
compared to 8000 counts/s (Figure 4.20 and Figure 4.21). This is understandable as the presence 
of a greater number of particles makes it more difficult for secondary nucleation to take place, as 
was observed in the case of SSC3. For both cases with narrow bounds, a greater number of 
heating/cooling cycles were required to maintain the system close to the target number of counts. 
Narrow bounds effectively produce on/off control where the heating and cooling phases switch 
between their maximum rates, producing overshoot in both the dissolution and nucleation events. 
The effect of narrow bounds is more pronounced in the case of 4000 target counts, where the 
largest number of heating/cooling cycles was required. The heating/cooling cycles for all ADNC 
experiments are shown in the phase diagrams on Figure 4.24 (a), (b), (c) and (d). Analysis of 
these figures helps in understanding the reduction of MSZW in the presence of particles and how 
ADNC adapts to this change in the MSZW.  
 
In all four ADNC experiments the primary MSZW was approximately 45 °C and nucleation took 
place at about 5 °C. The very large primary nucleation zone generated very high initial 
supersaturation, leading to a very fast and significant nucleation. This has led to an overshoot of 
the target number of counts and the ADNC system switched to the heating stage. This first 
cooling and heating stage is indicated by the large cycles in the phase diagrams of all four 
experiments. Once the particles were generated, a significant reduction in MSZW was observed, 
as shown by the points joined together in Figure 4.24, which correspond to the all the secondary 
nucleation events representing the MSZW for secondary nucleation. In the second and 
subsequent cooling cycles particles were already present leading to nucleation much earlier and 
hence automatically switching to the heating stage. This leads to the smaller cycles in the phase 
diagram. These results demonstrate the main advantage of the ADNC approach, that it can detect 
any variations in MSZW and can change the operating conditions (heating or cooling rates) 
accordingly. This variation in the MSZW and ADNC’s ability to adapt accordingly is evident in 
all the experiments. Additionally the ATR-UV/Vis spectroscopy ability to automatically 
determine the solubility curve is also shown. Starting from the slurry and slowly heating the 
system, the calibrated ATR-UV/Vis spectroscopy indicates the increase of the concentration with 
temperature in the suspension, which closely corresponds to the solubility curve of the system. 
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Figure 4.24 Phase diagrams for direct nucleation control (ADNC) experiments (a) ADNC1 (b) ADNC2 (c) 
ADNC3 (d) ADNC4 
 
It has been seen in case of the seeded crystallizations and the SSC experiments that secondary 
nucleation events generated fines which adversely affected the final CSD. The evolutions of fine 
(<23 µm) and coarse particles (100-250 µm) in Figure 4.25 help in understanding the advantages 
of the ADNC approach. Fines are responsible for the broad CSD. ADNC works by dissolving 
fines and promoting growth of bigger particles. In Figure 4.25, for all ADNC runs, the first 
dissolution step after nucleation shows an increase in the number of coarse particles at the 
expense of fines. This increase in the number of coarse particles can be attributed to the size 
range used here i.e. 100-250 µm. As the temperature is increased the fines would dissolve while 
the bigger particles will reduce in size. The bigger particles undergoing dissolution were counted 
by the FBRM in the range used and the increase is coarse counts is thus the result of particles 
bigger than 250 µm undergoing dissolution. Heating/cooling cycles, which are used by the 
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ADNC approach, have been reported in literature as a method to improve the CSD by reducing 
the number of fines (Hojjati and Rohani, 2005; Bakar et al., 2009). 
  
  
   
 
Figure 4.25 Evolution of fine and course particles for ADNC experiments (a) ADNC1 (b) ADNC2 (c) ADNC3 
(d) ADNC4 
 
 
Figure 4.26 Evolution of CSD during ADNC1. The time shown is in minutes. 
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The CSD for ADNC1 at different times is shown in Figure 4.26. At approximately 360 minutes 
the CSD is shown just before the dissolution started as shown by the decreasing concentration in 
Figure 4.20. At 415 minutes the dissolution had started as shown by the increase in 
concentration. The subsequent CSDs apparently show growth of bigger crystals, which is in 
contrast to the dissolution of fines as both phenomenon cannot take place simultaneously as the 
temperature is increased. This shift in CSD towards the right side can be because of the 
“snowstorm effect” (Abu Bakar et al., 2010). This phenomenon takes place in the presence of 
large number of fine particles, which can hinder the FBRM ability to measure the large crystals. 
When the dissolution starts the number of fine particles is decreased and as a result more large 
particles are counted by the FBRM. In all ADNC experiments the number of fine particles was 
very large (always greater than 10000 counts/s), hence it is likely that the snowstorm effect is the 
cause of the shift in the CSD as the temperature was increased. 
 
The same observation is illustrated by the SWMCL results for the ADNC experiments shown in 
Figure 4.27. The slight decrease in SWMCL at the time of dissolution events further supports the 
above argument, however, an overall increasing trend is seen in all cases.  ADNC3 and ADNC4, 
which had the lowest target counts/s show the most growth. Continuous growth is observed 
throughout the process and as a result much larger crystals are obtained compared to the 
previously described approaches.  
 
The SWMCL of 158 µm for the ADNC4 experiment is significantly more than the value of 77 
µm obtained from the unseeded, slow linear cooling experiment. Furthermore, ADNC4 produced 
much larger crystals than were obtained in SSC3 (SWMCL of 101 µm). The SWMCL for the 
seeded SSC experiments started to decrease towards the end of the batch, because of late 
secondary nucleation event, the effect of which was seen as a bimodality in the CLD. Figure 4.28 
shows a comparison of the CLD for the various ADNC and the SSC3 experiments. The ADNC 
results show mono-modal size distributions for all cases. 
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Figure 4.27 SWMCL for ADNC experiments (a) ADNC1 (b) ADNC2 (c) ADNC3 (4) ADNC4 
  
 
Figure 4.28 CSD (at the end of the batches) comparison of ADNC experiments with SSC3, the setpoints for 
each ADNC run are shown in the bracket. 
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Figure 4.29 Microscopic images of selected experiments for comparison (a) unseeded linear cooling 
experiment (b) seeded linear cooling experiment (c) SSC3 run (d) ADNC4 
 
The difference in the quality of crystals obtained is evident from the microscopic images of 
samples of the product obtained from each experiment, shown in Figure 4.29. The unseeded 
cooling crystallization produced a broad size distribution of agglomerated particles, as shown in 
Figure 4.29 (a). Some agglomeration is evident in Figure 4.29 (b) and (c) for the seeded linear 
cooling experiment, and SSC3. In contrast there is very little agglomeration seen for the ADNC4 
experiment in Figure 4.29 (d) and the crystals are large with a narrow size distribution. In this 
last case, the continuous heating/cooling cycles in ADNC help in breaking any agglomerates that 
exist in the system, as well as preventing solvent inclusion between the crystals. Moreover, the 
crystals obtained from ADNC have well-defined shapes and sharp edges, indicating fewer 
defects on the crystal surfaces. 
   
Two further ADNC experiments were carried out to evaluate the effect of different heating and 
cooling rates on the crystal product. In both cases the target counts were 4000 counts/s and the 
upper/lower limits were set at ±100 counts/s. The heating/cooling rates were 0.2 °C/min for 
   (a)                                              (b) 
   (c)                                               (d) 
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ADNC5 and 0.4 °C/min for the ADNC6 experiments. The results are shown in Figure 4.30 and 
Figure 4.31, respectively. Fewer heating/cooling cycles were required for ADNC5, which shows 
that this particular system is better controlled with slower heating/cooling rates, however, this 
may also depend on other factors such as the upper and lower bounds for the target counts/s. The 
greater number of cycles for ADNC6 also leads to longer batch times. 
 
 
Figure 4.30 ADNC5, heating/cooling rate 0.2 °C/min 
 
 
Figure 4.31 ADNC6, heating/cooling rate 0.4 °C/min 
 
The phase diagrams for both runs in Figure 4.32 (a) and (b), show similar behaviour in terms of 
the MSZW variation and subsequent detection of secondary nucleation events by the ADNC 
approach. In both cases continuous growth of crystals was obtained, as was observed in the 
previous ADNC experiments (Figure 4.24).  ADNC6 takes somewhat longer, but produces 
similar crystals, as expected since similar final counts were achieved. The yields in all 
experiments are similar and are fixed by using the same initial concentration and final 
temperature.  
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Figure 4.32 Phase diagrams for (a) ADNC5 (b) ADNC6  
  
4.4.4 Combined ADNC and SSC Approach 
 
So far the two control approaches, namely ADNC and SSC, have been applied independently. 
Both have their advantages and disadvantages. For example, the longer batch times and multiple 
heating/cooling cycles required in ADNC may not be feasible in some cases, especially at 
industrial or pilot plant scale, because of the slow dynamics of the heat transfer system. SSC on 
the other hand may result in secondary nucleation and smaller crystal sizes compared to ADNC 
as shown by the experimental results. For SSC, although a higher seed loading may partially or 
completely suppress the secondary nucleation, it is not always possible or feasible to seed the 
system. Furthermore variability in size distribution and quality of the seeds used can affect the 
final CSD (Aamir et al., 2010). To address these problems, in this section a combined ADNC and 
SSC approach is proposed which is based on the sequential application of the ADNC and SSC. 
ADNC is started first to create seed crystals by primary nucleation event (in situ seed 
generation), with the ADNC regulating the process to a desired number of counts/s, where it had 
been established that no further nucleation should occur. When the target number of counts/s has 
been achieved, the control is switched to the SSC to maintain the supersaturation constant 
throughout the remainder of batch time and hence to obtain crystals of the desired size and 
distribution. The approach is not limited to in situ seed generation and can be extended for 
external seed addition.  
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Two experiments with the combined approach were carried out, with the aim of obtaining larger 
crystals without any bimodality. For the first experiment (ADNC-SSC1), the target counts/s were 
8000 (±1000), the heating rate was 0.2 °C/min, cooling rate was 0.4 °C/min and the 
supersaturation setpoint was at 0.01 g/g. For the second experiment (ADNC-SSC2), the target 
counts/s were 14000 (±1000), the heating rate was 0.2 °C/min, cooling rate was 0.4 °C/min and 
the supersaturation setpoint was 0.005 g/g. After initial dissolution, ADNC was turned on in both 
cases, and once the target counts were reached control was switched to SSC until the process 
reached the lower temperature limit of 5 °C. The operating profiles are shown in Figure 4.33 and 
Figure 4.34 for ADNC-SSC1 and ADNC-SSC2, respectively. 
  
For ADNC-SSC1 a smaller number of particles were present, so the rate of generation of 
supersaturation was almost equal to the rate of consumption either by growth or secondary 
nucleation, resulting in almost a linear temperature profile. The presence of a smaller number of 
particles leads to secondary nucleation, similarly as it was shown in the previous experiments.  
 
 
Figure 4.33 ADNC-SSC1, target counts were 6000, supersaturation setpoint was 0.010 g/g 
 
The temperature profile resulted from the ADNC-SSC2 is significantly different. Although the 
supersaturation setpoint is smaller compared to the ADNC-SSC1 experiment, the presence of a 
large number of particles consume the supersaturation quickly, forcing the temperature to 
decrease at a higher rate. In both cases, the batch times are considerably shorter than for the 
ADNC runs. 
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Figure 4.34 ADNC-SSC2, target counts were 14000, supersaturation setpoint = 0.005 g/g 
 
Phase diagrams for both experiments are shown in Figure 4.35 (a) and (b) respectively. In both 
cases the primary nucleation happens at very high supersaturaion, leading to a fast decrease in 
concentration and steep increase in the number of counts/s. The target counts/s for the ADNC-
SSC1 was 8000 counts/s, which is significantly lower than for the second experiment. This target 
was quickly exceeded by the increasing number of particles and hence the ADNC switched 
sooner to the heating stage. Furthermore, the temperature had to be raised significantly more than 
for ADNC-SSC2, to dissolve the excessive number of in situ generated particles, to achieve the 
low target count. This is indicated by the larger secondary loop in the phase diagram. After 
switching to SSC the controller was able to maintain the supersaturation at the required level 
throughout the process as shown in Figure 4.36, although significant nucleation took place.  
 
   
 
Figure 4.35 Phase diagrams for (a) ADNC-SSC1 (b) ADNC-SSC2 
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Figure 4.36 Supersaturation profile for ADNC-SSC1 experiment, SS setpoint was 0.01 g/g 
 
For the ADNC-SSC2 nucleation took place at 5 °C and since the target counts/s was set at 14000, 
the decrease in concentration is significantly less than in the case of ADNC-SSC1 before the 
heating started, to generate the larger number of particles. To stabilize the system at the larger 
target number of counts, the heating phase stops at a lower temperature than for the ADNC-
SSC1, and the approaches switches to the SSC. In this case also SSC is able to maintain 
supersaturation at the desired level throughout the process. Higher target counts and lower 
supersaturation setpoint were selected for the ADNC-SSC2 to suppress secondary nucleation 
event. Compared to the ADNC-SSC1 no nucleation took place in the case of ADNC-SSC2 
because of presence of large number of particles and lower supersaturation setpoint during the 
SSC. 
 
The SWCLDs for both experiments are shown in Figure 4.37. Bimodality is seen in the case of 
ADNC-SSC1, however, a uni-modal distribution is observed for ADNC-SSC2. For ADNC-SSC2 
the distribution is shifted significantly more towards the right indicating the presence of larger 
crystals and less broader distribution than for ADNC-SSC1. This seem counterintuitive at first 
since the target counts/s for the initial seed generation was smaller for the ADNC-SSC1, 
suggesting that smaller number of seed particles were present in this case when the SSC started 
than in the case of the ADNC-SSC2. However, the subsequent significant secondary nucleation 
that occurred in the ADNC-SSC1 experiment increased the number of particles significantly 
above the particles present in the ADNC-SSC2 experiments, leading to the smaller SWCLD for 
the final product. During the ADNC-SSC2 experiment no secondary nucleation was observed 
resulting in more uniform crystals with larger mean size. Microscopic images of crystals obtained 
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from ADNC-SSC1 and ADNC-SSC2 are shown in Figure 4.38 (a) and Figure 4.38 (b). The 
crystals obtained from ADNC-SSC1 were smaller in size compared to that of ADNC-SSC2, the 
pictures are in correlation with the previous figures and show a better product quality using 
ADNC-SSC2. The batch time in both cases was significantly shorter than for the ADNC 
experiments but longer than the SSC experiments. There is a trade-off between batch time, 
crystal size and distribution, and any approach, or combination of approaches, will need to be 
tailored to the individual system and process requirements. 
 
 
Figure 4.37 CSD distributions for ADNC-SSC1 and ADNC-SSC2 experiments at the end of the batches 
 
  
 
Figure 4.38 Microscopic images of (a) ADNC-SSC1 (b) ADNC-SSC2 
   
4.5 Conclusions 
 
Three control approaches, namely SSC, ADNC and ADNC-SSC using FBRM and ATR-UV/Vis 
spectroscopy were compared with each other and for the cases of seeded and unseeded cooling 
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crystallizations. Various statistics were used to assess the performance of each approach and it 
has been shown that the direct nucleation control approach, which requires no a priori 
information about the system, outperformed the other control strategies. For the paracetamol in 
isopropyl alcohol system, significant variations were found in the MSZW in the presence of 
crystals, which were responsible for the poor performance of control strategies other than the 
direct nucleation control approach. 
 
The ADNC approach was able to detect any changes in the MSZW caused by the presence of 
particles or impurities. The phase diagrams automatically generated during these experiments 
helped in understanding why the ADNC approach is superior to the other approaches used. The 
main advantage of the ADNC is that continuous in situ removal of fines occurs during the 
heating stages, whereas the cooling stages help in the growth of bigger crystals. The largest 
crystals with uni-modal distribution were obtained with ADNC compared to other operating 
policies. The mean size of the crystals mainly depends on the target counts/s: a lower target 
counts/s resulted in larger crystals, but at the same time it was difficult to control the process and 
there was a need for more heating/cooling cycles, which resulted in longer batch times. The 
continuous heating/cooling cycles in ADNC also helped in de-agglomeration of the particles, 
resulting in reduced amounts of solvent inclusion. The crystals obtained had a well-defined 
shape, sharp edges and fewer surface defects.  
 
Bimodal CSDs were observed for the SSC experiments and for the linear seeded experiments 
(the exception was SSC3 which used a higher seed loading). The SSC experiments showed how 
the seed loading can help in controlling or suppressing secondary nucleation events: runs with a 
higher seed loading gave the best results compared to the other seeded crystallization approaches. 
The ADNC approach has the disadvantage of longer batch times to accommodate the multiple 
heating/cooling cycles, whereas on the other hand the success of SSC largely depends on the seed 
loading and quality, any variation in the these two parameters can affect the final CSD. A hybrid 
approach of combining ADNC and SSC was used to address some of these issues. The batch 
times for ADNC-SSC were significantly shorter than for ADNC alone, but longer than simple 
SSC experiments. The mean crystal size obtained was smaller than with ADNC alone, but uni-
modal CLD and larger crystals were obtained compared to when the SSC was used alone.
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Chapter 5 Assessment of Direct Nucleation Control Approach for 
 Different Process Conditions during Cooling 
 Crystallization 
5.1 Introduction 
 
During crystallization a variety of disturbances can take place. The majority of the typical control 
approaches in this case fail to bring the system back to the required state. Secondary nucleation is 
a frequently occurring phenomenon because of various reasons, including breakage and attrition, 
variations in MSZW and the presence of impurities. Other disturbances include formation of 
encrustation and its detachment (Briancon et al., 1997; Vendel and Rasmuson, 2000, Chianese et 
al., 1993). Encrustation is a naturally occurring undesirable process because of differences in the 
supersaturation at the wall and in the solution (Mersmann, 1988).  There is a high probability of 
the crust detachment, causing secondary nucleation and leading to an undesired final CSD. 
 
The current chapter is a continuation of the ADNC work presented in the previous chapter. 
Previously it was shown that ADNC gave superior results than SSC, programmed cooling or 
linear cooling. The main aim of this chapter is to test the robustness of ADNC approach when the 
system encounters different disturbances during the crystallization process. For comparison 
purposes, a disturbance free experiment from the previous chapter is selected. The results from 
several experiments running under ADNC in which different disturbances were introduced are 
then compared to assess the performance of this control approach. The experimental setup used 
was the same as described in chapter 3. The results obtained are as follows. 
 
5.2 Results and Discussion  
 
The performance of the ADNC approach was tested under various conditions, which included 
different seeding conditions to assess the effect of external seeding and in situ seed generation on 
the product quality. Details of all the experiments carried out are summarized in Table 5.1. The 
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solute (paracetamol in isopropanol) concentration in all experiments was 0.206 g/g. Details of the 
model used for concentration calculation have been previously described in chapter 3. 
 
Table 5.1 Summary of the experimental conditions 
 
No. Experiment Heating 
/cooling rate 
(°C/min) 
Amount and type 
of seeds (mass %) 
ADNC setpoint 
(Total counts/s) 
and bounds 
1 Direct Nucleation Control run  
(ADNC4) 
0.2/0.4 In situ seed 
generation 
4000 (±1000) 
2 Seeded ADNC 1 (S-ADNC1) 0.2/0.4 10 (crystalline) 4000 (±1000) 
 
3 Seeded ADNC 2 (S-ADNC2) 0.2/0.4 5(crystalline) 6000 (±1000) 
 
4 Accidental seeding with ADNC 1 
(AS-ADNC1) 
0.2/0.4 5 (crystalline) 4000 (±1000) 
5 Accidental seeding with ADNC 2 
(AS-ADNC2) 
0.2/0.4 0.78 (powder) 4000 (±1000) 
 
ADNC 4 was used as a bench mark to compare the performance of ADNC for different scenarios 
as mentioned in Table 5.1. Accidental seeding will be used to simulate the affects of breakage of 
crust and subsequent addition in the solution. For this purpose seeds of different sizes will be 
added to the system once the nucleation has taken place in the system. Two seeded ADNC 
experiments were also carried out to check the performance of ADNC for seeded systems. 
 
5.2.1 Seeded Direct Nucleation Control Experiments 
 
A seeded experiment (S-ADNC1) was performed to check the performance of the ADNC in the 
case of external seeding. All the parameters such as target counts, upper and lower limits and 
heating/cooling rates were kept the same as in the ADNC4 experiment. After the initial 
dissolution the solution was cooled down to 48 °C i.e. just below the saturation temperature and 
10 g of seeds were added. The seed addition is indicated by an increase in the FBRM counts to 
approximately 8000 in Figure 5.1 (a). The heating cycle was immediately started as the counts 
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crossed the upper limit. In this case, the control was able to bring the counts quickly to the 
setpoint. In the unseeded experiment ADNC4, nucleation occurred at a high supersaturation 
resulting in a rapid and significant increase in the number of counts/s, whereas in the case of 
experiment S-ADNC1, there is no nucleation occurring in the system as the seed is added at a 
low supersaturation and the number of particles is determined by the amount (and size) of seed 
particles added. During the S-ADNC1 experiment the counts for most of the time remained close 
to the target value, unlike in the case of the ADNC4 experiment where more oscillations in total 
counts were observed.  
 
 
 
 
 
Figure 5.1 (a) Total counts/s, concentration and temperature for S-ADNC1 (b) Phase diagram for S-ADNC1  
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These results demonstrate that the most difficult part to control during crystallisation is the 
primary nucleation, when generally a very large number of small particles form suddenly. This 
sudden nucleation can induce more oscillations of the ADNC approach until stable counts are 
achieved, compared to the seeded operation when the system is never operated at a very high 
supersaturation. The phase diagram for the S-ADNC1 experiment (Figure 5.1 (b)) shows similar 
MSZW for the secondary nucleation as that of the ADNC4 experiment with the same target 
counts/s. This is expected since the secondary MSZW depends on the amount and properties of 
solids in the system. In both experiments similar number of seed particles with similar quality 
were used (both used crystalline seed, although for ADNC4 the seed was generated in situ). 
Figure 5.2 shows the variations in fine and coarse particles during the run, indicating that the 
number of larger particles were less susceptible to changes compared to the fines. The number of 
larger particles was affected more significantly only at higher temperature, while at lower 
temperatures no significant changes in their number took place. 
 
 
Figure 5.2 Evolution of fine and coarse particles for S-ADNC1 
 
In the previous seeded experiment the main aim was to directly compare the performance of 
ADNC for internally generated and externally added seeds. Typically in seeded crystallization 
experiments it is expected that the added seeds will grow, suppress the secondary nucleation 
resulting in uni-modal CSD with minimum number of fines. Another seeded experiment was 
therefore performed in which the target counts were selected based on the total counts obtained 
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after the seed addition. The total counts, concentration and temperature profiles are shown in 
Figure 5.3 (a).  
 
 
 
 
Figure 5.3 (a) Total counts/s, concentration and temperature profile for S-ADNC2 (b) Phase diagram for S-
ADNC2  
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critical limit. ADNC detected the secondary nucleation events and brought the counts back to the 
setpoint. Fewer heating/cooling cycles were required in this case as shown in Figure 5.3 (a). 
Figure 5.3 (b) shows similar reduction in MSZW as for the ADNC4 experiment. Smaller number 
of heating/cooling cycles can be explained as the presence of more particles suppresses 
secondary nucleation.  
 
 
 
 
Figure 5.4 (a) Evolution of fine and coarse particles for S-ADNC2 (b) Variation in CSD for S-ADNC2 
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end of the run is shown in Figure 5.4 (b), despite the occurrence of several secondary nucleation 
events bigger crystals with unimodal distribution were obtained, showing that ADNC was able to 
eliminate the fines that were generated during the run. 
 
5.2.2 Evaluation of Direct Nucleation Control in Case of Accidental Seeding 
 
The main aim of these experiments was to test the ability of the ADNC approach, against 
accidental seeding, which is a common disturbance in industrial crystallisation systems generally 
caused by encrustation and subsequent detachment of solid particles.  
 
 
 
 
Figure 5.5 (a) Total counts/s, concentration and temperature profile for AS-ADNC1 (b) Phase diagram for 
AS-ADNC1 
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Two experiments were performed with the conditions specified in Table 5.1. Target counts in 
both cases were set to 4000 so that a direct comparison of the performances with ADNC4 and 
seeded ADNC experiments is possible.  
 
In the first run (AS-ADNC1) crystalline seeds were added as a disturbance. After the initial 
dissolution and nucleation (Figure 5.5 (a)), heating was started until the setpoint counts of 4000/s 
was reached, once the counts were stabilized 5 g of crystalline seeds were added as a disturbance. 
 
The disturbance was corrected by the controller by increasing the temperature. The effect of 
correction can be seen as an increase in concentration because of the dissolution. Several 
heating/cooling cycles were needed as shown in Figure 5.5 (a) and (b) before the counts 
stabilized just above the setpoint at 5 °C. The phase diagram (Figure 5.5 (b)) is similar to the 
phase diagrams of the previous runs, indicating the adaptive dissolution cycles characteristic to 
the ADNC approach. 
 
The variation in CSD before and after the moment of the simulated accidental seeding is shown 
in Figure 5.6 (b). The addition of seeds caused a significant change in the CSD, resulting in a 
much broader distribution. The first heating/cooling cycle after the seed addition started shifting 
the CSD towards the right, i.e. the added disturbance was being corrected accompanied by 
growth of the crystals. As a result of this, a CSD with bigger crystals was obtained in the end. 
 
The plot of fines and coarse particles in Figure 5.6 (a) gives information about the nature of the 
disturbance in terms of the size range of particles. At the seed addition the number of course 
particles increased more significantly than for the fines, indicating that the particles were 
relatively large in size. This is expected since in this experiment crystalline seed was added. 
After the heating/cooling cycle which corrected the disturbance, the number of coarse particles 
stabilized at a value higher than the value before the disturbance also indicating that particles 
similar to the ones already present in the solution were added as part of the disturbance. After the 
correction a proportion of these particles was dissolved. The number of fine particles decreased 
to the same level, this is also evident from Figure 5.6 (b) where the shift in distribution indicates 
that particles contributing to the fines were gradually eliminated from the suspension. 
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Figure 5.6 (a) Evolution of fine and coarse particles for AS-ADNC1 (b) Variation in CSD for AS-ADNC1, 472-
482 min CSD prior to seed addition, 491-502 min CSD immediately after seed addition, 556-566 min CSD 
after the correction, end of the experiment 
 
For the second accidental seeding experiment (AS-ADNC2) raw material in the form of powder 
was added as disturbance. The powder was added once the counts had reached the setpoint 
counts (4000 counts/s) after the first correction (Figure 5.7 (a)). Because of the very fine nature 
of the powder only 0.78 g was added which resulted in an increase in counts from 4000 to about 
12000 counts/s.  
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Figure 5.7 (a) Total counts/s, concentration and temperature profile for AS-ADNC2 (b) Phase diagram for 
AS-ADNC2 
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Figure 5.8 (a) Evolution of fine and coarse particles for AS-ADNC2. (b) Variation in CSD for AS-ADNC2, 
500-510 min CSD prior to seed addition, 539-549 min CSD immediately after seed addition, 579-589 min CSD 
after the correction, end of the experiment 
 
A comparison of the final CSDs of all the runs is shown in Figure 5.9. ADNC4 and AS-ADNC2 
are very similar to each other as the disturbance in case of AS-ADNC2 consisted of very fine 
particles and was eliminated quickly from the solution, a very similar evolution of SWMCL can 
be seen for both cases as shown in Figure 5.10 (a) and Figure 5.10 (e). CSD for S-ADNC2 was 
expected to be different as the setpoint counts were different from the other runs. The SWMCL 
for this run, shown in Figure 5.10 (c) indicates that the presence of greater number of particles 
resulted in crystals relatively smaller than the other runs.  
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Figure 5.9 Comparison of CSD (at the end of the batches) of all the experiments 
 
 
 
 
Figure 5.10 SWMCL for (a) ADNC4 (b) S-ADNC1 (c) S-ADNC2 (d) AS-ADNC1 (e) AS-ADNC2 
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of the ADNC approach and its ability to produce consistently products of similar quality. No 
bimodality was observed in any of the experiments. 
 
Micrographs of the products obtained from different runs are shown in Figure 5.11 (a)-(e). Large 
crystals without any agglomerations were obtained in all runs.  
 
    
 
  
 
Figure 5.11 Micrographs of the products (a) ADNC4 (b) AS-ADNC1 (c) AS-ADNC2 (d) S-ADNC1 (e) S-
ADNC2 
 
5.3  Conclusions 
An evaluation of the ADNC approach under different conditions has been  presented for the first 
time in the case of cooling batch crystallisation using Paracetamol in IPA as the model system. 
The results of an experiment in which ADNC was used for in situ seed generation were used as a 
benchmark for the experiments with external seed additions and to study the effect of 
(a)                                      (b)                                       (c) 
  (d)                                      (e)                                                     
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disturbances, such as accidental seeding, that may occur during cooling crystallization process. 
The ADNC control was able to correct the disturbances and in all cases was able to bring the 
number of particles in the system close to the setpoint values. The different experimental 
conditions showed the robustness and effectiveness of the approach, especially its ability to 
detect any changes in the MSZW and number of particles. The final CSD obtained in all cases 
showed no bimodality, also no agglomeration was observed in any of the experiments.  
 
The results provide evidence that FBRM can be used effectively as a process control tool in 
addition to its widespread application as a monitoring tool. The ADNC approach is simple and 
does not require model building, extensive modelling or experimentation.  
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Chapter 6 Assessment of the Automated Direct Nucleation Control 
 Approach as a Scale up Tool  
6.1 Introduction 
 
Crystallization is a widely used separation and purification technique in various industries. In the 
pharmaceutical industries it is mostly carried out as a batch process for both cooling and anti-
solvent operating modes. Crystallization is a two phase process, i.e. liquid and solids exist in a 
suspension and considered as a difficult process to scale up. There are several reasons which 
make the scale up of crystallization process from laboratory to pilot and eventually to industrial 
scale a challenging task. It is reasonable to assume that perfectly mixed suspension can be 
obtained at laboratory scale (e.g. 1 L scale) (Rielly and Marquis, 2001). Also heating and cooling 
of the suspension can be easily controlled and the system can be made to follow desired 
temperature profiles because of sufficient heat transfer area. The same can be assumed for anti-
solvent crystallization, where the anti-solvent is quickly dispersed in the bulk of the solution and 
therefore very little supersaturation gradients exist between the point of addition and the rest of 
the vessel (Myerson, 2002). 
 
The situation on larger scale is quite different; it is almost impossible to achieve perfectly 
homogeneous conditions. Supersaturation gradients exist throughout the vessel because of 
differences in the temperatures near the heating surface or close to the point of anti-solvent 
addition. Variations in MSZW and secondary nucleation are some of the other problems that are 
encountered on large scale operations. It is a well know fact that crystals in larger vessels 
respond to changes in the microenvironments, which are in turn affected by changes in the 
macroenvironment (Myerson, 2002). These differences can have profound effect on the 
nucleation and crystal growth resulting in undesired CSD. To determine optimum set of 
operating conditions such as mixing and vessel geometry, computational fluid dynamics and 
population balance models are generally used. These models require accurate information about 
the vessel geometry, physical properties of the suspension such as viscosity, crystal size and 
other system and process related parameters. The output from these methods greatly facilitates 
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the design and scale up of crystallization processes, however, these methods are computationally 
very extensive and require considerable expertise for their development.  
 
The ADNC approach, described previously, gave superior results compared to the open loop 
profiles. The main aim of this chapter is to evaluate the performance of this approach as a robust 
scale up tool. The approach as described previously requires no a priori information about the 
system. Another motivation of the work was to apply the control approach based on PAT tools 
on pilot plant scale. The topic of application of PAT tools for controlling crystallization process 
on larger scale is under-represented in the literature, only a handful of studies are available 
(Bakeev, 2010). One of the reasons that prevents the use of sophisticated control approaches on 
pilot or industrial scale is the difficulty in implementation of these strategies because of the very 
different process control environment, for example the connecting of an in situ spectroscopic tool 
to an industrial distributed control system (DCS) may require significant effort because of the 
different interfaces and connectivity issues. The later issue has been addressed in the CryPRINS 
software which enables quick and easy connectivity with different control environments using on 
OPC client/server architecture.  
 
The work presented here aims to evaluate the potential application of the model-free ADNC 
approach on pilot plant scale crystallisation. Two case studies are presented here; in the first case, 
the ADNC approach for a new system, ortho-amino benzoic acid (OABA) and water, will be 
discussed. The new system was selected to demonstrate the applicability of the control approach 
for another system. A laboratory scale experiment was carried out initially as the basis for 
comparison. Based on this, the evaluation of the ADNC approach is carried out on the larger 
scale. A comparison with linear and natural cooling profiles is also performed at a pilot plant 
scale.  
 
The second case is related to application of the same approach for paracetamol/isopropanol 
(PCM/IPA) system on a pilot plant scale. Based on the thorough evaluation of the ADNC 
approach presented in the earlier chapters, experimental conditions and operating protocol are 
recommended for experiments on a 100 L scale crystallisation system located at the AstraZeneca, 
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Charnwood site, and the results are briefly presented, which clearly indicate the potential of the 
ADNC approach to provide good product quality at industrial scale. 
 
6.2 Experimental Procedure 
6.2.1 Materials and Instrumentation 
 
For the first case study, OABA, 98 % pure purchased from Sigma Aldrich was used with DI 
water as solvent. A 100 L stainless steel glass lined vessel fitted with glass coated anchor type 
impeller was used. PT 100 thermocouple was used for measurement of process temperature and 
an FBRM probe model A100 (Lasentec, USA) was used for monitoring the solid phase and 
implementation of the ADNC approach via the CryPRINS software. The jacketed crystallizer 
was connected to a heating/cooling unit (manufactured by Tool Temp, Switzerland, model TT-
280). The temperature control unit was fitted with a digital controller (manufactured by CAL 
Controls, model CAL9400) capable of sending and receiving data via the MODBUS protocol. A 
software interface for the controller was developed in LabVIEW (National Instruments, U.K.), 
which allowed the communication with the digital controller using the MODBUS protocol and 
connection via the RS232 interface. At the same time the software allows communication with 
external systems (e.g. CryPRINS) via an OPC interface. The vessel was fitted with an overhead 
motor and the impeller speed used was 74 rpm. A picture of the experimental rig used is shown 
in Figure 6.1 and a schematic diagram is shown in Figure 6.2. The DSC analyses were carried out 
using a Q 10 model instrument (TA Instruments, Crawley, UK). In all the DSC runs the samples 
were kept at 40 °C for one minute in the beginning and after that heated up to 200 °C at a rate of 
15 °C/min. 
 
The experiments at AstraZeneca, Charnwood were conducted in a 100 L pilot scale 
crystallisation system using paracetamol (4-acetaminophenol 98 % purity, purchased from 
Aldrich) and analytical grade 2-propanol as solvent. The same methodology and software 
(CryPRINS) was used in the pilot plant as in the rest of the experiments presented in this chapter.  
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Figure 6.1 Pilot plant crystallizer, 100 L capacity 
 
 
 
Figure 6.2 Schematic representation of the rig used, dimensions shown are in cm 
 
 
 
FBRM
FBRM
Tool Temp
Jacket 
Inlet
Jacket 
Outlet
Thermocouple
420
210
220
Chapter 6 Assessment of Automated Direct Nucleation Control Approach as a Scale up Tool 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  135 
 
6.3 Results and Discussion 
6.3.1 Scale-up Experiments Using the OABA in Water System 
Laboratory Scale Experiments 
 
The main purpose of this case study was to analyze the performance of the ADNC for a different 
system used under different operating conditions. The pilot scale experimental setup used here 
had two hard constraints which limited the optimisation of the experimental conditions. Firstly 
the vessel was fitted with an anchor type impeller and could not be replaced. This type of 
impeller is used for highly viscous liquids and not recommended for suspensions. In the literature 
therefore the correlations are not available for optimizing impeller speed in correlation with the 
vessel geometry for suspending particles in the solution. The second hard constraint was related 
to the large delays in heat transfer between the jacket and the bulk of the solution resulting in 
slow changes in the temperature especially during the cooling phase. Because of the slow 
dynamics of the system it was decided to use jacket temperature directly as the manipulated input 
set by the ADNC.  
 
Prior to the commencement of the experiments on the pilot plant scale, ADNC was used for 
OABA/water system on laboratory scale. The results obtained are shown in Figure 6.3. 
 
 
Figure 6.3 Total counts/s and temperature profile for OABA/water laboratory scale experiment 
 
Since the counts/s measurement obtained from the FBRM, depends on the volume of the 
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different scales is important for consistent results. Selecting similar target counts/s in absolute 
value most likely would not be a feasible option. To address this issue it was decided to use “a 
certain percentage of the maximum counts” obtained by linear cooling, as obtained on each scale, 
as setpoint for the ADNC. For example a linear cooling experiment was carried out at laboratory 
scale and from its results a setpoint of 2500 counts was selected, which was approximately 60 % 
of the maximum counts from the linear cooling run. The upper and lower limits were selected as 
2000 and 3000 respectively, kc and kh (proportional gain) values were kept at 1.  
 
Figure 6.3 shows that nucleation event took place at about 50 °C, several small heating cooling 
cycles were required to keep the counts at the desired level until the process reached the lower 
temperature limit of 25 °C and the counts stabilized close to the target value of 2500. The 
evolution of coarse particles indicates steady growth in the system, as shown in Figure 6.4. These 
results show similar trend as seen previously for the PCM experiments, indicating dissolution of 
fines and growth of bigger crystals during heating cooling cycles. A micrograph of the product 
crystals obtained at the end of the batch is shown in Figure 6.5. These figures show that the 
ADNC approach was able to generate product with bigger crystals by continuous growth 
throughout the process by alternating heating/cooling cycles. 
 
Having established that ADNC was applicable for the OABA/water system on the laboratory 
scale, pilot plant scale experiments were carried out, which are discussed in the next section. 
 
 
Figure 6.4 Evolution of coarse particles for the laboratory scale OABA/water run using ADNC 
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Figure 6.5 Micrograph of OABA crystals (form 2) obtained by ADNC at laboratory scale (1 L) 
 
Pilot Scale Experiments 
 
The ADNC parameters used for ADNC at pilot plant scale are as follows: 4 °C/min was selected 
as the heating and cooling rate for the jacket temperature, kc and kh values were 1. These set of 
parameters were selected as they were able to change the process temperature at a rate of 
approximately 0.28 °C/min, very close to the heating/cooling rates on the laboratory scale. Same 
concentration of OABA was used and 25 °C was selected as the lower temperature limit.  
 
Initially unseeded linear and natural cooling experiments were carried out for selection of a 
suitable setpoint for the ADNC, and for comparison of the product quality. Process and jacket 
temperature profiles are shown in Figure 6.6 and Figure 6.7 for both linear and natural cooling 
profiles, for understanding the heat transfer dynamics.  
 
 
Figure 6.6 Process and jacket temperature profiles for the linear cooling experiment at pilot plant scale 
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Figure 6.7 Process and jacket temperature profiles for natural cooling experiment at pilot plant scale 
 
These profiles show that a considerable lag exists between the jacket and process temperatures. 
The lag is very noticeable once the jacket temperature falls below 45 °C. The process temperature 
obtained by using a linear jacket temperature approximately corresponds to a linear cooling (but 
of course with slower rate than that for the jacket temperature), whereas the steep natural cooling 
curve in the jacket temperature results in a much slower but natural cooling profile in the reactor. 
The crystallisation results obtained from these two profiles are shown in Figure 6.8 and Figure 
6.9.  
 
 
Figure 6.8 Total counts/s and process temperature profile for linear cooling experiment at pilot plant scale 
 
In both cases the nucleation took place approximately at the same temperature between 45 °C and 
50 °C, followed by cooling. The solution for natural cooling experiment was kept at this 
temperature for some time to observe if any secondary nucleation might take place. The total 
counts for linear cooling profile remained generally between 9500 and 10000, while counts in the 
case of natural cooling remained between 7500 and 8000. 
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Figure 6.9 Total counts/s and process temperature profile for natural cooling run 
 
 
Figure 6.10 Total counts/s and temperature profile for ADNC run 
 
Analysis of these figures shows that natural cooling resulted in small and agglomerated crystals. 
Less agglomeration was observed in the case of linear cooling, and the products in both cases had 
similar crystal sizes. Both products show the presence of a significant amount of fines, which is 
probably due to secondary nucleation and breakage of the crystals during the process. The 
ADNC approach in contrast with the two approaches produced significantly larger crystals 
without any agglomeration. The product crystals are with well-defined shapes and edges, with no 
fines present in the system. The results show that by maintaining the number of crystals at a 
lower level favours growth of larger crystals. The heating/cooling cycles prevent agglomeration 
of particles as shown in previous results and eliminate fines, which may form due to breakage or 
secondary nucleation.  
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Figure 6.11 Micrographs of crystals (a) linear cooling (b) natural cooling (c) ADNC approach 
 
These experiments also illustrated the excellent performance of the ADNC approach to remove 
the fines that form due to breakage, which is a common problem in the case of large-scale 
industrial crystallisation processes. Many pharmaceutical compounds crystallize as brittle needle 
or plate shaped particles prone to significant breakage due to impeller-crystal collisions, 
especially in larger crystallisers, causing bimodal product distributions and difficulties during the 
subsequent isolation of the product (e.g. long filtration times). Finding a suitable cooling rate for 
controlling the crystallisation of products prone to breakage is difficult, since a suitable 
compromise has to be found between potential nucleation and breakage. In order to avoid 
secondary nucleation, a slow cooling rate is preferred, which operates the system at low 
supersaturation. However this results in longer batch times, and hence can increase breakage due 
to longer period in which particles are exposed to collisions. A typical crystallisation operation 
that keeps the operating trajectory within the supersaturated region is unable to eliminate the 
formation of fines, whereas the ADNC is able to detect increase in number of particles, whether 
produced by secondary nucleation or breakage, and by automatically initiating heating cycles 
preferentially dissolve the unwanted fines. 
 (a)                                             (b) 
                                                                        
 
(c) 
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A comparison of the ADNC approach on both scales show that smaller number of 
heating/cooling cycles was required on laboratory scale, on the other hand the temperature cycles 
in case of pilot plant were bigger in magnitude. This difference could be attributed to mixing and 
heat transfer differences at the two levels. This is also consistent with the earlier observations 
related to the more significant breakage observed at the large scale crystallisation process, which 
required a larger number of heating cooling cycles, to eliminate the fines. Additionally, the 
laboratory scale system swiftly follows any change in the temperature and as a result of this a 
better control over number of crystals is achievable. On the pilot scale the heat transfer dynamics 
especially for this particular experimental setup were significantly slower, resulting in a delayed 
response, and more significant overshoots. Even with these differences and limitations of the 
large scale crystallisation system, the ADNC approach gave better results than the natural and 
linear cooling profiles, and product crystals which were similar in size. 
 
The difference in shape between the crystals resulting from the ADNC experiments is due to the 
different polymorphic forms of the products. OABA exists in three polymorphic forms. The 
transition temperature between form 1 and 2 was reported to be in the range of 45 °C (Jiang et 
al., 2008). Form 1 is thermodynamically more stable at lower temperatures, whereas form 2 is 
more stable at higher temperatures.  
 
 
Figure 6.12 DSC thermogram of OABA sample obtained at laboratory scale. Same results were obtained for 
samples from pilot scale experiments using the natural and linear cooling profiles. 
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Figure 6.13 DSC thermogram of OABA sample obtained at pilot plant using the ADNC approach 
 
The DSC analysis (shown in Figure 6.12 and Figure 6.13) confirmed that at large scale the more 
stable (at lower temperatures) form 1 crystals were produced in the DNC experiment, whereas in 
the linear and natural cooling experiments on the large scale and at the laboratory scale DNC 
experiment the metastable form 2 crystals were formed. The peak at 108.1 °C indicates 
transformation of form 1 to form 2 and the melting point of form 2 is 144 °C (Jiang et al., 2008). 
Since all nucleation events occurred above the transition temperature (49 °C for the laboratory 
scale DNC, and 52 °C for the large scale DNC), most likely form 2 crystals were initially formed 
in all cases. The transformation of the metastable polymorph into the more stable form 1 is 
generally favoured by the increase in the temperature (Dang et al., 2009). Since during the large 
scale ADNC experiments the slurry was kept for long period of times at higher temperatures due 
to the more pronounced temperature cycles, than during the linear and natural cooling or the 
laboratory scale DNC experiments, which could increased the rate of transformation from form 2 
to form 1. Furthermore, since the solubility of form 2 below 45 °C is higher than for form 1, the 
temperature cycles around the solubility curve can promote the dissolution of any form 2 
potentially present in the system (Abu Bakar et al., 2009).  
 
The MSZW is narrower on the large scale than on the laboratory scale; however the results 
indicate the ability of the ADNC to adapt the operating profile to variations in the MSZW. The 
DNC approach was able to produce similar CSD and mean crystal size on the large and 
laboratory scale however it was unable to detect the polymorphic transformation. For systems 
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with potential polymorphic transformations more careful design of the temperature cycling 
procedure is required based on the phase diagram of the polymorphic system (Abu Bakar et al., 
2009). 
 
To further evaluate the robustness of this approach on the pilot plant scale a second case study 
was performed, with the results described in the next section. 
 
6.3.2  Industrial Scale-up Experiments Using the Paracetamol in IPA System 
 
Experiments for PCM in IPA were performed at an industrial scale batch cooling crystallisation 
process located at AstraZeneca, Charnwood, following the procedure and recommendations 
obtained on the laboratory scale experiments. The objective was to evaluate the effectiveness of 
the approach on pilot scale for the PCM/IPA system. The same software system (CryPRINS) and 
methodology was used as in all the other experiments presented in the thesis. The ADNC 
obtained the measurements from industrial FBRM and ATR-UV/Vis spectroscopy probes. The 
calibration of the probe was performed following similar procedure as described in Chapters 3 
and 4. The temperature profile was calculated by the ADNC controller and sent as a setpoint to 
the temperature control system via an industrial distributed control system (DCS), running an 
ABB Satellite Server. All communications were implemented via OPC protocol. Several 
experiments were performed, and sample results from one ADNC experiments are presented 
next. In this experiment a PCM concentration of 0.145 g/g was used, heating/cooling rates were  
0.2 °C/min, DNC setpoint was 2000 (based on total counts/s), while 2040 and 1960 were used as 
upper and lower limits receptively. The results of the experiment carried out are shown in Figure 
6.14. 
 
The temperature was initially increased to 50 °C to ensure complete dissolution of the solids. At 
this point the DNC was started. The control approach successfully detected the increase in counts 
and managed to bring the system to the setpoint. After three heating and cooling cycles the 
counts were stabilized close to the setpoint and lower temperature limit was reached. The 
temperature profile obtained is similar to the temperature profiles obtained at the laboratory scale 
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(shown in chapters 4 and 5). The heating/cooling cycles removed fines and promoted growth of 
the crystals. This observation is evident from the phase diagram as shown in Figure 6.15, where 
control pushes the system to the undersaturated region for the dissolution of fines. 
 
 
Figure 6.14 Total counts/s, concentration and temperature profile for PCM/IPA run in the industrial pilot 
plant crystallizer 
 
The operating curve in the phase diagram Figure 6.15, indicates similar variations in MSZW as 
observed for the laboratory scale experiments presented in chapters 4 and 5; a much wider 
MSZW for primary nucleation and narrower MSZW for subsequent secondary nucleations. The 
primary nucleation occurred at a higher temperature (lower supersaturation) compared to the 
laboratory scale experiments. This is also in correlation with the observations in the case of the 
OABA experiments, which indicated a narrower MSZW for the larger scale. This again shows 
that dynamic changes take place in the crystallization vessels at different scales and the control 
approaches which do not take into account these variations can result in poor product quality. 
The heating/cooling cycles resulted in dissolution of fines and growth of crystals. The trend of 
the SWMCL (Figure 6.16.) shows a continuous growth of the particles at the expense of the 
dissolution of fines. Similarly to the laboratory scale experiments, large product crystals with 
uni-modal CSD were obtained in this case as shown in Figure 6.17.  
 
These results shown here and in the previous chapters indicate that the ADNC approach for 
different systems and on both laboratory and large scales is able to successfully and consistently 
produce large crystals with a uni-modal distribution and without any agglomeration. The 
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approach works without any information about the process that might have been required for 
other control approaches. 
 
Figure 6.15 Operating curve in the phase diagram during the ADNC of the industrial crystallisation reactor. 
The difference between the primary and secondary MSZW can be clearly seen. 
 
 
Figure 6.16 Evolution of the SWMCL for the PCM/IPA run at the industrial scale crystallizer using the 
ADNC approach 
 
 
Figure 6.17 CSD for PCM/IPA experiment at the end of the batch 
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6.4 Conclusions 
 
A thorough assessment of the ADNC approach on pilot plant scale was presented using two 
different systems. The main purpose was to test the ability of this approach to be used as a robust 
scale approach, and to analyze its performance on pilot scale in comparison with conventional 
linear and natural cooling profiles. Comparison of the results at laboratory and pilot scales 
validated that the ADNC approach can be used effectively to obtain non-agglomerated, large 
crystals with uni-modal size distribution on both scales without extensive experimentation and 
modelling. The approach also outperformed linear and natural cooling profiles in that it produced 
larger crystals with more uniform and uni-modal CSD, with minimal amount of fines. The results 
show that the ADNC approach can be used as a useful and robust tool for obtaining crystals with 
desired properties on both laboratory and pilot plant scales. 
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Chapter 7 Separation and Monitoring of the crystallization of  
 mixtures of Aminobenzoic Acid Isomers using ATR 
 UV/Vis and FBRM 
7.1 Introduction 
 
This work focuses on the development of a calibration model for monitoring of a complex multi-
component system using ATR-UV/Vis spectroscopy, covering both cooling and anti-solvent 
crystallizations, and on the development of an interconnected crystallisation system for the 
separation of the positional isomers of amino benzoic acid, via seeded cooling crystallization. 
Two cases are discussed, the separation of two and three isomers, when they are present together 
in the solution. The separation are to be achieved by using interconnected crystallizers system 
seeded with different isomers in each crystallizer (all at the same temperature) and ATR-UV/Vis 
spectroscopy and FBRM have been used to monitor the liquid and solid phases respectively. 
 
Isomers are a class of compounds frequently encountered in the pharmaceutical, fine chemicals 
and agrochemical industries. They include geometrical and positional isomers, enantiomers and 
stereoisomers. Often these isomers exist as mixtures and since they have different physical and 
chemical properties their monitoring and isolation in the purest form is required. High 
performance liquid chromatography (HPLC) and capillary zone electrophoresis (CZE) are the 
most widely used techniques for the separation of the isomers. A significant literature deals with 
the application of these techniques, Hardy and Townsend (1988) separated positional isomers of 
oligosaccharides and glycopeptides by high performance ion exchange chromatography. 
Račaitytė et al. (2005) used CZE and reversed phase HPLC for the quantitative analysis of the 
monosaccharides. 
 
Several applications of crystallization have been reported for the separation of isomers. Rousseau 
and O’Dell (1980) used seeded cooling crystallization for the separation of multiple solutes 
present together. Seeds for the desired solute were added causing secondary nucleation of that 
solute. Supersaturation was generated by reducing the temperature for growth of the added and 
generated seeds. The solution was filtered, heated up again and seeds for second solute were 
Chapter 7 Separation and Monitoring of the crystallization of mixture of Aminobenzoic Acid Isomers 
using ATR UV/Vis and FBRM 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  148 
 
added. The problems with this approach are multiple filtration steps, precise temperature control, 
the requirement of many small cooling steps as the undesired component can also nucleate in the 
vessel as the temperature is lowered, and possibly very low yield. A better approach for 
separation of enantiomers of mandelic acid using crystallization was proposed by Elsner et al. 
(2007), which involved two coupled crystallizers. In their theoretical approach only solids free 
liquid was to be interchanged between the two vessels and simulation studies suggested that this 
approach could increase the yield and purity of the product. Elsner et al. (2009) in another work 
demonstrated the use of a coupled crystallizer approach experimentally for the separation of dl-
threonine. Svang-Ariyaskul et al. (2009) successfully used the coupled crystallizers concept for 
chiral separation of DL-glutamic acid. The solids free liquid was exchanged between the vessels 
using a 0.1 µm membrane. The product obtained using this system was 94 % pure and an 
increase in yield by 56.3 % compared to simple cooling crystallization. 
 
In this contribution monitoring and separation of aminobenzoic acid (ABA) isomers has been 
carried out. ABA has three positional isomers namely ortho (OABA), meta (MABA) and para 
(PABA). These isomers are widely used, e.g.  OABA is used in pharmaceuticals, in the 
manufacturing of perfumes, dyes, pigments and saccharin (Jiang et al., 2008), MABA is used in 
the manufacturing of analgesics and other chemicals (Svard et al., 2010), PABA is also used in 
pharmaceuticals, dyes and as additive (Gracin and Rasmuson, 2004). Apart from their clinical 
importance monitoring the concentrations of ABA isomers is also important in waste water when 
they are present together with other compounds. Schmidt et al. (1997) carried out analysis of 
ABA in waste water using HPLC. Zheng et al. (2006) used HPLC with four ionic liquids to 
separate the three ABA isomers, CZE was used by Fujiwara and Honda (1987) for the same 
separation. 
 
In the current work the interconnected crystallizer approach is used for the separation of the 
positional isomers, ortho-, meta- and para-aminobenzoic acids for the first time. The work also 
demonstrates for the first time that a system with three interconnected crystallizers can be used 
successfully for the separation of three positional isomers. The methodology behind this 
approach is described as follows. The two or three isomers when dissolved together in the 
solution can be considered as separate compounds i.e. each component will have its own 
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supersaturation regardless of the other, assuming that there is no interaction between the different 
species. In coupled crystallizers setup the solution is continuously exchanged between the vessels 
through filters so as to maintain supersaturation at the same level. The isomers are seeded 
separately in their respective vessels. The supersaturation generated for each isomer now is used 
up by the respective seeds; a slow cooling rate will prevent any nucleation event. The 
supersaturations generated during the cooling for all components are continuously used up by the 
seeds which grow in their corresponding vessels, so there is less chance of any of the species 
nucleating in the vessels of the other species. Hence, pure isomers may be obtained from their 
respective vessels in the end. 
7.2 Experimental Section 
7.2.1 Materials and Equipment 
 
Ortho-aminobenzoic acid (OABA), meta-aminobenzoic acid (MABA) and para-aminobenzoic 
acid (PABA), all 98 % pure from Sigma Aldrich were used in the experiments. Laboratory 
reagent grade iso-propanol (IPA), (Fisher Scientific) was used as solvent, while de-ionized water 
from a Milli-Q unit was used as anti-solvent. The experimental setup used was same as described 
in chapter 2. 
 
For calibration experiments, reference measurements were made in clean IPA, water or 
IPA/water mixtures at 20 °C. Artificial neural network calculations for the development of the 
nonlinear calibration model were carried out using the Neural Network toolbox in MATLAB 
(The Mathworks), R2008b version, design of experiments was carried out using the statistical 
toolbox in R2008b version. 
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7.3 Calibration Model Development 
7.3.1 Design of Experiments 
 
A calibration model capable of determining the concentrations of OABA and PABA 
simultaneously was developed. Because of the presence of several variables design of 
experiments was used to minimize the number of experiments required. Four variables were 
considered for calibration model development, including the concentrations of OABA and 
PABA, solvent/anti-solvent ratio and temperature. In order to have a robust calibration model, it 
was decided to have 5 concentration levels. According to full factorial designs,   experiments 
are needed to investigate the effect of m variables at   levels. In this case 1024 experiments 
would have been required, which is practically not feasible to carry out. As an alternative, the 
central composite design method was used for the design of experiments, as it gives a good 
coverage of the entire design space (Brereton, 2003), whilst providing a significantly smaller 
number of experiments than the full factorial design. Compared to the full factorial design, the 
number of experiments was reduced from 1024 to 36 experiments. 
 
7.3.2 Monitoring and Calibration Model Development 
 
Separately recorded sample spectra of OABA, PABA and MABA are shown in Figure 7.1 in 
IPA. The peak absorbance values for OABA, PABA and MABA are 339 nm, 293 nm and 311 
nm respectively. The spectrum for the isomers when present together in the mixture is shown in 
Figure 7.2. From these figures it is evident that ATR-UV/Vis spectroscopy can be used to 
distinguish between the two isomers i.e. OABA and PABA even when they were present as 
mixture. MABA shows lower peak intensities in general; hence it is more difficult to detect the 
peak in the plot. 
Chapter 7 Separation and Monitoring of the crystallization of mixture of Aminobenzoic Acid Isomers 
using ATR UV/Vis and FBRM 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  151 
 
 
Figure 7.1 Separately recorded spectra of OABA, PABA and MABA in IPA, all concentrations were 0.01 g/g 
 
 
Figure 7.2 Spectrum of OABA, PABA and MABA when present together. The spectrum was recorded with 
100 % IPA, concentrations of OABA and PABA were 0.219 g/g. 
 
The calibration experiments were designed to cover several different solvent and anti-solvent 
ratios ranging from 100 % IPA to 80 % IPA along with several concentrations of OABA and 
PABA. For all calibration experiments the temperature was raised 10-15 °C above the saturation 
temperature for complete dissolution. The temperature was then decreased in steps at a rate of 
0.6 
°
C/min and kept at certain temperatures for half an hour. The temperature was lowered in 
each case to 10 
°
C or until the nucleation took place.  Only the spectral data obtained in the clear 
solution (i.e. when no solids were present) was used in the calibration model development. 
Typical experimental results from one of the experiments carried out during the calibration 
model development are shown in Figure 7.3. The robustness of the ATR-UV/Vis spectroscopy 
signal at various temperatures and its ability to detect dissolution and nucleation events can be 
seen. The decrease in the FBRM counts/s and increase in the UV signal in first part of the 
experiment indicate the dissolution of the compounds. Similarly the sudden decrease in the UV 
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signal and the sudden increase in the FBRM total counts/s show the nucleation event towards the 
end of the experiment. The variation of the absorbance during the temperature steps in the clear 
solution indicates the effect of the temperature on the absorbance. At the same concentration the 
absorbance increases with the decrease of the temperature. When the temperature was constant 
the UV absorbance showed very stable signal and negligible drift. The different concentrations 
used at several IPA/water ratios are shown in Table 7.1. 
 
 
Figure 7.3 Absorbance, total counts/s and temperature profiles for a calibration experiment 
 
Table 7.1 Concentrations of OABA and PABA used at several IPA/water ratios for model building 
 
The data used for calibration consisted of 78 inputs, 76 wavelengths from 242 – 400 nm, 
temperature and solvent/anti-solvent ratio. The test data i.e. the data from the calibration 
experiments was pre-processed using SNV transformation. The data as mentioned in chapter 3 
was checked for the presence of nonlinearity by plotting absorbance against the concentration as 
shown in Figure 7.4. A nonlinear relationship between absorbance at 339 nm and concentration 
can be seen here, suggesting that a nonlinear model would be required. Similar behaviour in the 
variation of absorbance values was observed at different wavelengths and temperatures as well. 
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Total Counts/s
Temperature (C)
Absorbance
NucleationDissolution
80 % IPA 85 % IPA 90 % IPA 95 % IPA 100 % IPA 
OABA 
(g/g) 
PABA 
(g/g) 
OABA 
(g/g) 
PABA 
(g/g) 
OABA 
(g/g) 
PABA 
(g/g) 
OABA 
(g/g) 
PABA 
(g/g) 
OABA 
(g/g) 
PABA 
(g/g) 
0.145 0.097 0.136 0.136 0.108 0.108 0.152 0.152 0.18 0.12 
0.145 0.145 0.187 0.136 0.145 0.145 0.209 0.152 0.18 0.179 
0.178 0.145 0.187 0.186 0.161 0.145 0.209 0.209 0.18 0.219 
0.194 0.145 0.204 0.203 0.161 0.163 0.2279 0.228 0.199 0.219 
0.194 0.178     0.203 0.202     0.219 0.219 
0.194 0.194                 
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Another source of nonlinearity is shown in Figure 7.5, absorbance values at constant temperature 
of 30 °C with same concentrations of OABA and PABA (0.145 g/g) are plotted but at different 
IPA ratios. The plot shows that even if both the solutes are present in the same amounts the 
absorbance values are affected by the percentage of IPA present.  It was discussed in chapter 3 
that presence of nonlinearity can result in poor performance of linear models and a simple 
nonlinear model was proposed for calibration model development. The application of nonlinear 
models in cases where single absorbance/derivative can be used is quite straightforward, 
however, in this case multiple species were present therefore making it difficult to select 
absorbance(s) which could be used for model development. Furthermore, the presence of 
multiple components and their overlapping spectra also suggested that absorbance/derivative at 
single wavelength would not be sufficient to model the whole system accurately. For comparison 
purpose models using PCR and ANN were developed, the results are discussed as follows. 
 
Two calibration models (using the data from experiments shown in Table 7.1), one using PCR 
and one based on ANN were initially developed and tested for their predictive ability. The PCR 
model using 8 principal components (PCs) and the ANN model with one hidden layer with 22 
neurons were selected as they gave better results during model testing.  
 
 
Figure 7.4 Variation in absorbance at 339nm at constant temperature 
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Figure 7.5 Absorbance values at 30 °C. Concentrations of OABA and PABA were 0.145 g/g 
 
For validation of the calibration model developed two validation experiments were performed, a 
simple cooling crystallization experiment and a combined cooling and anti-solvent crystallization 
experiment. The models developed were initially validated using the cooling crystallization 
experiment. 
 
The cooling crystallization experiment for validation of the developed models was carried out 
with 0.22 g/g of OABA and 0.15 g of PABA, the solvent used was 95 % IPA and 5 % water (by 
weight). The variation of peak absorbance values of OABA and PABA along with FBRM and 
temperature data are shown in Figure 7.6 and Figure 7.7. The temperature was raised to 60 °C to 
ensure complete dissolution of both isomers. The temperature was then decreased in steps until 
the nucleation took place. Both isomers nucleated approximately at the same time. 
 
 
Figure 7.6 Variation in peak OABA absorbance at 339 nm with temperature and total counts/s 
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Figure 7.7 Variation in peak PABA absorbance at 293 nm with temperature and total counts/s 
 
The predicted concentration of OABA by PCR is shown in Figure 7.8 and for PABA in Figure 
7.10. ANN model predictions for OABA and PABA are shown in Figure 7.9 and Figure 7.11. 
For this cooling experiment both models were able to capture the temperature effect satisfactorily 
for both isomers as shown from the concentration profiles. The root mean square error of 
prediction was used for the selection of the model. The values obtained for OABA were 0.0012 g 
and 0.0113 g for the ANN and PCR models, respectively. For PABA these values were 0.0016 g 
and 0.0050 g for the ANN and PCR models, respectively. Based on these results the ANN model 
was selected, and a combined cooling and anti-solvent experiment was then conducted to further 
validate the accuracy and prediction of the selected model.  
 
 
 
Figure 7.8 Predicted concentration of OABA by the PCR model 
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Figure 7.9 Predicted concentration of OABA by the ANN model 
 
 
 
Figure 7.10 Predicted concentration of PABA by the PCR model 
 
 
Figure 7.11 Predicted concentration of PABA by the ANN model 
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and cooling crystallization. The variation in the peak absorbances of OABA and PABA with 
changing temperature and concentration can be seen here. At approximately 200 minutes 
complete dissolution of OABA took place, while PABA dissolved at approximately 300 minutes. 
Between 300-500 minutes, there is a small decrease in FBRM counts which can be attributed to 
the presence of bubbles or impurities (which may have dissolved during the water addition). In 
both cases the absorbance values decrease after complete dissolution because of the increasing 
temperature. The complete dissolution of solids is also clearly indicated by a decrease in the total 
counts as detected by the FBRM. Water was used as an anti-solvent in this experiment. 40 g of 
water was added in four intervals. The dilution affect caused by water addition is visible by 
decreasing absorbance values at constant temperature. The system was cooled and held at 5 °C 
until it nucleated. The nucleation event was detected by both FBRM and ATR-UV/Vis 
spectroscopy by an increase in number of total counts/s and decrease in the absorbance values, 
respectively.  
 
The ANN model in this case failed to predict the concentrations of both isomers accurately, 
especially during the anti-solvent addition part. Another disadvantage was the extremely long 
computational times which further hindered the usage and optimization of ANN based model. 
The PCR based model which was developed earlier also failed to predict the concentrations 
accurately and with significant differences in the actual and predicted values, especially during 
the anti-solvent addition part. In order to reduce the computational time and accuracy of the 
prediction for this validation experiment it was decided to test a combined PC-ANN based 
model. This approach applies a PCA in the first step to decrease the number of input parameters 
for the ANN model, and then uses an ANN model with the PCs as the input. This approach can 
significantly decrease the number of parameters in the ANN model. 
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Figure 7.12 Variation in total counts and absorbance at 339 nm for OABA 
 
 
Figure 7.13 Variation in total counts and absorbance at 293 nm for PABA 
 
The structure of the PC-ANN model developed is shown in Figure 7.14. The inputs to the ANN 
model were 8 principle components (PC1-PC8), which is a significant reduction in the number of 
inputs compared to the original test data, furthermore the computational time required to train the 
ANN model was substantially reduced, i.e. from several hours to less than 10 minutes. Several 
different network structures using Levenberg-Marquardt algorithm were tested with different 
number of neurons and iterations for the training. The network with 6 neurons and 400 iterations 
was selected as it gave the best results. The network consisted of 1 input layer, 1 hidden layer and 
an output layer. The transfer functions for the hidden layer were tansigmoid, while purelin (both 
of these are standard transfer functions available in the artificial neural networks toolbox) was 
used as the transfer function in the output layer. Tansigmoid was used because of its ability to 
handle nonlinear data.  
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Figure 7.14 Structure of PC-ANN model used with 8 inputs and 2 outputs 
 
The performance and robustness of the model developed is shown in Figure 7.15 and Figure 
7.16. The RMSEP values obtained were 0.2916 g and 0.3561 g for OABA and PABA 
respectively. Since concentration is influenced by the dilution effect when anti-solvent is added 
to the system, instead of concentrations, dissolved mass is plotted here to show the prediction 
capability of the model for cooling and anti-solvent crystallization. The initial dissolution phase 
is indicated by an increase in the dissolved mass in steps with regards to variations in the 
temperature. After this no significant change is seen for both OABA and PABA dissolved 
masses, even during the water additions until the nucleation took place towards the end as 
indicated by a decrease in masses. The model developed was thus able to capture temperature 
and anti-solvent effects satisfactorily.  
 
 
Figure 7.15 Predicted dissolved mass of OABA 
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Figure 7.16 Predicted dissolved mass of PABA 
 
As a next step separation of the two and three isomers was carried out using water as solvent. 
Water was used as solvent for separation experiments to simplify the setup and minimize 
material usage as solubilities of OABA and PABA are significantly higher in IPA or the 
IPA/water mixtures used during the calibration model development.  
 
7.4 Separation of the two Isomers 
 
Initially separation of OABA and PABA using water as solvent was carried out. The 
experimental setup for separation of two isomers is shown in Figure 7.17. The jackets of both 
vessels were connected to each other to maintain the same temperature in both vessels. In vessel 
1, FBRM and ATR-UV/Vis spectroscopy probes were present, while the second FBRM along 
with the thermocouple were present in vessel 2. The solution prepared was saturated with respect 
to OABA at 35 °C and at 30 °C with respect to PABA. Approximately equal amounts of OABA 
and PABA were added in both vessels. The temperature was then raised to 55 °C for complete 
dissolution. The system was cooled down to 40 °C before the inter vessel circulation of solution 
started through sintered disk filters at a rate of 60 mL/min using peristaltic pumps. The solution 
was cooled down to 22 °C at a rate of 0.1 °C/min, maintaining the same temperature in each 
vessel. 
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Figure 7.17 Experimental setup used for the separation of the two isomers 
 
The results for vessels 1 and 2 are shown in Figure 7.18and Figure 7.19 respectively. Inter vessel 
mixing was started earlier to make sure homogeneous solutions were present in both vessels. The 
small decreases in absorbance values at approximately 90 minutes indicate the start of the inter 
vessel mixing. An amount of 15 % of OABA seeds based on the initial amount of solute, and size 
range of 125-185 µm (according to sieve analysis), were added in vessel 1 at 34 °C, as indicated 
by the increase in total counts. The absorbance values at 339 nm show an increasing trend, which 
was probably as a result of dissolution and temperature decrease, also indicated by a slight 
decrease in the FBRM counts/s. However, after about 135 minutes the absorbance remains 
relatively unchanged indicating that the temperature effect has been countered by the decrease in 
OABA concentration (and hence absorbance) because of growth of the seed crystals. The 
increase in the FBRM counts/s at 180 minutes gave a false indication of nucleation. These 
increases in the counts were caused by the presence of the bubbles on the probe window. This is 
further supported by the absorbance values, which should have shown a sharp decrease in case of 
nucleation. The phenomenon of bubbles affecting the FBRM readings has been reported by 
Simon et al. (2009). Saarimaa et al. (2006) showed results for FBRM measuring bubbles and 
materials together and FBRM also showed counts even for a blank sample, purely because of the 
presence of the bubbles. The other factors, which favoured the formation of bubbles on the probe 
were probe orientation with respect to the impeller and low solid concentration, as the solids 
were expected to wash away any bubbles, which may form on the probe window. 
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Figure 7.18 Absorbance and total counts profile for vessel 1 (OABA) 
 
 
Figure 7.19 Absorbance and total counts profile for vessel 2 (PABA) 
 
 
In vessel 2, 14.9 % PABA seeds were added at 29 °C, based on the initial amount, with size 
range 125-185 µm according to the sieve analysis. The slight decrease in counts/s at 167 minutes 
indicates a dissolution event as supported by the increase in absorbance values at 293 nm. The 
sharp peak at 173 minutes indicates an artefact in FBRM readings as no changes are seen in the 
absorbance values. The counts after this peak fluctuate between 3000-6000 counts/s. These 
fluctuations were caused by sticking of crystals on the filter and their cleaning by reversing the 
flow in the pipe by the peristaltic pump. The inter vessel flow was periodically reversed for 
cleaning the filters. Only the liquid present in the pipe was used during this cleaning, this was 
made sure by keeping the pipes above the liquid level in both vessels.   
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The purpose of this experiment was to separate the two isomers. The purity of the recovered 
product is therefore of primary importance. For this purpose DSC analyses were performed on 
the solids recovered from each vessel. The melting points of OABA and PABA are 147 °C and 
187 °C, respectively. In Figure 7.20 DSC analysis of the products recovered from vessel 1 along 
with the DSC analysis of the seeds used are shown. The results of the DSC analysis of the 
product from vessel 2, along with the seeds used are shown in Figure 7.21.  
 
  
Figure 7.20 DSC thermogram of OABA (a) seeds (b) recovered product from the 2 isomers separation 
experiment. Heating rate was 15 °C/min. 
 
The plots show no cross contamination of the two isomers in either of the vessels. The small 
peaks close to 100 °C for the OABA samples indicate polymorphic transformation of form 1 to 
form 2. Figure 7.22 and Figure 7.23 show microscopic images of seeds and recovered product 
from both vessels. In both cases larger crystals were obtained compared to the seed crystals.  
 
  
Figure 7.21 DSC thermogram of PABA (a) seeds (b) recovered product from the 2 isomers separation 
experiment. Heating rate was 15 °C/min. 
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Figure 7.22 Microscopic images of OABA (a) seed (b) recovered product from the 2 isomers separation 
experiment 
 
  
 
Figure 7.23 Microscopic images of PABA (a) seed (b) recovered product from the 2 isomers separation 
experiment 
   
A positive yield with respect to both isomers was obtained. An amount of 1.203 g of OABA 
seeds was added and 2.5478 g were recovered. In case of PABA, 1.0629 g seeds were added and 
1.3134 g solids were recovered. The recovered products correspond to 36.33 % and 13.439 % of 
the theoretical yield based on solubility data for OABA and PABA respectively. Low yield here 
can be attributed to a number of factors. Presence of multiple organic solutes can enhance the 
aqueous solubility of the solutes as compared to when they are present in water in the absence of 
other cosolutes (Chiou et al., 1986). This increase in solubility explains the dissolution of some 
seed crystals, although they were added below the saturation temperatures in case of both 
isomers. Another factor was the loss of product during recovery at the end as the solids had a 
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tendency to stick on the filters. After the successful separation of the two isomers, separation of 
the three isomers was also carried out, this is discussed in the next section. 
 
7.5 Separation of the three Isomers 
 
For separation of the three isomers, OABA, PABA and MABA were used as solutes, while water 
was used as solvent. The experimental setup used for separation of the three isomers is shown in 
Figure 7.24, indicating the third vessel which was added for MABA. The vessel configurations in 
terms of equipment were same as for the two vessels setup, no data were recorded in the second 
vessel (used for MABA seeding).  
 
 
Figure 7.24 Experimental setup used for the separation of the three isomers 
 
Solution prepared was saturated with respect to OABA at 35 °C, MABA at 33 °C and at 30 °C 
with respect to PABA. Approximately equal amounts of OABA, MABA and PABA were added 
in all three vessels, the temperature was then raised to 55 °C for complete dissolution. The 
system was cooled down to 40 °C before the inter vessel circulation of solution was started 
through sintered disk filters at a rate of 60 mL/min using three peristaltic pumps. The solution 
was cooled down to 20 °C at a rate of 0.1 °C/min.  
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Inter vessel mixing was started at 125 minutes as indicated by the change in absorbance values as 
shown in Figure 7.25 and Figure 7.26. 15 % OABA seeds based on the initial amount of solute, 
within the size range of 125-185 µm, according to the sieve analysis, were added in vessel 1 at  
34 °C, as indicated by an increase in the total counts/s.  
 
 
Figure 7.25 Absorbance and total counts profile for vessel 1 (OABA) 
 
 
Figure 7.26 Absorbance and total counts profile for vessel 3 (PABA) 
 
Absorbance values at 339 nm show an increasing trend, after the dissolution event, as seen in the 
case of the 2 isomer separation experiment previously. The noisy FBRM data, prior to seed 
addition and from 350 minutes onwards is the result of bubbles sticking on the probe window. 
MABA seeds, again 15 % of the initial amount of solute, with size range 125-185 µm, according 
to sieve analysis, were added in the second vessel at 32 °C. Decrease in absorbance values in 
Figure 7.25 can be seen, indicating decrease in concentration of both isomers.  
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In vessel 3, 14.9 % PABA seeds based on the initial solute content, with size range of 125-185 
µm, according to sieve analysis, were added at 29 °C. The absorbance data at 293 nm (Figure 
7.26) is rather flat even after addition suggesting that temperature and growth effects were 
countered in case of PABA. Flow directions were also reversed in this experiment as well to 
eliminate filter clogging. DSC analyses were carried out to check the purity of the products 
recovered from all three vessels. The results are shown in Figure 7.27, Figure 7.28 and Figure 
7.29 respectively. Again no cross contamination of isomers in either of the vessels was observed. 
Melting point of MABA is 178 °C. The peak at 160 °C in the MABA thermogram indicates the 
polymorphic transformation of form 1 to form 2 (Svard et al., 2010). 
 
 
  
Figure 7.27 DSC thermogram of OABA (a) seed (b) recovered product from the 3 isomers separation 
experiment. Heating rate was 15 °C/min. 
 
 
Figure 7.28 DSC thermogram of PABA (a) seed (b) recovered product from the 3 isomers separation 
experiment. Heating rate was 15 °C/min. 
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Figure 7.29 DSC thermogram of MABA (a) seed (b) recovered product from the 3 isomers separation 
experiment. Heating rate was 15 °C/min. 
 
The amount of solids added in this case were 1.7283 g OABA, 1.5801 g PABA and 1.6972 g 
MABA, while the recovered products were 2.4166 g OABA, 2.1572 g PABA and 1.8884 g 
MABA. The recovered products correspond to yields of 12 %, 17.05 % and 4.98 % with respect 
to the theoretical yield. The reasons for low yield have been discussed previously. MABA had 
the lowest yield in this case which was as a result of solids sticking and forming lumps which 
were difficult to break, hence resulting in little growth of the crystals, due to decreased surface 
area.  
 
Figure 7.30 shows the microscopic images of recovered OABA and PABA crystals, showing 
growth when compared with the seed crystals. MABA images were not taken as solids were 
recovered in the form of lumps. 
 
  
 
Figure 7.30 Microscopic image of recovered products from the 3 isomers separation experiment (a) OABA (b) 
PABA 
50 100 150 200
0
20
40
60
80
Temperature (C)H
e
a
t 
F
lo
w
 (
W
/g
) 
  
  
50 100 150 200
0
20
40
Temperature (C)H
e
a
t 
F
lo
w
 (
W
/g
) 
  
  
178.6C
175.2C
160.8C
161.4C
(a) 
(b) 
            (a)                                                (b)                                                     
Chapter 7 Separation and Monitoring of the crystallization of mixture of Aminobenzoic Acid Isomers 
using ATR UV/Vis and FBRM 
 
Strategic Feedback Control of Pharmaceutical Crystallization Systems  169 
 
7.6 Conclusions 
 
A calibration model using PC-ANN was developed for a complex multi component solution 
covering both cooling and anti-solvent crystallization processes. The PC-ANN based calibration 
proved to be a useful chemometric tool for nonlinear and complex systems. ATR-UV/Vis 
spectroscopy has been shown as a potentially powerful PAT tool with potential applications in 
monitoring multi-component crystallization processes. FBRM and ATR-UV/Vis spectroscopy 
complement each other and provide useful information about the system. Separations of the two 
and three isomers were carried out successfully, using two and three interconnected 
crystallization vessels. Despite the low yield, pure products were obtained. The process can be 
optimized further by using a better filter design, however the designed methodology has the 
potential to be used on a larger scale as a system for isomer separation. 
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Chapter 8 Conclusions and Future Work 
8.1 Conclusions 
 
The main aim of the work presented was to use PAT and chemometrics for process monitoring 
and control and hence improve the quality of the product in a consistent way. For this purpose 
control approaches using ATR-UV/Vis spectroscopy and FBRM were developed and 
successfully implemented. The second aim was to use chemometrics combined with PAT for 
monitoring complex multi-component systems. In the following section the main conclusions are 
summarized: 
 
A systematic methodology for calibration model development for ATR-UV/Vis spectroscopy 
was presented, different linear and nonlinear model were compared for their predictive ability. It 
was shown that the selection of the variables and choice of calibration method must be carried 
out by analyzing the data for nonlinearities, as the predictive ability of model strongly depends 
on these factors. A simple nonlinear model was developed and subsequently used in SSC 
implementation. 
 
A SSC approach using ATR-UV/Vis spectroscopy was developed and implemented for 
PCM/IPA system. This was the first time that an experimental study of feedback supersaturation 
control using ATR-UV/Vis spectroscopy had been carried out. The system controlled by this 
approach was able to follow particular profiles in the phase diagram yielding better quality 
product. This approach offers a quick direct design approach for crystallization processes.   
 
An automated DNC approach using FBRM was successfully implemented and evaluated for the 
PCM/IPA system. The ADNC approach outperformed the traditionally used linear and natural 
cooling profiles and crystals with bigger mean size and uni-modal distributions were obtained for 
all cases. A combined ADNC-SSC using innovative internal seeding methodology was also 
developed. The approach combined the information provided by FBRM and ATR-UV/Vis 
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spectroscopy. Results show that the crystalline product obtained using this approach was better 
than the crystals obtained from linear cooling profiles. 
 
The performance of ADNC was analyzed under different disturbances that are frequently 
encountered in the industrial environment and for external seeding as well. The results indicate 
that ADNC responded well to these disturbances and big uniform crystals and CSD without any 
bi-modality were obtained. The approach performed equally well in the case of external seeding 
also A robust scale-up approach using ADNC was then implemented successfully on 100 L scale 
for the OABA and water system and again performed better than the natural and linear cooling 
profiles. 
 
A complex nonlinear calibration model using PC-ANN was developed for simultaneous 
concentration monitoring of multicomponent system using ATR-UV/Vis spectroscopy 
absorbances. A novel multiple crystallizer setup was developed and successfully used for the 
separation of the isomers of ABA. ATR-UV/Vis spectroscopy and two FBRM’s were used for 
monitoring the process. The isomers with higher degree of purity were successfully separated. 
This approach offers an alternative to expensive HPLC for separation of multiple compounds. 
The approach is simple to implement and gave satisfactory results. 
 
A number of useful and easy to implement control approaches were developed, implemented and 
evaluated for their performance. The use of ATR-UV/Vis spectroscopy and FBRM for control 
approaches can be a valuable addition in the QBD framework. The robust scale-up approach has 
huge potential for application on industrial scale. The key feature of these approaches has been to 
obtain desired crystalline product consistently, commercially these can lead to minimize 
operation costs by minimizing the batch to batch variability and hence improved product quality. 
A simple but effective approach based on seeded cooling crystallization can be implemented on 
industrial scale as well for the separation of the compounds. All these factors are in line with the 
FDA’s PAT initiative of improving product quality, reduction in development and manufacturing 
costs and time. 
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8.2 Future Work 
 
The following section includes several recommendations for future work based on the results 
presented in this thesis: 
 
The efficiency of the ADNC approach has been demonstrated for two model pharmaceutical 
systems. Considering the much broader scope of crystallization there is great potential for the 
ADNC approach to be applied in other sectors at different scales, e.g. crystallization of food 
related compounds, other fine and bulk chemical compounds etc. 
 
The SSC control approach also has similar potential and should be evaluated further for its 
application for other compounds especially for fast growing systems. In the present work 
supersaturation was controlled at a constant level. Production of a particular polymorph by 
following mode complex supersaturation profiles in the phase diagram using the SSC can be 
another application with significant potential. Similarly the combined ADNC-SSC approach has 
not been fully explored and can be a beneficial tool in the crystallization processes. Anti-solvent 
crystallization is also frequently used for many crystallisation processes and the automated 
ADNC approach based on solvent/antisolvent addition can be developed.  
 
The separation of isomers can be optimized further especially the yield can be increased by using 
a more efficient setup, and solvent in which the isomers have higher solubility. Also the proposed 
approach should be extended for other frequently occurring mixtures as well, e.g. a smaller but 
similar setup, consisting of crystallisation cells separated by membranes (which allow the mixing 
of liquid but not the solid) could be developed and applied for protein separation.  
 
The model compound OABA showed some interesting polymorphic behaviour, during the large 
scale trials of the ADNC approach. Work is currently underway to quantify the productions and 
presence of different polymorphs under different conditions using the PAT tools used in the 
work.  
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Finally the current trends in continuous manufacturing and crystallisation call for the 
development of new control approaches for continuous processes. The approaches developed and 
evaluated in this thesis can be tailored and applied for continuous crystallisation, with significant 
potential benefits and impact in the pharmaceutical industries.  
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Appendix A 
Process monitoring  
Zhou et al., 2006 Anti-solvent crystallization of a proprietary Supersaturation control, dissolution and nucleation ATR-FTIR 
 
 drug compound using toluene as solvent, detection 
 
 
 n-heptane as antisolvent 
  
Liotta and  Cooling crystallization of a proprietary drug 
Solubility and MSZW determination, 
supersaturation ATR-FTIR 
Sabesan, 2004  compound using toluene as solvent  control 
 Barrett and  Potash alum in water Solubility and MSZW determination PVM 
Glennon, 2002 
   
Fujiwara et al., 2002 Cooling crystallization of paracetamol in water 
MSZW determination, size, monitoring, 
supersaturation  ATR-FTIR 
  
control, monitoring 
 Yu et al., 2005 Anti-solvent crystallization of paracetamol in Agglomeration, effects of stirring and anti-solvent 
 
 
 acetone-water mixtures, water as anti-solvent  addition rate 
 
Yu et al., 2006 Anti-solvent crystallization of paracetamol in 
Growth monitoring, seeding policy and 
supersaturation ATR-FTIR 
 
 acetone-water mixtures, water as anti-solvent  control 
 Yi and Myerson, Cooling and anti-solvent crystallization of Effects of seeding, mixing, vessel size, nucleation 
 2006  glycine in water, water-methanol mixtures,  detection, size monitoring 
 
 
 methanol as anti-solvent 
  Lindenberg et al., 
2009 
Combined cooling and anti-solvent 
crystallization 
Population balance modelling,  estimation of 
growth ATR-FTIR 
 
crystallization of acetylsalicylic acid in ethanol  and nucleation parameters, growth monitoring 
 
 
 water mixtures 
  
Deneaue and Steele, Proprietary drug compound in ethanol-water Monitoring of oiling out and crystallization 
ATR-UV/Vis spectroscopy, 
PVM 
2005 mixture 
  Nagy et al., 2008 Paracetamol in water Estimation of kinetic parameters, MSZW ATR-FTIR 
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determination 
Howard et al., 2009 Sodium benzoate in water Monitoring of hydrate formation 
 Kougoulos et al., 
2004 unknown Nucleation detection and growth monitoring PVM 
De Beer et al., 2004 Medroxyprogesterone acetate 
Calibration model development for raman 
spectroscopy 
 Falcon and 
Berglund, 2004 Progestrone and acetone, water as anti-solvent PCA of raman spectra 
 
Liu et al., 2011 
Sodium scutellarien and water, acetone as anti-
solvent Monitoring of liquid and solid phases NIR, Raman 
Polymorphism 
O’Sullivan et al., 
2003 D-manitol and sucrose in ethanol-water and Monitoring of polymorphic transformation and  PVM, Raman 
 
toluene comparison with other in situ techniques  
 O’Sullivan and  Cooling crystallization of D-manitol in water Monitoring of polymorphic transformation  ATR-FTIR 
Glennon, 2005 
   Shaikh et al., 2005 Sodium carbonate in water Monitoring of polymorphic transformation  PVM 
Barthe et al., 2008 Paracetamol in water Monitoring of polymorphic transformation  
 
Sathe et al., 2010 Acitretin in IPA 
Solubility measurements, monitoring of 
polymorphic  NIR, Raman 
  
transformation  
 
Jia et al., 2008 Pravastatin Sodium in IPA-water 
Monitoring of polymorphic transformation and 
effects of  PVM 
  
temperature, solvent ratio and mixing speed 
 CLD to CSD 
Barthe and  Cooling crystallization of paracetamol in ethanol 
Conversion of CLD to CSD, growth monitoring, 
fines 
 Rousseau, 2006 
 
 removal 
 Worlitschek and Cooling crystallization of paracetamol in ethanol Conversion of CLD to CSD, estimation of kinetic  
 Mazzotti, 2004 
 
 parameters and optimal temperature trajectory 
 Worlitschek et al.,  Cermic beads and titanium dioxide particles Conversion of CLD to CSD 
 2005 
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Ruf et al., 2000 Glass, ceramic, potassium sulphate, toluene Conversion of CLD to CSD 
 
 
and water 
  Hukkanen and 
Braatz, Polyvinylchloride Conversion of CLD to CSD 
 2003 
   Li and Wilkinson, Unknown Conversion of CLD to CSD 
  
Instrument analysis and performance 
 Barrett and  Alkaline frit in water Effects of probe position and orientation 
 Glennon, 1999 
   
Bontha et al., 2000 Graphite, silica, kaolin, gibbsite, bentonite, mica 
Effect of slurry concentration, flowrate, solution 
colour, 
 
 
  flakes and plastic beads in water scan time, comparison with sieve analysis, 
 
  
effect of air bubbles 
 
Heath et al. 2002 Aluminium and alcite particles 
Comparison with other measuring techniques, 
focal 
 
  
position, mixing, effect of solids concentration 
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Appendix B 
List of Publications 
Journal Papers 
1. A. N. Saleemi, Z. K. Nagy, C. D. Rielly, Comparison of Supersaturation Control and Direct 
Nucleation Control of Crystal Size Distributions using ATR-UV/Vis and FBRM, Crystal 
Growth and Design. In review 
 
2. A.N. Saleemi, Z. K. Nagy, C. Rielly, Separation and monitoring of the crystallization of 
mixture of aminobenzoic acid isomers using ATR-UV/Vis and FBRM, Chemical 
Engineering Science. In review 
 
3. A.N. Saleemi, Z. K. Nagy, C. Rielly, Assessment of Automated Direct Nucleation Control 
Approach for Different Process Conditions during Cooling Crystallization, Organic Process 
Research and Development. In review 
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